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and sufficient to mediate the EphB-NMDAR interaction. In a novel molecular mechanism, I show that
extracellular phosphorylation of this residue after ephrin-B binding is sufficient to induce the EphB-NMDAR
interaction. Furthermore, I show that in the mature brain, the EphB-NMDAR interaction preferentially
regulates NR2B-subunit containing NMDA receptor localization, function, and downstream gene
transcription. Together, these findings impact our understanding of synapse formation and function, and
highlight the EphB-NMDAR interaction as a potential target to treat neurological disease.
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ABSTRACT 
 
Molecular mechanisms of pre- and postsynaptic EphB/ephrin-B 
signaling in synapse formation and function  
 
Sean Isaac Sheffler-Collins 
Matthew B. Dalva 
 
Proper function of the central nervous system relies on precise and coordinated 
cell-cell interactions and communication via synaptic transmission to assemble 
neuronal networks.  Aberrant synaptic transmission is a hallmark of neuronal 
disease.  The EphB family of receptor tyrosine kinases and their ephrin-B ligands 
play critical roles in the central nervous system in axon guidance, formation of 
pre- and post-synaptic specializations, localization of glutamate receptors, 
synaptic plasticity, and disease.  EphB/ephrin-B signaling has been reported to 
modulate these processes, but the molecular mechanisms remain poorly 
understood.  Our laboratory has previously shown that EphBs organize the 
formation of both pre- and postsynaptic specializations, and interact directly with 
NMDA-type glutamate receptors.  Therefore, I sought to investigate the 
molecular mechanisms for formation of presynaptic specializations and the 
interaction domain between EphBs and NMDA receptors.  I found that EphBs 
can induce the formation of presynaptic specializations by trans-synaptic 
 iv
interactions with both ephrin-B1 and ephrin-B2.  These ephrin-Bs can then recruit 
the machinery for neurotransmitter release through the multiple PDZ-domain 
containing adaptor protein syntenin-1.  Furthermore, ephrin-B1 and ephrin-B2 act 
independently for formation of presynaptic specializations, but together to recruit 
syntenin-1 to synaptic sites.  Based on this work and that of other laboratories, I 
was able to define the molecular pathway from postsynaptic EphBs to 
presynaptic glutamatergic vesicles.  Furthermore, on the postsynaptic side of the 
synapse, I define a single amino acid that is necessary and sufficient to mediate 
the EphB-NMDAR interaction.  In a novel molecular mechanism, I show that 
extracellular phosphorylation of this residue after ephrin-B binding is sufficient to 
induce the EphB-NMDAR interaction.  Furthermore, I show that in the mature 
brain, the EphB-NMDAR interaction preferentially regulates NR2B-subunit 
containing NMDA receptor localization, function, and downstream gene 
transcription.  Together, these findings impact our understanding of synapse 
formation and function, and highlight the EphB-NMDAR interaction as a potential 
target to treat neurological disease.    
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Abstract 
Assembly and function of neuronal circuits rely on selective cell-cell interactions 
to control axon targeting, generate pre- and postsynaptic specialization, and 
recruit neurotransmitter receptors. In neurons, EphB receptor tyrosine kinases 
mediate excitatory synaptogenesis early in development, and then later 
coordinate synaptic function by controlling NMDAR synaptic localization and 
function. EphBs direct synapse formation and function to regulate cellular 
morphology through downstream signaling mechanisms and by interacting with 
glutamate receptors. In humans, defective EphB-dependent regulation of 
NMDAR localization and function is associated with synaptopathies such as 
neuropathic pain, anxiety disorders, and Alzheimer’s disease. Here, we propose 
that EphBs act as a central organizer of excitatory synapse formation and 
function, and as a key regulator of diseases linked to NMDAR dysfunction.  
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Introduction 
Synapses are the fundamental unit of information flow within the central 
nervous system. Early in development there is a period of new synapse addition 
followed by synapse maturation (Fu et al., 2011; Shen and Cowan, 2010; Shen 
and Scheiffele, 2010; Tallafuss et al., 2010). Formation of excitatory synapses 
requires precise coordination between two contacting neurons to organize a 
presynaptic terminal capable of neurotransmitter release, and a postsynaptic 
specialization equipped with the proper neurotransmitter receptors (Fu et al., 
2011; Jin and Garner, 2008; McMahon and Diaz, 2011; Shen and Scheiffele, 
2010; Siddiqui and Craig, 2010; Tallafuss et al., 2010). Maturation of synapses 
involves the pruning of inappropriate connections, stabilization of pre- and 
postsynaptic components, and formation of appropriate morphological 
specializations. Finally, maintenance and plasticity are required at sites of 
contact for proper function (Fu et al., 2011; Shen and Scheiffele, 2010). The 
improper formation and function of synapses can have devastating 
consequences for the adult brain. Malformations in synaptic formation and 
maturation are implicated in a wide variety of disease including Angelman 
syndrome, autism spectrum disorders, neuropathic pain, anxiety disorders, and 
Alzheimer’s disease (Mabb et al., 2011; Penzes et al., 2011; Sloniowski and 
Ethell, 2011; Sudhof, 2008; van Spronsen and Hoogenraad, 2010) (see Glossary 
for definitions).  
Excitatory synaptic transmission is mediated by α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)-type (Bredt and Nicoll, 2003; Kessels 
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and Malinow, 2009) and N-Methyl-d-aspartate (NMDA)-type (Lau and Zukin, 
2007; Perez-Otano and Ehlers, 2005) glutamate receptors. AMPARs and 
NMDARs are directed to the cell surface and synaptic sites by both neuronal 
activity and intermolecular interactions. At synaptic sites, glutamate receptors are 
dynamically regulated and changes in the size and number of AMPARs and 
NMDARs at synaptic sites are thought to underlie the expression of synaptic 
plasticity (Groc et al., 2009; Henley et al., 2011; Kerchner and Nicoll, 2008; Lu 
and Roche, 2011; Yashiro and Philpot, 2008). Many of the molecular 
mechanisms governing glutamate receptor trafficking, retention, and 
maintenance at synaptic sites are well characterized. Especially important are 
associations of glutamate receptors with scaffolding proteins such as PSD-95 
and GRIP, and with synaptic adhesion molecules such as EphBs, neuroligins, 
and ErbBs (McMahon and Diaz, 2011; Siddiqui and Craig, 2010; Tallafuss et al., 
2010). Dynamic glutamate receptor trafficking is not only important for normal 
brain function, but deficits in trafficking are associated with diseases including 
Alzheimer’s disease, addiction and schizophrenia (Lau and Zukin, 2007; Opazo 
and Choquet, 2010).  
Numerous cell signaling and adhesion molecules coordinate the 
differentiation, morphological changes, and precise organization of proteins 
required to generate a functional synapse (Dalva et al., 2007; McMahon and 
Diaz, 2011; Shen and Scheiffele, 2010; Siddiqui and Craig, 2010; Tallafuss et al., 
2010). An important member of these multifunctional synaptogenic molecules are 
the EphBs (Chen et al., 2011; Klein, 2009; Lai and Ip, 2009; Sloniowski and 
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Ethell, 2011). The EphBs are part of the larger Eph (erythropoietin-producing 
hepatocellular carcinoma) family of receptor tyrosine kinases (RTKs), which is 
the largest family of RTKs in the human genome. The Eph receptors are divided 
into two classes (A and B) by their ability to bind their membrane-attached ephrin 
ligands. In mammals there are nine members of the EphA class (A1-A8, A10) 
and five members of the EphB class (B1-B4, B6) (Klein, 2009). Ephrin-As (A1-
A5) are attached by a Glycophosphatidylinositol (GPI) anchor, whereas ephrin-
Bs (B1-B3) contains a short intracellular signaling domain (Egea and Klein, 
2007). For the most part, EphAs specifically bind ephrin-A ligands, and EphBs 
bind ephrin-B ligands. However, EphA4 has a high binding affinity for ephrin-B 
ligands, and EphB2 binds ephrin-A5 (Flanagan and Vanderhaeghen, 1998; 
Himanen et al., 2004). Generally, Ephs act to coordinate signaling events that 
occur between cells including: axon guidance, synaptogenesis, dendritic filopodia 
motility, neural crest cell and stem cell migration, angiogenesis, cell sorting at 
compartmental boundaries, bone formation, and synaptic plasticity (Genander 
and Frisen, 2010; Klein, 2009; Lai and Ip, 2009; Pasquale, 2008; Suetterlin et al., 
2011).  
This review will focus on the role of EphB/ephrin-B signaling mechanisms 
that control NMDAR function and localization. We will highlight how EphB-
dependent misregulation of NMDARs contributes to synaptic diseases such as 
neuropathic pain, anxiety disorders, and Alzheimer’s disease.   
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EphBs and Synapse Formation 
In vivo and in vitro evidence suggest that there is a rapid phase of 
synapse addition early in neuronal development followed by a plateau phase, 
and later synaptic loss as contacts begin to mature (Kayser et al., 2008; Papa et 
al., 1995; Ziv and Smith, 1996). During the phase of rapid synaptogenesis, 
dendrites and axons have motile filopodia that appear to search for contacts. 
Different molecules control specific aspects of new synapse accumulation: 
SynCAM1 restricts the number of filopodia at axonal growth cones (Stagi et al., 
2010), neuroligin stabilizes dendritic filopodia (Chen et al., 2010), and EphBs 
controls dendritic filopodia motility enabling synapse formation (Kayser et al., 
2008). EphB-dependent synapse formation driven by filopodia motility requires 
ephrin-B binding, EphB kinase activity, and p21 activated kinase (PAK) (Kayser 
et al., 2008). These data are consistent with a model (Figure 1) in which filopodia 
find appropriate target axons, and motility subsequently decreases leading to 
stabilized synaptic contacts. Next, through transynaptic interactions with ephrin-
Bs, EphBs initiate a program of pre- and postsynaptic maturation through both 
extracellular protein-protein interactions and intracellular signaling.  
EphBs organize functional presynaptic specializations by binding specific 
ephrin-B ligands at sites of contact between dendrites and axons (Kayser et al., 
2006; McClelland et al., 2009). The number of presynaptic specializations is 
decreased by knockdown of postsynaptic EphB2 or presynaptic ephrin-B1 or 
ephrin-B2 (Ethell et al., 2001; Kayser et al., 2006; McClelland et al., 2009). 
Ephrin-B1 and ephrin-B2 organize presynaptic terminals through interactions with 
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presynaptic scaffolding molecules containing PDZ-binding domains. Specifically, 
ephrin-Bs recruit the adaptor protein syntenin-1 to new presynaptic sites 
(McClelland et al., 2009). Mixed culture assays indicate that the syntenin-1 is 
required in contacting axons for EphB-dependent presynaptic specializations 
(McClelland et al., 2009). Syntenin-1 could then recruit synaptic vesicles by 
interacting with ERC2/CAST1/RM1 (Ko et al., 2006). Together, these results 
provide a direct link (Figure 1.1) from postsynaptic EphB through presynaptic 
ephrin-B1/2 and syntenin-1 to formation of functional presynaptic specializations.  
EphBs regulate maturation of postsynaptic sites by inducing spine 
morphogenesis and recruiting neurotransmitter receptors. Consistent with their 
importance in these functions, in EphB1−/−, 2−/−, 3−/− triple knockout (TKO) mice 
there is a significant reduction in excitatory synapse density (~40% cortex, ~25% 
hippocampus) (Henkemeyer et al., 2003; Kayser et al., 2006). The effects of 
EphBs on spine development appear similar in cortex and hippocampus. Spine 
density and postsynaptic density size are reduced in the hippocampus of EphB 
TKO animals (Henkemeyer et al., 2003). Similarly, synapse and spine density 
are decreased in the cortex of EphB TKO, but not DKO animals (Kayser et al., 
2006). In the cerebellum it appears that EphBs may act differently because EphB 
TKO mice have increased numbers of spines (Cesa et al., 2011). However, these 
may be so called “naked” spines that lack presynaptic specializations and are 
associated with defective synaptogenesis in the cerebellum (Hendelman and 
Aggerwal, 1980). More work will be need to resolve the mechanisms mediating 
these differences in EphB function. 
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Changes in spine and synapse density in the cerebral cortex are likely due 
to the decreases in dendritic filopodia motility (Kayser et al., 2008). Filopodia 
motility is impaired in cortical slices from EphB TKO, but not DKO animals 
(Kayser et al., 2008). Interestingly in cultured hippocampal neurons, expression 
of any EphB is sufficient to rescue defects in synapse development (Henkemeyer 
et al., 2003). This finding suggests that any EphB is sufficient to initiate EphB-
dependent synaptogenesis. Similarly, re-expression of EphB2 in EphB TKO 
slices rescues deficits in synapse density and spine formation (Kayser et al., 
2006). Although EphBs may play redundant functions, individual EphBs appear 
to exert their effects on specific circuits or domains of neurons. The pattern of 
EphB expression in the hippocampus reflects the possibility of localized function: 
EphB2 and EphB3 are expressed in CA1, and EphB2 and EphB1 are expressed 
in CA3 (Henderson et al., 2001; Henkemeyer et al., 2003; Liebl et al., 2003). In 
the cortex, EphBs appear to preferentially affect dendritic protrusions in basal 
dendrites of pyramidal neurons (Kayser et al., 2011). Together, these finding 
suggest that in addition to regulating synapse formation, specific EphB family 
members may have selective functions in different brain regions.  
EphBs control neuronal morphology and motility by modulation of the actin 
cytoskeleton. EphBs exert these effects through GTPases such as Rho, Rac1, 
and Cdc-42 (Klein, 2009; Sloniowski and Ethell, 2011), by activation of the actin-
severing protein cofilin (Shi et al., 2009; Simon et al., 2009), and by the 
phosphorylation of the cell surface proteoglycan syndecan-2 (Ethell et al., 2001). 
A principle mechanism enabling EphBs to signal to the actin cytoskeleton is by 
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interacting with guanine exchange factors (GEFs), which accelerate the 
exchange of GDP for GTP (Klein, 2009; Sloniowski and Ethell, 2011). EphBs 
interact directly with GEFs such as Rho/Rac1-GEF Kalirin-7(Penzes et al., 2003), 
Rac1-GEF Tiam1 (Tolias et al., 2005; Tolias et al., 2007), and with Rho-GEF 
intersectin-1 through the adaptor protein Numb (Irie and Yamaguchi, 2002; 
Nishimura et al., 2006) recruiting these proteins to synapses and spines. In 
addition to their interaction with EphBs, intersectin-1 and Tiam1 can associate 
directly with NMDARs at synaptic sites to modulate receptor function (Irie and 
Yamaguchi, 2002; Nishimura et al., 2006; Tolias et al., 2005; Tolias et al., 2007). 
By linking to both Rac1 and Rho/Cdc-42 signaling pathways, EphBs can prevent 
depolymerization of the actin cytoskeleton. Preventing depolymerization drives 
synapses to mature and form mushroom shaped spines.  
In addition to coupling with positive regulators of synapse development, 
the synaptogenic activities of EphBs are subjected to a specific negative 
regulatory pathway. EphB activity is inhibited by binding the RhoA-GEF called 
Ephexin5 (Margolis et al., 2010). Ephexin5’s inhibition of EphB is released by 
ephrin-B activation of EphBs (Margolis et al., 2010). EphB activation causes 
phosphorylation of Ephexin5 on tyrosine-361 that enables the E3 ligase Ube3A 
to bind and ubiquitinate Ephexin5 (Margolis et al., 2010). Then ubiquitinated 
Ephexin5 undergoes proteasomal degradation, which allows EphBs to initiate 
synapse formation (Margolis et al., 2010). Notably, Ephexin5 knockout mice have 
increased synapse number (Margolis et al., 2010). Consistent with a negative 
regulatory function, overexpression of Ephexin5 reduces the number of excitatory 
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synapses (Margolis et al., 2010). Intriguingly, these findings link EphBs to human 
cognitive disorders: Angelman syndrome (AS) and Autism Spectrum Disorders 
(ASDs). Mutations or deletions of Ube3A are a cause of AS and duplications in 
the 5q11–q13 locus, which includes Ube3A, are found in genetic forms of ASDs 
(Mabb et al., 2011). Whether these diseases result from a misregulation of 
Ube3a function during synapse maturation (Yashiro et al., 2009), or regulation of 
AMPAR trafficking (Greer et al., 2010) remains to be elucidated. However, these 
findings place EphB signaling pathways in a key position to regulate diseases of 
cognitive dysfunction. 
As neurons mature, synapse addition slows while synaptic function 
becomes more stable and reliable (Papa et al., 1995; Ziv and Smith, 1996). 
EphBs also act as central organizers to coordinate these events. In the mature 
cerebral cortex and hippocampus, both immuno-electron microscopy and 
biochemical fractionation experiments indicate that EphBs are localized to the 
pre- and postsynaptic terminal suggesting that EphBs continue to play a role at 
mature synapses (Bouvier et al., 2008; Buchert et al., 1999; Nolt et al., 2011). 
However, EphBs are not critical to maintain synapse density once synapses have 
formed (Kayser et al., 2008). Thus, if EphB2 expression is reduced with shRNA 
knockdown at mature synapses (DIV14-21), there is no effect on synapse density 
(Kayser et al., 2008). Moreover, overexpression of EphB2 in neurons from TKO 
mice rescues synapse density early in development (DIV3) but fails to rescue 
synapse formation when expressed later (DIV10) (Kayser et al., 2008). These 
findings suggest that EphBs control synaptogenesis selectively during the rapid 
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phase of synapse addition (DIV0-14) (Kayser et al., 2008). Interestingly, 
Ephexin5 expression is down regulated as EphBs begin to function to control 
synaptogensis (DIV7-8) (Margolis et al., 2010; Sahin et al., 2005) suggesting a 
possible restrictive mechanism. After synapses begin to mature (>DIV14), EphBs 
are not required for synapse maintenance and function of EphBs appears to shift 
to the regulation of synaptic function. While it remains to be determined what 
causes this change in EphB function, the role of EphBs in the mature brain is the 
focus of the next two sections of this review.  
  
EphB Trafficking and Regulation of AMPARs 
Receptors undergo regulated delivery to the plasma membrane and 
removal from the cell surface (Andersson, 2011; Conner and Schmid, 2003). For 
EphBs, receptor trafficking is critical to coordinate pre- and postsynaptic 
formation, and to regulate glutamate receptor function, while EphB receptor 
cleavage and internalization may mediate detachment of contacts and repulsion 
(Cowan et al., 2005; Egea and Klein, 2007; Lin et al., 2008; Litterst et al., 2007; 
Marston et al., 2003; Pitulescu and Adams, 2010; Zimmer et al., 2003). Although 
the mechanisms controlling EphB delivery to the membrane are poorly 
understood, work from non-neuronal and neuronal systems demonstrate that 
EphB membrane localization is tightly regulated (Egea and Klein, 2007; Fasen et 
al., 2008; Pitulescu and Adams, 2010). The key points of regulation are EphB 
receptor cleavage, internalization, and degradation (Pitulescu and Adams, 2010). 
Activated EphBs undergo proteolytic processing by ADAM10 and matrix 
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metalloproteinases (MMPs) (Lin et al., 2008; Litterst et al., 2007). To enable 
events such as growth cone collapse, the EphB2 receptor can be endocytosed 
via clathrin-mediated mechanisms, ubiquitinated, and targeted for degradation in 
the proteasome (Andersson, 2011; Fasen et al., 2008; Margolis et al., 2010; 
Pitulescu and Adams, 2010). Interestingly, the entire EphB-ephrin-B receptor-
ligand complex can be trans-endocytosed bidirectionally into the EphB or ephrin-
B expressing cell (Marston et al., 2003; Zimmer et al., 2003). Although what 
differentiates amoung these various modes of receptor trafficking is poorly 
understood, receptor trafficking is clearly important for regulation of synaptic 
proteins.  
      EphBs can regulate both surface localization and function of AMPA-
type glutamate receptors (Figure 1.2). In cultured neurons, EphB2 and AMPARs 
associate by each binding to the PDZ-adaptor proteins PICK1 and GRIP1 
(Contractor et al., 2002; Torres et al., 1998). Both PICK1 and GRIP1 bind directly 
to AMPARs and are thought to act in opposition: GRIP1 promotes AMPAR 
surface retention, while PICK1 acts to remove AMPARs from the cell surface (Lu 
and Roche, 2011). However, a link between PICK1, EphB2 and AMPAR 
trafficking has not been shown (Calo et al., 2006). Instead, PICK1 appears to 
cluster EphB/ephrin-Bs at synaptic sites (Torres et al., 1998). In neurons, GRIP1 
appears to help localize both EphB2 and GluA2-containing AMPARs to the 
dendritic plasma membrane (Hoogenraad et al., 2005). Consistent with a role for 
EphBs in control of AMPAR trafficking, EphBs are important for retention of 
AMPARs in the receptor recycling pool (Kayser et al., 2006). This control of 
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AMPAR trafficking requires ephrin-B activation, the PDZ-binding domain, and 
kinase activation of EphB2 receptors (Kayser et al., 2006). EphB-dependent 
internalization of AMPARs likely relies on synaptojanin-1, which is 
phosphorylated by EphB2, promoting its activation (Irie et al., 2005). Since 
GRIP1 and PICK1 preferentially interact with the GluA2 subunits, which regulate 
calcium influx through AMPARs (Bredt and Nicoll, 2003; Kessels and Malinow, 
2009; Lu and Roche, 2011), these findings suggest that EphB receptors may be 
an important regulator of AMPAR subunit composition at synaptic sites.  
Physiological evidence demonstrates that EphBs modulate AMPAR 
function at synapses. The AMPAR-dependent component of mEPSC in mature 
(DIV21-23) neurons can be increased by EphB2 overexpression, and reduced by 
knockdown of EphB2 (Nolt et al., 2011). However, consistent with the different 
developmental functions of EphB2, knockdown of EphB2 in younger neurons has 
no effect on mEPSC amplitude (Kayser et al., 2006). The changes in AMPAR 
currents may be explained by the observation that levels of GluA2 in EphB TKO 
mice are unchanged at cortical synapses compared to wild-type mice (Nolt et al., 
2011). These observations suggest that EphBs may act to regulate synaptic 
AMPAR subunit composition rather than overall number. However, additional 
work is required to demonstrate the overall impact of EphB-dependent regulation 
of AMPARs. 
 14
EphBs and NMDA Receptors 
 EphB receptors regulate multiple facets of NMDAR surface localization, 
function, and downstream signaling. EphBs and NMDARs colocalize at synaptic 
sites, and mice lacking EphB2 have reduced levels of NMDARs at synapses in 
the hippocampus and cortex (Dalva et al., 2000; Henkemeyer et al., 2003; 
Kayser et al., 2006). Upon ephrin-B binding, EphBs interact directly with 
NMDARs through their extracellular domains (Attwood et al., 2011; Dalva et al., 
2000; Grunwald et al., 2001; Slack et al., 2008). However, the specific region of 
the extracellular domains involved in this interaction for both EphB2 and the 
NMDAR remains to be identified. Ephrin-B activation of EphBs not only induces 
the EphB-NMDAR interaction, but also potentiates NMDAR function (Dalva et al., 
2000; Takasu et al., 2002). Ephrin-B activation of the EphB-NMDAR interaction 
causes src kinase-dependent phosphorylation of the NR2B subunit of the 
NMDAR at tyrosines 1226, 1336 and 1472 (Takasu et al., 2002). Phosphorylation 
at tyrosine 1472 of NR2B-containing NMDARs blocks binding of the AP-2 
complex preventing clathrin-mediated endocytosis (Chen and Roche, 2007). 
Thus, the EphB-NMDAR interaction can increase the surface retention of NR2B-
containing NMDARs. Additionally, EphB2 can increase calcium influx through 
NR2B-containing NMDARs by decreasing calcium-dependent inactivation rates 
(Nolt et al., 2011; Takasu et al., 2002). Notably, EphB2 does not appear to act 
similarly on calcium inactivation of NR2A-containing NMDARs (Nolt et al., 2011). 
The enhanced calcium influx through the NMDAR also results in enhanced 
downstream gene transcription (Takasu et al., 2002). In EphB TKO mice there is 
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a reduction in NR2B at synaptic sites in cerebral cortex and cultured 
hippocampal neurons (Henkemeyer et al., 2003; Kayser et al., 2006). At the 
mature synapse, knockdown of EphB2 causes a reduction in mEPSC amplitude 
and NMDAR-dependent decay time (Nolt et al., 2011). Similarly, overexpression 
of EphB2 causes an increase in mEPSC amplitude and NMDAR-dependent 
decay time (Nolt et al., 2011). This study specifically implicated NR2B-containing 
NMDAR being trafficked onto the surface at synaptic sites after ephrin-B 
activation in the mature brain (Nolt et al., 2011). Interestingly, a recent report 
suggests that EphBs may also interact with and regulate the function of nAChRs 
(Liu et al., 2008), suggesting the possibility that EphBs play a larger role in the 
regulation of neurotransmitter function than previously appreciated. Regardless, 
these data support a model (Figure 1.2) where EphBs are not required for 
synapse maintenance, but are instead critical regulators of NMDAR localization, 
function, and signaling in the mature brain.  
The extracellular domain mediated EphB-NMDAR interaction has also 
been implicated in NMDAR-dependent forms of hippocampal synaptic plasticity, 
particularly for EphB2. EphB2−/− null mice have reduced synaptic NMDAR, but 
not AMPAR currents, reduced long-term potentiation (LTP), and long-term 
depression (LTD) (Grunwald et al., 2001; Henderson et al., 2001). Importantly, 
these effects are rescued by transgenic expression of a truncated EphB2 
receptor lacking its kinase domain (Grunwald et al., 2001). These data suggest 
that EphB-dependent regulation of synaptic plasticity requires the extracellular 
domain-mediated interaction between EphB and the NMDAR. Consistent with 
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these deficits in synaptic plasticity, EphB2−/− mice perform poorly in behavioral 
learning tasks such as the Morris water maze (Grunwald et al., 2001). Taken 
together, these data imply that the EphB-NMDAR interaction is required for 
proper synaptic function, synaptic plasticity, and behavior. 
 
EphB-NMDAR Interaction in Disease 
 There is a growing body of evidence that suggests a synaptic origin for 
diseases of neuronal development and in the aging brain. Proper NMDAR 
synaptic localization and function has long been placed at the epicenter of these 
synaptopathies. By direct interaction and functional modulation of the NMDAR, 
EphBs and ephrin-Bs appear to be key synaptic regulators implicated in many of 
these diseases.  Specifically, we will discuss three examples of EphB/ephrin-B 
signaling in disease: neuropathic pain, anxiety disorders and Alzheimer’s disease 
(AD).  
 
Neuropathic pain and hyperalgesia 
 Control of NMDAR function by EphBs plays a critical role in the 
enhancement of pain. In the spinal cord and periphery, neuropathic pain (chronic 
pain caused by injury) and hyperalgesia (increased sensitivity to painful stimuli) 
are linked to EphB1/ephrin-B signaling through modulation of NMDAR function. 
Remarkably, in four different models of pain - thermal hyperalgesia, 
spontaneous, crush, and mechanical allodynia - EphB1 functions similarly 
(Figure 1.3). Despite differences in models, neurons, and brain regions 
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mediating pain, downstream signaling mechanisms are well conserved. 
Therefore, EphB-dependent modulation of NMDAR function may be an important 
target for the control of pain.  
Induction of neuropathic pain in the spinal cord is mediated by 
dysregulation of excitatory glutamatergic synapses between the axons from 
sensory neurons in the dorsal root ganglia (DRG) and second-order neurons in 
the dorsal horn (DH) (Kuner, 2010). At the DRG-DH synapses, induction of 
neuropathic pain depends on NMDAR function (Kuner, 2010). Specifically, 
NMDAR dependent LTP-like changes in synaptic strength are suggested as the 
cellular mechanism for pain amplification and hyperexcitability of the DRG-DH 
circuit (Kuner, 2010).  
The levels of ephrin-B1, ephrin-B2, and EphB1 expression are 
upregulated after injury in the DRG and spinal cord suggesting that these 
proteins are involved in the response to pain (Kobayashi et al., 2007; Song et al., 
2008a; Song et al., 2008b). Indeed, intrathecal injection of EphB1/B2-Fc or 
shRNA against ephrin-B2 prevents EphB/ephrin-B signaling, and decreases 
hyperalgesia and mechanical allodynia suggesting a role for EphB signaling in 
regulation of pain after injury (Kobayashi et al., 2007; Song et al., 2008b). 
Moreover, injection of ephrin-B2-Fc to activate EphBs induces pain (Battaglia et 
al., 2003; Conover et al., 2000; Slack et al., 2008; Song et al., 2008b).  
EphB-dependent modulation of NMDAR function appears to drive EphBs’ 
function in pain responses (Figure 1.3). Similar to the cerebral cortex, injury 
induced upregulation of EphB1 and ephrin-B expression appear to directly 
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modulate the function of NR2B-containing NMDARs. EphB-dependent 
hyperalgesia depends upon tyrosine phosphorylation of NR2B in the spinal cord 
(Guo et al., 2002), while blocking NMDARs and src kinase activity is sufficient to 
prevent hyperalgesia (Battaglia et al., 2003; Slack et al., 2008; Song et al., 
2008b). As expected from work on the EphB-NMDAR interaction, src kinase 
exerts its effects by phosphorylating NR2B at Y1472 (Dalva et al., 2000; Slack et 
al., 2008; Takasu et al., 2002). EphB-dependent regulation of NMDAR function 
also appears to regulate the changes in synaptic strength thought to underlie 
induction and maintenance of hyperalgesia. In the spinal cord, EphB activation 
lowers the threshold for LTP induction and increases phosphorylation of NR2B-
containing NMDARs (Battaglia et al., 2003; Song et al., 2008b). Moreover, 
inhibition of EphB signaling blocks pain-induced activity-dependent gene 
transcription of the immediate early gene c-Fos (Battaglia et al., 2003; Song et 
al., 2008b). These findings suggest that EphB/ephrin-B signaling is critical for 
suppressing the injury-induced hyperexcitability of the DRG-DH circuit.  
EphB-dependent neuropathic hyperalgesia appears to be mediated 
specifically by EphB1. EphB1 is expressed at high levels in the spinal cord, and 
EphB1-/- and EphB1+/- mice have significantly reduced thermal hyperalgesia and 
pain-induced hyperexcitablity of DH neurons (Han et al., 2008; Liu et al., 2009). 
Consistent with the importance of EphB1 in control of pain sensitivity, EphB1-/- 
mice show defects in enhancement of pain after morphine-induced withdraw 
(Han et al., 2008). EphB1 appears to be the only EphB receptor required for 
ephrin-B1 induced hyperalgesia because treatment with ephrin-B1-Fc has no 
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effect on pain sensitivity in EphB1-/- or EphB1+/- mice (Han et al., 2008). These 
changes in hyperalgesia in EphB1-/- mice are linked to NMDAR-dependent 
increases in p-CaMKII, p-ERK and p-CREB and the induction of c-fos expression 
(Han et al., 2008; Liu et al., 2009). Interestingly, EphB1 upregulation after injury 
appears to be dependent on MMP-2/9, although the specific signaling 
mechanisms remain to be determined (Liu et al., 2011).  
The EphB-dependent modulation of NMDAR function is also critically 
important in pain sensitivity outside of the spinal cord in the periphery. As in the 
spinal cord, in the peripheral nervous system injection of ephrin-B1-Fc, which 
activates EphBs, induces hyperalgesia dependent on NMDARs (Cao et al., 2008; 
Guan et al., 2010; Ruan et al., 2010). This leads to increased c-fos expression 
and activation of NMDAR-dependent phosphorylation of two pathways: MAPKs 
(p-p38, pERK and pJNK) (Cao et al., 2008; Ruan et al., 2010) and PI3K, Akt, and 
ERK (Guan et al., 2010). Taken together, these results suggest that in the 
periphery a similar mechanism for hyperalgesia occurs with EphB1 upregulation, 
NMDAR-dependent phosphorylation of targets required for synaptic plasticity, 
and changes in gene transcription. 
 Similar to the central and peripheral pain mechanisms, the EphB-
dependent modulation of NMDAR function is implicated in cancer-induced pain 
for both bone and pancreatic cancer. In models of cancer-induced pain, 
expression of ephrin-B1 and EphB1 are upregulated (Dong et al., 2011; Liu et al., 
2011; Orikawa et al., 2010). Here, the EphB-NMDAR interaction is also 
specifically implicated because blocking EphB1 signaling alleviates mechanical 
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allodynia (Liu et al., 2011). The mechanism for this alleviation is decreased 
activation of NR2B-containing NMDARs, which reduces the phosphorylation of 
downstream targets pSrc (Tyr418), pERK1/2, pCaMKII, and pCREB, and gene 
transcription of c-fos (Liu et al., 2011). The changes in EphB and ephrin-B1 
expression in cancer-induced pain are likely to be downstream of the 
inflammatory cytokines IL-1β, IL-6 and TNF-α (Dong et al., 2011). Consistent 
with this, inhibiting the CCK2/gastrin receptor with a drug (Z-360) reduces IL-1β 
levels, prevents upregulation of ephrin-B1 expression, and reduces NR2B 
phosphorylation in models of cancer pain (Orikawa et al., 2010). The observation 
that blocking EphB1 with EphB receptor bodies also alleviates morphine 
tolerance in models of bone cancer pain (Liu et al., 2011) suggests that 
modulating EphB receptor signaling may be a promising avenue for treating 
chronic pain. More broadly, there is extensive evidence linking EphB-dependent 
regulation of NMDAR function to the induction and expression of chronic pain.  
  
Anxiety 
 Emerging evidence links both regulation of EphB receptor cleavage and 
EphB-dependent regulation of NMDAR function to anxiety (Figure 1.4). Severe 
or sustained stress can result in changes to synaptic architecture and function 
mirroring those found after induction of synaptic plasticity, and lead to behavioral 
changes associated with fear and anxiety disorders (Lupien et al., 2009). The 
pathogenic plasticity involved in these changes requires NMDAR activation and 
increases neuronal activity in the hippocampus and amygdala (Lupien et al., 
 21
2009). Antagonists of NMDAR receptors can produce anxiolytic effects in animal 
models of anxiety like the elevated plus maze (Barkus et al., 2010). Several lines 
of evidence suggest that changes in the extracellular matrix mediated by 
proteolysis promote an anxiety response (Lohman et al., 2009; Matys et al., 
2004; Pawlak et al., 2003; Pawlak et al., 2005). The serine protease neuropsin 
(also known as kalikrein-related peptidase 8) is highly expressed in the 
hippocampus and amygdala (Chen et al., 1995). Furthermore, genetic variations 
in human neuropsin are associated with bipolar disorder and cognitive functions 
(Izumi et al., 2008). Neuropsin-deficient mice have defects in spatial working 
memory, impaired ability in the Morris water maze assay, and reduced long-
lasting LTP (Chen et al., 1995; Ishikawa et al., 2008b; Matsumoto-Miyai et al., 
2003; Tamura et al., 2006). In the amygdala, EphB2 and neuropsin colocalize 
and neuropsin expression is upregulated after stress (Attwood et al., 2011; Izumi 
et al., 2008). Furthermore, neuropsin upregulation and colocalization with EphBs 
in the amygdala result in cleavage of the EphB2 ectodomain (Attwood et al., 
2011; Izumi et al., 2008). Neuropsin-dependent cleavage of EphB2 decouples 
the EphB-NMDAR interaction, likely explaining the changes in NMDAR currents 
observed in neuropsin null mice (Attwood et al., 2011). Furthermore, injection of 
function blocking antibodies to EphB2 or neuroposin can prevent behaviorally 
stress-induced anxiety in the elevated plus maze task (Attwood et al., 2011). 
Taken together, these data suggest that targeting neuropsin-dependent cleavage 
of EphB2 is a potential strategy for treating stress-related and anxiety disorders.  
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In models of stress, EphBs appear to increase the amount of NMDAR 
currents at the synapse after neuropsin-dependent cleavage (Attwood et al., 
2011). One potential explanation for the molecular mechanism of these findings 
comes from the studies on γ-secretase cleavage of EphB2 (Litterst et al., 2007; 
Xu et al., 2009). Intriguingly, after MMP-dependent cleavage of the EphB2 
extracellular domain, the γ-secretase releases a kinase-active fragment in non-
neuronal cells (Xu et al., 2009). Expression of a soluble kinase active intracellular 
fragment was shown to phosphorylate NR2B subunits of NMDARs, resulting in 
increased NMDAR surface localization (Xu et al., 2009). Whether a similar 
mechanism plays a role in neurons remains to be determined. However, these 
non-neuronal experiments raise the possibility that EphBs may regulate NMDAR 
function both through direct interactions and by indirectly phosphorylating the 
NMDAR. It will be important to determine whether direct or indirect interactions 
between EphBs and the NMDAR are important for anxiety.  
 
Alzheimer’s disease 
 EphB-dependent modulation of NMDAR function appears to play a role in 
the pathogenesis of Alzheimer’s disease (AD). AD is a progressive 
neurodegenerative disorder characterized by declarative memory defects and 
dementia (Walsh and Selkoe, 2004). Among the many pathological changes 
seen in patient brains is the loss of excitatory synapses and increased neuronal 
death (Penzes et al., 2011; Selkoe, 2002). The reduction in synapse density in 
the cortex and hippocampus is found early during the onset of AD and correlates 
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with the level cognitive impairment (Penzes et al., 2011; Selkoe, 2002). These 
observations suggest that elucidating the underlying mechanisms causing 
deficits in synaptic function will be important to understanding the disease. AD 
patient data links EphBs and NMDARs with the observation that both EphB and 
NMDAR subunit expression is reduced early in AD progression (Ikonomovic et 
al., 1999; Simon et al., 2009; Sze et al., 2001). In addition, there are reduced 
levels of NR2 subunit phosphorylation in AD patient brains (Sze et al., 2001).  
Building on these observations in patients, work has focused on whether 
these effects on NMDAR expression are linked to prominent disease 
mechanisms such as amyloid-β (Wilcox et al., 2011). In patients with AD, the 
level of a 40- or 42-amino acid peptide called amyloid-β (Aβ) in the brain 
correlates with disease onset and progression (Wilcox et al., 2011). In mouse 
models and in cell culture, the presence of Aβ can cause NMDAR endocytosis, 
reduced surface expression of NMDARs, and reduced NMDAR currents (Snyder 
et al., 2005). Also in mouse models of AD, the Aβ-dependent reduction in EphB2 
expression levels occurs prior to detectable behavioral impairments (Simon et al., 
2009). Interestingly these effects appear more pronounced on NR2B-containing 
NMDARs (Snyder et al., 2005).  
Recently, a strong link has emerged between EphB2, Aβ, and Alzheimer’s 
disease through NMDAR phosphorylation and regulation at the plasma 
membrane (Figure 1.4). Consistent with experiments demonstrating reduced 
EphB2 expression levels in AD (Simon et al., 2009), Aβ binds to the extracellular 
FnIII domains of EphB2, causing receptor internalization and degradation (Cisse 
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et al., 2011). The functional consequence of the removal of EphB2 from the cell 
surface by Aβ appears to be reduced NMDAR surface expression (Cisse et al., 
2011). Furthermore, EphB2 depletion by knockdown or knockout, can phenocopy 
the Aβ-dependent reduction in NMDAR surface localization (Cisse et al., 2011; 
Nolt et al., 2011). Similarly, targeted knockdown of EphB2 in the dentate gyrus 
causes deficits in LTP and NMDAR (but not AMPAR) currents (Cisse et al., 
2011). These findings are consistent with previous observations on the effects on 
LTP in mice lacking EphB2 and on synaptic function following the knockdown of 
EphB2 in cortical neurons (Dalva et al., 2000; Grunwald et al., 2001; Henderson 
et al., 2001; Nolt et al., 2011). The effects of targeted knockdown of EphB2 in the 
dentate gyrus are mirrored in the hAPP overexpressing mouse (Cisse et al., 
2011). Not only does knockdown of EphB2 cause defects in LTP, but viral 
overexpression of EphB2 in the dentate gyrus of hAPP overexpressing mice 
rescues LTP and NMDAR current deficits to wild-type levels (Cisse et al., 2011). 
Remarkably, targeted overexpression of EphB2 in the dentate gyrus rescues 
hippocampal-dependent cognitive deficits in the Morris water maze in hAPP mice 
(Cisse et al., 2011). These effects were seen despite infection of a relatively low 
percentage of neurons in the dentate gyrus, suggesting that functional 
modulation of synapses for only a subset of neurons in a network can have 
significant effects on behavior. In summary, increasing neuronal EphB2 levels in 
hAPP mice reversed cognitive and behavioral defects associated with AD, while 
EphB2 knockdown appears to mimic many of the defects in NMDAR function in 
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these mice. Therefore, these findings suggest that Aβ may principally 
dysregulate synaptic and NMDAR function in AD.  
  
Conclusions and future directions 
EphBs regulate excitatory synapse development and function at 
mammalian synapses by controlling dendritic morphology and excitatory 
neurotransmitter receptor content. Dysfunction of EphB-dependent control of 
synaptic NMDAR function and surface localization appears to lead to profound 
synaptopathy including AD and pain. In each of these diseases, the role of 
EphBs is linked to direct extracellular interaction between EphB and the NMDAR. 
However, the domain mediating this interaction has yet to be identified (see 
Outstanding Questions). In anxiety, EphB-dependent regulation of NMDAR 
function is also important, but may be regulated by a different mechanism 
governed by the release of the EphB intracellular domain. However, in these 
three cases, EphB-dependent regulation of NMDAR function and surface 
localization has profound consequences. Given the potential significance for 
modulation of the EphB-NMDAR in treating human disease, understanding the 
mechanisms enabling these proteins to interact will be of significant importance.  
It will be especially important for future work to understand the 
extracellular nature of the EphB-NMDAR interaction.  One intriguing idea is that 
since the EphB-NMDAR interaction occurs in the extracellular space, the 
interaction may be dependent on an extracellular modification to either protein 
such as extracellular phosphorylation.  Phosphorylation of residues destined to 
 26
be extracellular has been shown to be critical to Drosophila limb and wing 
development in vivo (Ishikawa et al., 2008a).  Soluble and membrane-attached 
protein kinases have been found in neurons to regulate synaptic plasticity and 
aggregation of Aβ in AD patients (Chen et al., 1996; Fujii et al., 2000; Kumar et 
al., 2011; Redegeld et al., 1999).  Furthermore, the extracellular domain of 
EphB2 receptors is phosphorylated after ligand binding (D.S.S., T.A.N., S.I.S-C, 
and M.B.D., unpublished observations).  Thus, extracellular phosphorylation 
appears to an underappreciated mechanism for disease, and a potential modifier 
of the EphB-NMDAR interaction.   
In addition to EphBs, a number of other regulators of synapse 
development have developmental shifts in function. Focal adhesion kinase 
(Moeller et al., 2006; Shi et al., 2009), synCAM (Robbins et al., 2010), SALM1/2 
(Ko et al., 2006; Wang et al., 2006), and neuroligin/neurexin (Sara et al., 2005; 
Varoqueaux et al., 2006) all regulate synaptic function in more mature neurons, 
while controlling synaptogenesis early in development. These findings suggest 
that synaptic organizing proteins play dual functions, first to generate synapses 
and later to control their function. The dual function of these proteins could 
explain some of their complex linkage to disease. We propose that there may be 
sufficient redundancy in synaptogenic factors that most synapses are still able to 
form normally after malfunction of any one of these organizers. Once the circuitry 
begins to mature, however, each of these proteins is required for proper mature 
synaptic function and breakdowns in these molecules might then manifest as 
neuronal or cognitive dysfunction. Thus, a better understanding of these synaptic 
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organizing proteins is needed in three broad areas: 1) to investigate their 
functions in organizing synapses, 2) to appreciate how the activity of these 
molecules changes during development, and 3) to determine their different roles 
in controlling synaptic function. Exploring these three areas will be critical to 
discerning brain function and treating synaptopathies. 
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 Outstanding Questions Box: 
• What are the domains on EphBs and the NMDAR that mediates the EphB-
NMDAR interaction? 
• How do EphBs differentially regulate downstream GEF signaling 
pathways? 
• Does Ephexin-5 signaling contribute to autism spectrum disorders? 
• What is the mechanism for EphBs in regulating the function of NR2B-
containing NMDARs?   
• Do EphBs regulate AMPARs at mature synapses? 
• How is the activity of EphBs switched from synaptogenesis to synaptic 
maintenance? 
• Are there pharmacological agents that can block the EphB-NMDAR 
interaction for neuropathic pain? 
• What is the specific domain for Aβ binding to EphB2? 
• Are there pharmacological agents that can potentiate the EphB-NMDAR 
interaction for human cognitive disorders? 
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Glossary Box: 
Adaptor protein: A protein with multiple protein-protein interaction domains that 
recruits other proteins to a signaling complex. 
Allodynia: Pain caused by an innocuous stimulus.  
Alzheimer’s disease (AD): The most common form of dementia and a fatal 
neurodegenerative disease characterized by progressive memory loss, deficits in 
cognitive ability, and aberrant behavior.  
AMPA receptor: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type 
ionotropic glutamate receptor. 
Amyloid precursor protein (APP): Neuronal integral membrane protein 
concentrated at synaptic sites. Proteolysis of APP first extracellular by Beta-
secretase 1 (BACE1) then subsequently γ-secretase generates the 40-42 amino 
acid β-amyloid (Aβ) found in amyloid plaques of AD patients.  
Angelman syndrome (AS): Neuro-genetic disorder characterized by intellectual 
and developmental delay, lack of speech, seizures, and disorders in walking and 
balance.  
Crush pain model: Under deep anesthesia a spinal nerve distal to the dorsal 
root ganglions (DRG) is crushed. Thermal hyperalgesia or mechanical allodynia 
are then tested.  
Dendritic filopodia: Thin, motile dendritic process seeking axonal contact and 
thought to be the precursor of dendritic spine synapses. 
Dendritic spine: Mushroom-shaped extension from the dendrite equipped with 
neurotransmitter receptors to review local axonal input.  
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DH neuron: Integration of DRG inputs occurs in deep layers of spinal dorsal 
horn (DH) neurons. Output is carried to projection sites in the brain.  
DRG neuron: Nocioceptive afferents carrying noxious stimuli (heat, noxious 
cold, pressure, or chemicals) have glutamatergic synapses onto relay neurons in 
the dorsal root ganglion (DRG). 
GTPase: Small momeric G-proteins which binds and hydrolyzes guanosine 
triphosphate (GTP) to guanosine diphosphate (GDP) to stimulate downstream 
effectors. 
Guanine Nucleotide Exchange Factor (GEF): A protein which activates small 
monomeric GTPase activity by accelerating the exchange of guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP). 
Hyperalgesia: Increased sensitivity to pain. 
Hyperexcitability of DRG neurons: This is characterized by lower current 
threshold for action potentials, an increase in spontaneous activity, and repetitive 
discharge. 
Intraplantar injection: Injection into the plantar surface of the paw.  
Intrathecal injection: Injection into the arachnoid membrane of the spinal cord. 
Long-term Depression (LTD): Prolonged weakening of synaptic inputs. 
Long-term Potentiation (LTP): Prolonged strengthening of synaptic inputs. 
Mechanical Allodynia model: The plantar surface of each hind paw with a 
sharp, cylindrical probe. Incidence of foot withdraw is measured.  
Miniature synaptic current: Postsynaptic current evoked by single vesicle (or 
quanta) of neurotransmitter.  
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Neuropathic pain: Chronic pain caused by injury to the central or peripheral 
nervous system.  
NMDA receptor: N-Methyl-d-aspartate-type ionotropic glutamate receptor. 
PDZ-domain: A carboxy-terminal protein binding domain named after its three 
indentifying member proteins (PSD-95, Drosophila discs large protein and Zona 
Occludens-1). 
Receptor Trafficking: Active process by which receptor proteins are moved 
between regions of the cell, and on and off of the plasma membrane.  
Receptor tyrosine kinase (RTK): Cell-surface localized single-subunit 
transmembrane protein with intracellular catalytic activity to autophosphorylate 
and phosphorylate tyrosine residues on signaling substrates. 
RNA Interference (RNAi): A method using small hairpin RNAs (shRNAs) to bind 
the mRNA encoding a protein of interest to suppress its expression.  
Spontaneous pain model: Formalin is subcutaneously injected into a hind paw. 
Amount of time licking, biting, and flinching on the injected paw is assessed.  
Synaptic cell adhesion molecules (SAMs): Pairs of molecules that interact 
across adjacent cells to stabilize the initial contacts between axon and dendrite to 
form a synapse. SAMs also regulate function of existing synapses through 
protein-protein interactions and intracellular signaling cascades. 
Thermal hyperalgesia pain model: Animals are placed in a testing box with a 
temperature-controlled floor. A heat source is then focused on the hind paw 
flushed to the floor and foot withdraw latency is measured.  
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Figure Legends: 
 
Figure 1.1. EphBs regulate excitatory synapse development. (a) The domain 
structure of the EphB receptor: G - Gobular domain (purple). C - Cistine Rich 
domain (yellow), F – Fibronectin type III domains (light blue), K – Kinase domain 
(red), S – SAM domain (green), and P – PDZ binding domain (orange).   (b) 
Early in neuronal development (DIV0-10), EphB receptors direct formation of 
excitatory synapses by regulating motility of filopodia via p21 activated kinase 
(PAK) and receptor tyrosine kinase activity. (c) During the rapid phase of 
synapse addition (DIV7-14), EphBs interact in trans with ephrin-B1 or ephrin-B2 
expressed on axons of adjacent cells. This EphB/ephrin-B interaction activates 
EphB kinase activity, which removes inhibition of synapse formation by the 
specific negative regulator Ephexin-5. EphB activation phosphorylates Ephexin-
5, inhibiting RhoA-GTPase activity, and promoting ubuiqitination and 
proteasomal degradation of Ephexin-5 by the E3 ligase Ube3A.  To promote 
synapse maturation, EphB kinase activation recruits GEFs to hydrolyze GDP into 
GTP, activating Rho-GTPases that enable synapse formation through PAK. (d) 
Postsynaptically, EphBs directly cluster NMDA-type glutamate receptors (green) 
through an extracellular interaction, and cluster AMPA-type glutamate receptors 
(purple) via a PDZ-domain dependent interaction with GRIP1. Furthermore, 
EphBs modulate the change in morphology of the actin cytoskeleton into mature 
mushroom-shaped dendritic spines. Presynaptically, EphBs direct presynaptic 
differentiation by clustering ephrin-B1 and ephrin-B2 at presynaptic terminals. 
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The EphB/ephrin-B1/2 interaction recruits the adaptor protein syntenin-1 to these 
signaling complexes through the PDZ-binding domain of ephrin-Bs. Syntenin-1 
enables EphBs to recruit the machinery required for neurotransmitter release to 
presynaptic specializations.   
 
Figure 1.2. EphBs regulate glutamate receptor trafficking and function.  (a) 
EphBs regulate AMPAR trafficking through a PDZ-dependent interaction with 
GRIP1 and indirect interactions with synaptojanin-1 (Stj1), a phosphatidylinositol 
5'-phosphatase. If an EphB receptor is interacting with GRIP1, kinase activation 
by ephrin-Bs promotes AMPAR insertion into the membrane from the recycling 
pool. Alternatively, EphB kinase activation by ephrin-Bs can also promote 
AMPAR internalization by phosphorylation of synaptojanin-1, which activates 
clathrin-mediated endocytotic mechanisms. (b) After binding ephrin-B ligand, 
EphBs directly interact with NMDARs to regulate their synaptic surface 
localization and function. Activation of EphBs promotes insertion of NR2B-
containing NMDARs into the synaptic membrane of mature neurons. 
Furthermore, after activation, EphBs recruit src kinase to phosphorylate NR2B-
constaining NMDARs at Y1472 blocking binding of the AP-2 complex and 
clathrin-mediated endocytosis. Functionally, EphB activation decreases calcium-
dependent desensitization, mEPSC amplitude, and decay time of NR2B-
containing NMDAR. This increased calcium influx through NMDARs also leads to 
EphB-dependent increases in gene expression of c-fos.  
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Figure 1.3. EphBs and neuropathic pain.  (a) Under physiological pain 
conditions, ephrin-B and EphB1 expression remains low and NR2B-containing 
NMDAR signaling remains normal. (b) For pathological central pain, both ephrin-
Bs and EphB1 are upregulated. Activation of EphBs leads to recruitment and 
activation of src, insertion of NMDARs into the membrane, NR2B 
phosphorylation at Y1472, and increased calcium influx leading to c-fos gene 
transcription. (c) Pathological peripheral pain shares common mechanisms with 
central pain. However, three parallel signaling pathways have been well 
characterized leading to gene transcription of c-fos and CRE. First, src 
phosphorylates CamKII, which phosphorylates CREB causing nuclear 
translocation and CRE gene transcription. Second, PI3K is phosphorylated, 
which phosphorylates Akt, which phosphorylates ERK, which translocates to the 
nucleus to activate c-Fos gene transcription. Finally, JNK gets phosphorylated 
and activated, which phosphorylates p-38 and converges to activate ERK. (d) 
Pathological cancer-induced pain shares a remarkable number of the same 
mechanisms as pathological central and peripheral pain. Unique to cancer-
induced pain is that src kinase directly phosphorylates ERK to activate gene 
transcription of c-fos. Additionally, inflammatory cytokines TNFα, IL-6, and IL-1β 
are upregulated leading to hyperalgesia, and hyperexcitability of nerve afferents.  
 
Figure 1.4. EphBs and Synaptic Disease.  (a) Physiological EphB signaling 
affects both synaptic plasticity and synapse maturation. Ephrin-B activation of 
EphBs promotes the direct EphB- NMDAR interaction. This interaction modulates 
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NMDAR function by increasing calcium influx, inserting new NR2B-containing 
NMDARs into the membrane, and activating calcium-dependent gene 
transcription required for LTP. In anxiety disorders, there is a stress-induced 
upregulation of the serine protease neuropsin (also known as kalikrein-related 
peptidase 8). At the membrane, neuropsin cleaves the EphB receptor 
ectodomain, releasing the intracellular domain into the cytosol. This intracellular 
kinase may be active and able to phosphorylate downstream intracellular targets 
including NMDARs. Cleavage of the EphB ectodomain dissociates the EphB-
NMDAR interaction, leading to NMDAR internalization and activation of Fkbp51 
gene transcription in the nucleus. (b) In Alzheimer’s disease, there is an 
overabundance of soluble Aβ oligomers, which appear to bind directly to EphB2. 
The EphB2-Aβ interaction inhibits receptor activation and causes internalization 
and degradation of both EphBs and NMDARs. Degradation of EphB receptors 
inhibits their ability to retain NMDARs on the membrane potentially though the 
EphB-NMDAR interaction. Fewer NMDARs on the cell surface leads to 
decreased calcium influx and none of the changes in gene transcription required 
for LTP.  
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Figure 1.3 
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Abstract 
The development of central nervous system synapses requires precise 
coordination between presynaptic and postsynaptic components. The EphB 
family controls postsynaptic development by interacting with glutamate receptors 
and regulating dendritic filopodia motility, but how EphBs induce the formation of 
presynaptic specializations is less well understood. Here, we show that 
knockdown of presynaptic ephrin-B1, ephrin-B2, or syntenin-1, but not ephrin-B3, 
prevents EphB-dependent presynaptic development. Ephrin-B1, ephrin-B2, and 
syntenin-1 are clustered together with presynaptic markers, suggesting that 
these molecules function jointly in presynaptic development. Knockdown of 
ephrin-B1 or ephrin-B2 reduces the number of synaptic specializations and the 
colocalization of syntenin-1 with synaptic markers. Simultaneous knockdown of 
ephrin-B1 and ephrin-B2 suggests that they function independently in the 
formation of synaptic contacts, but act together to recruit syntenin-1 to 
presynaptic terminals. Taken together, these results demonstrate that ephrin-B1 
and ephrin-B2 function with EphB to mediate presynaptic development via 
syntenin-1.  
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Introduction 
 The EphB family of receptor tyrosine kinases directs postsynaptic 
development by interacting with NMDA- and AMPA-type glutamate receptors, 
controlling dendritic filopodia motility, and regulating spine formation (Dalva et al., 
2000; Kayser et al., 2006; Kayser et al., 2008). EphBs can also signal trans-
synaptically to induce presynaptic development, suggesting that EphB receptors 
are capable of coordinating the development of both presynaptic and 
postsynaptic compartments (Kayser et al., 2006). However, the mechanisms by 
which EphBs induce presynaptic development are not well described. The 
ligands for EphBs are the ephrin-Bs, a family of three (ephrin-B1–B3) 
transmembrane molecules that, in addition to “forward” signaling through the 
activation of EphBs, can also signal in the “reverse” direction through intracellular 
phosphotyrosines and a C-terminal PDZ-binding domain. Ephrin-Bs have 
recently been shown to regulate presynaptic development in the Xenopus tectum 
(Lim et al., 2008) and are expressed in mouse cortex (Lein et al., 2007; Migani et 
al., 2007, 2009; Tang et al., 1997). Although it is thought that ephrin-Bs might 
have unique functions at the synapse (Aoto and Chen, 2007; Essmann et al., 
2008; Grunwald et al., 2004), whether particular ephrin-Bs interact with 
postsynaptic EphBs to regulate synapse development in the mammalian CNS, 
and what the downstream mechanisms are that mediate this process, are not 
known.  
 The syntenin family consists of two (syntenin-1 and syntenin-2) tandem 
PDZ domain-containing proteins implicated in a number of cellular processes 
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such as trafficking, signaling, and cancer metastasis (Beekman and Coffer, 
2008). Initially identified as binding partners for the heparan sulfate proteoglycan 
syndecan (Grootjans et al., 1997), syntenins are comprised mainly of two PDZ 
domains that enable self-association and interactions with a number of 
synaptically localized transmembrane molecules such as glutamate receptors, β-
neurexin, SynCAM, and ephrin-Bs (Biederer et al., 2002; Grootjans et al., 2000; 
Hirbec et al., 2002; Koroll et al., 2001; Lin et al., 1999; Torres et al., 1998). In 
addition, syntenin-1 may regulate the organization of presynaptic active zones 
through interactions with the ERC/CAST family of active zone molecules (Ko et 
al., 2006).  
 Here, we show that two members of the ephrin-B family (ephrin-B1 and 
ephrin-B2) function to mediate EphB-dependent presynaptic development via 
PDZ-binding domain-dependent interaction with syntenin-1. Simultaneous 
knockdown of ephrin-B1 and ephrin-B2 suggest that these molecules function 
independently in the formation of synapses, but function together in the 
localization of syntenin-1 to synaptic specializations.  
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Results 
 
Ephrin-B Family Members Are Required for EphB2-Dependent Presynaptic  
Development. 
 A presynaptic role for ephrin-Bs has been suggested by the finding that 
EphB-expressing non-neuronal cells can induce presynaptic development 
(Kayser et al., 2006). To determine whether EphB-dependent presynaptic 
induction is mediated by specific presynaptic ephrin-B family members, we asked 
whether non-neuronal cells expressing EphB2 could induce presynaptic 
specializations when ephrin-B expression is reduced in axons by RNAi-mediated 
knockdown. We generated constructs encoding 19-nt shRNAs targeting 
individual ephrin-B family members and confirmed that these constructs were 
capable of reducing the expression of the target molecule (Figure 2.1F and 
Supplementary Figure 2.1). We transfected shRNA constructs into days in vitro 
(DIV) 3 cortical neurons along with a GFP-tagged version of the presynaptic 
vesicle marker synaptophysin (syn-GFP) to label transfected axons. At DIV9, 
transfected neurons were cocultured with HEK293T cells expressing either FLAG 
epitope-tagged EphB2 (fEphB2) or red fluorescent protein (RFP) and fixed 16–18 
h later. Because our transfection efficiency in neurons was low (<1%), expression 
of syn-GFP revealed easily identifiable stretches of axons with discrete puncta of 
syn-GFP that colocalized with the excitatory presynaptic marker VGlut1. Labeled 
HEK293T cells were scattered throughout the culture and occasionally found to 
be contacting a syn-GFP-expressing axon. To determine the effect of transfected 
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HEK293T cells on presynaptic development, we compared the linear density of 
syn-GFP in the stretch of axon contacting the HEK293T cells to the density in the 
adjacent axon region (see SI Text).  
 In control neurons coexpressing syn-GFP with the shRNA vector control, 
the density of syn-GFP in axon regions contacting RFP-expressing HEK293T 
cells was similar to that in adjacent regions, resulting in a density ratio near 1.0 
(Figure 2.1A and B). However, consistent with our previous findings (Kayser et 
al., 2006), syn-GFP puncta density increased by ≈1.5-fold underneath EphB2-
expressing HEK293T cells (Figure 2.1A and B). These results confirm that 
EphB2-expressing HEK293T cells can induce presynaptic differentiation in 
segments of single axons.  
 To test whether this process is mediated by presynaptic ephrin-Bs, 
neurons were cotransfected with syn-GFP and shRNA constructs targeting each 
ephrin-B family member (Figure 2.1F and Supplementary Figure 2.1). In axons 
from neurons transfected with shRNA targeting ephrin-B3, HEK293T cells 
expressing EphB2 caused a significant increase in syn-GFP density similar to 
that seen in control neurons (Figure 2.1A and B). However, in axons from 
neurons expressing shRNA targeting ephrin-B1 or ephrin-B2, HEK293T cells 
expressing EphB2 failed to induce presynaptic vesicle clustering (Figure 2.1A-
C). To confirm that the effect of these shRNAs are specific, we determined that 
blockade of EphB2-induced presynaptic differentiation can be rescued by 
coexpressing ephrin-B1 or ephrin-B2 shRNAs with constructs encoding the 
appropriate molecule rendered insensitive to knockdown (Figure 2.1A and E). 
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These results suggest that EphB-dependent presynaptic differentiation is 
controlled by ephrin-B1 and ephrin-B2.  
 Presynaptic assembly is mediated in part by protein–protein interactions 
with multidomain scaffolding molecules, many of which contain multiple PDZ 
domains (Bresler et al., 2004). To test whether the ephrin-B PDZ-binding domain 
is required for EphB-dependent presynaptic development, we coexpressed syn-
GFP with HA-tagged ephrin-B1 lacking the PDZ-binding domain (HAeB1ΔPDZ) 
in DIV3 neurons. Because the known intracellular signaling domains are highly 
conserved, overexpression of intracellular mutants such as HAeB1ΔPDZ are 
thought to act as dominant negatives and block PDZ-binding domain-dependent 
signaling through all ephrin-B subtypes (Segura et al., 2007; Zimmer et al., 
2003). In DIV9 axons coexpressing HAeB1ΔPDZ and syn-GFP, EphB2-
expressing HEK293T cells failed to induce an increase in syn-GFP density 
similar to that seen with knockdown of ephrin-B1 or ephrin-B2 (Figure 2.1D). 
These results indicate that, similar to other molecules that mediate presynaptic 
development (Dalva et al., 2007; Jin and Garner, 2008), EphB-dependent 
presynaptic differentiation likely relies on protein–protein interactions with the 
ephrin-B PDZ-binding domain.  
 Syntenin-1 Is Required for EphB-Dependent Presynaptic Development. 
Interactions between the ephrin-B PDZ-binding domain and the tandem PDZ 
domain-containing protein syntenin-1 have been demonstrated by GST pull-down 
(Grootjans et al., 2000; Lin et al., 1999), yeast two-hybrid assay (Ko et al., 2006; 
Terashima et al., 2004; Torres et al., 1998), and X-ray crystallography 
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(Grembecka et al., 2006). Because a recent report (Ko et al., 2006) 
demonstrated that syntenin-1 participates in the organization of presynaptic 
terminals through interactions with ERC/CAST family members, we hypothesized 
that ephrin-B may recruit presynaptic vesicles downstream of EphB by interacting 
with syntenin-1. To test whether EphB-dependent presynaptic induction is 
caused by syntenin-1 PDZ domain interactions, we generated a syntenin-1 
molecule lacking the second PDZ domain (syntenin-1ΔPDZ2). The second PDZ 
domain of syntenin-1 is required to bind ephrin-B (Grembecka et al., 2006; 
Grootjans et al., 2000; Ko et al., 2006; Lin et al., 1999), and we confirmed that 
syntenin-1ΔPDZ2 cannot bind ephrin-B1 by coimmunoprecipitation. Because this 
mutant cannot interact with ephrin-Bs, we predicted that it might act in a 
dominant negative fashion, similar to ephrin-B1ΔPDZ. We found that 
overexpression of syntenin-1ΔPDZ2 blocked the ability of EphB2-expressing 
HEK293T cells to induce an increase in syn-GFP in underlying axons (Figure 
2.2A and B), suggesting that EphB-dependent presynaptic recruitment depends 
on PDZ domain interactions between ephrin-Bs and syntenin-1.  
 To confirm the role of PDZ proteins in EphB-dependent presynaptic 
induction, we generated shRNA constructs targeting syntenin-1 and GRIP1 
(Figure 2.2D), a synaptically localized PDZ protein that can also interact with 
ephrin-B (Bruckner et al., 1999; Lin et al., 1999). Although GRIP1 is primarily 
thought to function postsynaptically, GRIP1 protein has also been identified in 
axons (Wyszynski et al., 1999). In axons expressing GRIP1 shRNA, EphB2-
expressing HEK293T cells induced a significant increase in syn-GFP density, 
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suggesting that GRIP1 is not involved in this process (Figure 2.2A and B). 
However, in axons expressing either of two unique syntenin-1-targeting shRNAs, 
fEphB2-expressing HEK293T cells failed to induce an increase in syn-GFP 
density (Figure 2.2A and B). Knockdown of syntenin-1 had no effect on the 
ability of ephrin-B1 or ephrin-B2 to bind exogenously applied EphB2-Fc, 
suggesting that ephrin-Bs were still found at the cell surface (Supplementary 
Figure 2.2). However, syntenin-1 knockdown did cause a decrease in the 
colocalization of both ephrin-B1 and EphB2-Fc with syn-GFP, consistent with a 
model in which syntenin-1 links ephrin-Bs to the presynaptic complex 
(Supplementary Figure 2.2). The effects of syntenin-1 knockdown were rescued 
by transfecting an shRNA targeting syntenin-1 together with a knockdown-
insensitive syntenin-1 molecule (Figure 2.2A and C), demonstrating that the 
effects of syntenin-1 shRNA constructs are specific. Taken together, these 
results demonstrate that EphB-dependent presynaptic development is likely 
mediated by ephrin-B1 and ephrin-B2, which can recruit presynaptic machinery 
through PDZ domain interactions with syntenin-1.  
 
Localization of Ephrin-B Subtypes and Syntenin-1 in Cultured Cortical 
Neurons. 
 To begin to address how ephrin-Bs and syntenin function together to 
regulate synapse development, we immunostained mature DIV21–30 cultures for 
ephrin-B1, ephrin-B2, and syntenin-1 along with synaptic markers to determine 
the distribution of these molecules in cortical neurons. We have previously 
 50
reported that ephrin-B1 and ephrin-B3 are colocalized with excitatory presynaptic 
and postsynaptic markers (Kayser et al., 2006). To determine how this 
localization compares for ephrin-B2, we stained DIV21 cortical neurons for 
ephrin-B2 and the presynaptic and postsynaptic markers VGlut1 and SynGAP 
(Rao et al., 1998). Ephrin-B2 staining was found throughout cortical neuron 
cultures. However, in contrast to the highly synaptic staining observed for ephrin-
B1 and ephrin-B3, the pattern of ephrin-B2 staining consisted of smaller puncta, 
some of which were colocalized with synaptic puncta (Figure 2.3A). Consistent 
with a previous report (Bundesen et al., 2003), we also observed a few cells with 
intense ephrin-B2 staining that were positive for the glial marker GFAP (Figure 
2.3B). We next directly compared the synaptic localization of ephrin-B1 and 
ephrin-B2 by costaining DIV30 cultures for these molecules and VGlut1. Similar 
to previous observations, ephrin-B1 was highly colocalized with VGlut1 (≈45%), 
whereas ephrin-B2 was found in small puncta that were also colocalized with 
VGlut1 (≈23%; see Supplementary Table 2.1, Figure 2.3C, and 
Supplementary Figure 2.3). In addition, many synaptic puncta colocalized with 
both ephrin-B1 and ephrin-B2, and there was a significant association of these 
two molecules at presynaptic sites (P < 0.0001; Pearson's χ2 test) (Figure 2.3C 
and Supplementary Table 2.1). Interestingly, we often observed several small 
ephrin-B2 puncta surrounding and adjacent to ephrin-B1-positive VGlut1 puncta 
(Figure 2.3C Insets). Thus, both ephrin-B1 and ephrin-B2 colocalize with 
synaptic markers, but the staining pattern is different from that for each ephrin-B 
protein.  
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 The ephrin-B PDZ-binding domain can bind the tandem PDZ protein 
syntenin-1 (Grembecka et al., 2006; Grootjans et al., 2000; Ko et al., 2006; Koroll 
et al., 2001; Lin et al., 1999; Terashima et al., 2004; Torres et al., 1998), and our 
findings that knockdown of syntenin-1 blocks EphB-dependent presynaptic 
development suggests a model in which ephrin-Bs interact with the presynaptic 
machinery via syntenin-1. To further address the relationship between syntenin, 
ephrin-Bs, and the presynaptic machinery, we coimmunostained mature DIV21–
30 neurons for syntenin-1, the excitatory presynaptic marker VGlut1, and either 
ephrin-B1 or ephrin-B2. Consistent with previous studies (Ko et al., 2006; Torres 
et al., 1998), we found that syntenin-1 is localized to presynaptic specializations 
(Figure 2.3D and E). In addition, we found that syntenin-1 is enriched at VGlut1-
positive presynaptic puncta containing ephrin-B1 or ephrin-B2 (P < 0.0001; 
Pearson's χ2 test) (Figure 2.3D and E and Supplementary Table 2.1). These 
results demonstrate that ephrin-B1, ephrin-B2, and syntenin-1 are associated at 
presynaptic specializations.  
 
Presynaptic Ephrin-B1 and Ephrin-B2 Are Required for the Development of 
Synapses and Recruitment of Syntenin-1. 
 To test whether ephrin-Bs regulate the formation of synaptic 
specializations, we examined the density of synapses in single axons after 
knockdown of ephrin-B1 or ephrin-B2 in the absence of exogenous stimulation 
with EphB2-expressing HEK293T cells. EphB-dependent synapse formation 
occurs between DIV7–14, and robust decreases in synapse number can be seen 
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by knocking down EphB2 from DIV3–21 (Kayser et al., 2008). Therefore, to 
identify the effects of ephrin-Bs on EphB-dependent synapse development, 
neurons were cotransfected with ephrin-B shRNA and syn-GFP constructs at 
DIV3, fixed at DIV21–23, and immunostained for GFP and the postsynaptic 
marker PSD-95. Synapses were identified as colocalization between syn-GFP 
and endogenous PSD-95 puncta. Our low transfection efficiencies allowed us to 
selectively examine the presynaptic role of ephrin-Bs during synapse 
development. Knockdown of ephrin-B1 or ephrin-B2 with either of two unique 
shRNA constructs for each led to a significant decrease in the density of both 
syn-GFP puncta and colocalized synaptic puncta (Figure 2.4A-E and 
Supplementary Figure 2.4). Together, these results demonstrate that reducing 
the expression of ephrin-B1 or ephrin-B2 results in fewer synapses.  
 To begin to investigate whether ephrin-B1 and ephrin-B2 function 
independently in the formation of synaptic contacts, we compared the effects of 
individual ephrin-B knockdown to simultaneous knockdown of ephrin-B1 and 
ephrin-B2 in the same axon. This approach is designed to mimic genetic 
experiments in which a single functional pathway is demonstrated by a more 
severe phenotype in double hypomorphic mutants than in the single mutants 
((Boone et al., 2007; Mani et al., 2008) and see SI Text). To achieve this we used 
partial shRNA knockdown for both ephrin-B1 and ephrin-B2 in tandem.  
 To interpret double-knockdown experiments, knockdown of each molecule 
must be sufficient to create a sensitized background but not to an extent that 
further changes cannot be observed. Because shRNA-mediated knockdown is 
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incomplete, and the effects we observe on synapse number is partial, it is likely 
that the effects of single knockdown can be modified by double knockdown. 
Nevertheless, to ensure that knockdown levels were moderate, we first identified 
reduced amounts of ephrin-B1 and ephrin-B2 shRNA that generated similar, but 
decreased, levels of knockdown in non-neuronal cells (Supplementary Figure 
2.5 and SI Text). The expression of this reduced amount of ephrin-B1 shRNA 
resulted in a small, but significant, reduction in the number of syn-GFP puncta 
without a change in the number of colocalized synaptic puncta (Figure 2.4F-H), 
suggesting that this level of ephrin-B1 knockdown creates a sensitized 
background. The expression of ephrin-B2 shRNA at this reduced level resulted in 
a significant effect on the number of both syn-GFP puncta and colocalized 
synaptic puncta, which is also consistent with a sensitized background. 
Interestingly, the differences between the effects of ephrin-B knockdown suggest 
that synaptic specializations are more susceptible to changes in the expression 
level of ephrin-B2 than ephrin-B1. These findings suggest that knockdown of 
ephrin-B1 and ephrin-B2 with reduced levels of shRNA is suitable for the 
evaluation of double knockdown.  
 We next asked whether coexpression of these shRNAs might potentiate 
the effects on synapse density. When expressed together at these reduced 
levels, simultaneous knockdown of both ephrin-B1 and ephrin-B2 caused a 
decrease in synapse density similar to knockdown of ephrin-B2 alone (Figure 
2.4F and H). Thus, the effects of ephrin-B1 and ephrin-B2 shRNAs do not 
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appear to be additive, consistent with ephrin-B1 and ephrin-B2 functioning 
nonredundantly in the formation of synaptic contacts.  
 Because syntenin-1 is required for EphB-dependent presynaptic 
development, and ephrin-Bs are enriched at synaptic specializations containing 
syntenin-1, we next asked how knockdown of ephrin-Bs specifically affects the 
localization of syntenin-1 to synapses. To address this question, we expressed 
ephrin-B1 and ephrin-B2 shRNA, alone or together, and determined the number 
of synapses that contain syntenin-1. We found that expression of reduced levels 
of ephrin-B2 shRNA, but not ephrin-B1 shRNA, led to a significant decrease in 
the number of synaptic puncta containing syntenin-1 (Figure 2.4F). However, 
simultaneous knockdown of ephrin-B1 and ephrin-B2 together resulted in a 
further significant reduction in the number of synapses containing syntenin-1 
compared with either ephrin-B1 or ephrin-B2 alone (Figure 2.4F). These results 
suggest that both ephrin-B1 and ephrin-B2 are involved in normal syntenin-1 
localization, and that ephrin-B1 and ephrin-B2 may function together during the 
formation of syntenin-1-containing synapses. Because decreases in the density 
of syntenin-1-containing synapses after ephrin-B knockdown might be caused by 
the overall loss in synapses number (Figure 2.4H), we asked how knockdown of 
ephrin-B1 and/or ephrin-B2 affected the ability of syntenin-1 to localize to the 
remaining synaptic contacts. For each axon, we determined the proportion of 
synapses that contain syntenin-1 by dividing the density of syntenin-1-containing 
synapses (Figure 2.4I) by the overall density of synaptic contacts (Figure 2.4H). 
We found that neither knockdown of ephrin-B1 nor ephrin-B2 led to a decrease in 
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the percentage of synaptic contacts containing syntenin-1 (Figure 2.4F and J), 
suggesting that ephrin-B1 and ephrin-B2 each can compensate for the loss of the 
other at the remaining synapses. However, simultaneous knockdown of ephrin-
B1 and ephrin-B2 together resulted in a significant reduction in the percentage of 
synaptic puncta that contain syntenin-1 (Figure 2.4F and J). Thus, simultaneous 
knockdown of both ephrin-B1 and ephrin-B2 results in a synergistic effect on the 
ability of syntenin-1 to localize to synaptic contacts. Taken together, these results 
suggest that ephrin-B1 and ephrin-B2 are required for normal numbers of 
excitatory synapses and appear to function in a partially redundant fashion in the 
recruitment of syntenin-1 to synaptic specializations.  
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Discussion 
 In this study we show that ephrin-B1 and ephrin-B2 are key regulators of 
EphB-dependent presynaptic development, likely through PDZ domain-
dependent interactions with syntenin-1. Ephrin-B1, ephrin-B2, and syntenin-1 
colocalize at synaptic contacts, and knockdown of ephrin-B1 or ephrin-B2 leads 
to a reduction in the number of synaptic contacts. Simultaneous knockdown of 
both ephrin-B1 and ephrin-B2 suggests that these molecules are required for the 
synaptic localization of syntenin-1, but function independently in the control of 
synapse formation. In sum, these results support a model in which excitatory 
synapse development occurs via a trans-synaptic interaction between 
postsynaptic EphB and specific presynaptic ephrin-Bs (Supplementary Figure 
2.6).  
 Further study will be necessary to elucidate the mechanisms that 
determine specificity among different ephrin-B family members. Potential 
mechanisms include differences in signaling, localization, or affinity for EphBs. 
Differences in signaling or localization could be mediated by domains of the well-
conserved juxtamembrane regions of ephrin-B1 and ephrin-B2, which diverges in 
ephrin-B3; affinity differences are possible given that ephrin-B3 has a slightly 
lower binding affinity for EphBs than ephrin-B1 or ephrin-B2 (Flanagan and 
Vanderhaeghen, 1998).  
 To study the role of ephrin-Bs in EphB-dependent presynaptic 
development, we have developed an assay that allows us to simultaneously 
manipulate both members of a trans-synaptic interaction pair. In previous 
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experiments using coculture assays (Biederer and Scheiffele, 2007), a single 
molecule of a potential interaction pair was expressed in heterologous cells, and 
the trans-synaptic binding partner was inferred. In contrast, our modified 
coculture system allows us to evaluate the effects of molecular interactions 
between pairs of cells that may occur in vivo. In addition, our assay allows us to 
study the intracellular events downstream of trans-synaptic interactions that 
induce presynaptic maturation. By coculturing heterologous cells expressing 
fEphB2 with neurons expressing shRNA constructs targeting ephrin-B family 
members, we provide direct evidence simultaneously implicating both members 
of a receptor–ligand pair in the trans-synaptic control of synapse formation. 
These findings are validated by our long-term knockdown experiments.  
 Presynaptic organization is supported by multidomain scaffolding 
molecules that regulate both structure and signaling at presynaptic terminals, 
including the PDZ domain-containing proteins Mint, CASK, Piccolo, RIM, and 
syntenin-1 (Jin and Garner, 2008). Syntenin-1 binds directly to the ephrin-B PDZ-
binding domain (Grembecka et al., 2006; Grootjans et al., 2000; Ko et al., 2006; 
Koroll et al., 2001; Lin et al., 1999; Terashima et al., 2004; Torres et al., 1998) 
and is linked to presynaptic maturation via ERC2/CAST1 (Ko et al., 2006). 
ERC2/CAST1 associates with a number of other presynaptic molecules, 
including RIM, Piccolo, Bassoon, and liprin-α. RIM1 binds the synaptic vesicle 
protein Rab3A, and ERC2/CAST1 interacts with RIM1 and Piccolo/Bassoon to 
regulate synaptic transmission (Jin and Garner, 2008). Thus, syntenin-1 provides 
a directly link by which ephrin-B can associate with a protein complex involved in 
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the recruitment and regulation of presynaptic vesicles (Supplementary Figure 
2.6).  
 The degree to which presynaptic development is mediated by specific 
interactions between synaptogenic factors and particular scaffolding proteins is 
not well established. The finding that disruption of syntenin-1 blocks EphB-
dependent presynaptic development suggests that presynaptic development can 
be mediated by specific interactions between ephrin-Bs and syntenin-1. This 
pathway is likely distinct from those involving other PDZ domain interactions such 
as that between neurexin and Mint/CASK (Jin and Garner, 2008). Thus, these 
results suggest that presynaptic terminals may be organized by independent 
pathways.  
 Knockdown of ephrin-B1 or ephrin-B2 alone disrupts EphB-dependent 
presynaptic development and results in a decrease in the number of synaptic 
contacts. To test whether ephrin-B1 and ephrin-B2 function together or 
independently in synaptogenesis, we transfected neurons with shRNAs targeting 
both of these proteins to induce a partial loss in single neurons. Because we 
selected shRNA levels that generated a partial loss of function, results from 
these experiments are interpreted as analogous to genetic experiment using 
trans-heterozygous animals (Boone et al., 2007). However, while knockdown 
using shRNAs has often been described as generating a hypomorphic condition, 
it remains possible that simultaneous use of two shRNAs results in unexpected 
effects. Therefore, to fully resolve the roles of these proteins additional complex 
genetic experiments will be needed. Regardless, our simultaneous knockdown 
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experiments suggest that ephrin-B1 and ephrin-B2 likely function independently 
to control EphB-dependent synapse development. There are several possible 
explanations that account for these findings. While ephrin-B1 and ephrin-B2 
share functional domains, they may coordinate synapse development through 
distinct pathways. Consistent with this idea, neurons display different sensitivities 
to the knockdown of ephrin-B1 versus ephrin-B2 for the formation of synaptic 
contacts, and the staining pattern of ephrin-B1 and ephrin-B2 is different at the 
level of individual synaptic puncta (Figure 2.3C). This specificity may be 
mediated by differences in trans-synaptic interactions or by distinct, currently 
unidentified, functional domains. Alternatively, while ephrin-B1 and ephrin-B2 
colocalize at many synapses, they are often found alone. Thus, one mechanism 
for the function of the ephrin-Bs in synapse formation might be their localization 
to different synaptic puncta.  
 Ephrin-B1 and ephrin-B2 do appear to function together to recruit 
syntenin-1 to synapses. Evidence for this synergy comes from our findings that 
combined knockdown of ephrin-B1 and ephrin-B2 lead to a significant further 
reduction in density and percentage of synaptic specializations that colocalize 
with syntenin-1. One likely mechanism is the identical PDZ-binding domains 
found on ephrin-B1 and ephrin-B2, suggesting that they can both bind syntenin-1 
with equal affinity. Although more work will be needed to resolve the different 
roles of ephrin-B1 and ephrin-B2 in synaptic development, our results provide 
evidence that ephrin-B1 and ephrin-B2 function to mediate EphB-dependent 
presynaptic maturation via syntenin-1.  
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Materials and Methods 
For detailed methods see SI Text.  
 
Cell Culture and Transfection. 
Primary dissociated cortical neurons were prepared from embryonic day 17 (E17) 
to E18 rats and transfected at DIV0 or DIV3 as described (Kayser et al., 2006; 
Kayser et al., 2008). See SI Text for details on the culture conditions for the 
heterologous cell culture assay.  
 
Expression and shRNA Constructs. 
Nineteen-nucleotide RNAi sequences were identified for ephrin-B1, ephrin-B2, 
and ephrin-B3. Sequences used for shRNAs and details for HA-ephrin-B1, HA-
ephrin-B2, and FLAG-syntenin-1 constructs are in SI Text. Except when noted, 
0.75 μg of shRNA construct per well (of 24-well plate) was transfected into 
neurons.  
 
Western Blot Analysis. 
See SI Text for more details.  
 
Imaging and Analysis. 
Cultures were fixed and immunostained using methods similar to those described 
in (Dalva et al., 2007). Significance between experimental conditions was 
determined by ANOVA, except where noted. Statistical measures were 
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conducted on a per-cell basis, collected from a minimum of three independent 
experiments. See SI Text for details.  
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Figure Legends 
 
Fig. 2.1. Ephrin-B1 and ephrin-B2 are required for EphB2-dependent 
presynaptic development. (A) Representative images of DIV10 cortical neuron 
axons transfected with syn-GFP and shRNA constructs at DIV3 and cocultured 
with HEK293T cells transfected with RFP or FLAG-EphB2 (fEphB2). Arrowheads 
indicate syn-GFP puncta colocalized with HEK293T cells. (Scale bar: 3 μm.) (B) 
Quantification of fold increase in syn-GFP puncta density in axon segments 
contacting HEK293T cells expressing fEphB2 or control constructs compared 
with adjacent axon segments (syn-GFP induction) for neurons transfected with 
indicated shRNA constructs: vector control (RFP: n = 19; fEphB2: n = 29), 
ephrin-B1 shRNA#1 (RFP: n = 14; fEphB2: n = 29), ephrin-B3 shRNA (RFP: n = 
21; fEphB2: n = 30). (C) Quantification of axonal syn-GFP induction: vector 
control (n = 40), ephrin-B1 shRNA#2 (n = 47), ephrin-B2 shRNA#1 (n = 24), or 
ephrin-B2 shRNA#2 (n = 20). (D) Quantification of axonal syn-GFP induction: 
vector control (n = 25), ephrin-B1 shRNA#1 (n = 26); HA-ephrin-B1ΔPDZ (n = 
24). (E) Quantification of axonal syn-GFP induction: vector control (n = 50), 
ephrin-B1 shRNA#1 (n = 25), ephrin-B1 shRNA#1 + rescue (n = 27), ephrin-B2 
shRNA#1 (n = 30), or ephrin-B2 shRNA#2 + rescue (n = 28). (F) Western blots of 
lysates from HEK293T cells transfected with HA-ephrin-B1 or HA-ephrin-B2 plus 
vector control, ephrin-B1 shRNA#1, ephrin-B1 shRNA#2, ephrin-B2 shRNA#1, or 
ephrin-B2 shRNA#2 and probed for HA and β-tubulin. Error bars indicate SEM. *, 
P < 0.04.  
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Figure 2.2. Syntenin-1 is required for EphB-dependent presynaptic 
development. (A) Representative images of DIV10 cortical neuron axons 
transfected with syn-GFP and indicated constructs and cocultured with HEK293T 
cells transfected with RFP or fEphB2. Arrowheads indicate syn-GFP puncta 
colocalized with HEK293T cells. (Scale bar: 3 μm.) (B) Quantification of axonal 
syn-GFP induction for neurons transfected with the indicated shRNA constructs: 
vector control (RFP: n = 76; fEphB2: n = 76), ephrin-B1 shRNA#2 (RFP: n = 26; 
fEphB2: n = 33), syntenin-1ΔPDZ2 (RFP: n = 32; fEphB2: n = 35), syntenin-1 
shRNA#1 (RFP: n = 30; fEphB2: n = 29), syntenin-1 shRNA#2 (RFP: n = 27; 
fEphB2: n = 30), or GRIP1 shRNA (RFP: n = 43; fEphB2: n = 47). (C) 
Quantification of axonal syn-GFP induction: vector control (RFP: n = 27; fEphB2: 
n = 31), syntenin-1 shRNA#1 (RFP: n = 31; fEphB2: n = 32), or syntenin-1 
shRNA#1 + rescue (RFP: n = 27; fEphB2: n = 30). (D) Western blots of lysates 
from HEK293T cells transfected with FLAG-syntenin-1 or myc-GRIP1 plus vector 
control, syntenin-1 shRNA#1, syntenin-1 shRNA#2, or GRIP1 shRNA and probed 
for FLAG or myc and β-tubulin. Error bars indicate SEM. **, P < 0.002; *, P < 
0.04.  
 
Figure 2.3. Localization of ephrin-B1, ephrin-B2, and syntenin-1 in cultured 
cortical neurons. (A) Representative image of DIV21 neurons stained for 
ephrin-B2 (green), SynGAP (blue), and VGlut1 (red). (Scale bar: 3 μm.) (B) 
Representative image of DIV21 neurons stained for ephrin-B2 (green) and GFAP 
(red). (Scale bar: 10 μm.) (C) Representative image of DIV30 neurons stained for 
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ephrin-B1 (green), ephrin-B2 (red), and VGlut1 (blue). See SI Text for staining 
details. Mask of merge is RGB image created from binary masks of the three 
individual channels. Image shown is of only the colocalized pixels with all other 
pixels removed. Colocalization in masks is indicated by: ephrin-B1 and ephrin-
B2, yellow; ephrin-B1 and VGlut1, cyan; ephrin-B2 and VGlut1, magenta. (Scale 
bar: 3 μm.) (Inset) High-magnification image of boxed region. (Scale bar: 1 μm.) 
(D and E) Representative image of DIV21 neurons stained for syntenin-1 (green), 
VGlut1 (blue) and either ephrin-B1 (D) or ephrin-B2 (E) (red). Arrowheads 
indicate triple colocalization. (Scale bar: 3 μm.)  
 
Fig. 2.4. Presynaptic ephrin-B1 and ephrin-B2 are required for synapse 
formation and synaptic localization of syntenin-1. (A) (Left and Center) 
Representative images of DIV21–23 axons transfected at DIV3 with syn-GFP 
and indicated shRNA construct costained for GFP (green) and PSD-95 (red). 
(Scale bar: 3 μm.) (Right) Mask of colocalization created by identifying 
colocalized puncta in binary masks from syn-GFP and PSD-95 images. (B–E) 
Quantification of density of syn-GFP puncta (B and D) and synaptic puncta 
defined by colocalized syn-GFP and PSD-95 (C and E) for vector control (n = 21) 
or ephrin-B1 shRNA#1 (n = 24) (B and C) and vector control (n = 19), ephrin-B1 
shRNA#2 (n = 19), ephrin-B2 shRNA#1 (n = 12), or ephrin-B2 shRNA#2 (n = 19) 
(D and E). (F) (Left and Center) Representative images of DIV21 axons 
transfected at DIV3 with syn-GFP and indicated shRNA construct costained for 
GFP (green), syn-GAP (red), and syntenin-1 (blue). Arrowheads indicate 
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synaptic puncta identified colocalization of syn-GFP and SynGAP puncta. Arrows 
indicate colocalized SynGAP and syntenin-1 puncta. (Scale bar: 3 μm.) (Right) 
Schematic showing outlines of synaptic syn-GFP puncta and areas of 
colocalization with syntenin-1 in blue. (G–J) Quantification of syn-GFP puncta 
density (G), synaptic puncta identified by colocalization of syn-GFP and SynGAP 
(H), synaptic syntenin-1 (triple colocalized syn-GFP, SynGAP, and syntenin-1) 
puncta density (I), and percentage of synaptic puncta that colocalize with 
syntenin-1 for neurons transfected with vector control (n = 30), ephrin-B1 
shRNA2 (n = 29), ephrin-B2 shRNA1 (n = 26), and ephrin-B1 shRNA2 + ephrin-
B2 shRNA1 (n = 25) (J). Error bars indicate SEM. *, P < 0.05; **, P < 0.003. 
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Supporting Information 
SI Text 
 
Ephrin-B3 Knockdown Validation. To confirm that knockdown constructs 
targeting ephrin-B3 are effective in reducing the expression of ephrin-B3 in 
neurons, we evaluated ephrin-B3 immunostaining in neurons expressing ephrin-
B3 knockdown constructs. DIV0 cortical neurons were transfected with GFP and 
ephrin-B3 shRNA or vector control. At DIV10, neurons were fixed and 
immunostained for GFP and ephrin-B3. We then measured both the number of 
endogenous ephrin-B3 puncta and the overall intensity of ephrin-B3 
immunostaining. We found a significant decrease in both the intensity of ephrin-
B3 immunostaining and the number of ephrin-B3 puncta (Supplementary Figure 
2.1). Moreover, consistent with recent reports (Aoto and Chen, 2007), we found 
that expression of this ephrin-B3-targeting knockdown construct leads to a 
significant decrease in the number of postsynaptic specializations.   
 
Syntenin-1 Knockdown Does Not Affect Ephrin-B Surface Localization.  To 
address whether the effects of syntenin-1 knockdown on EphB-dependent 
presynaptic induction are caused by a role for syntenin-1in ephrin-B trafficking, 
we tested whether ephrin-B1 and ephrin-B2 could localize to the cell surface in 
the presence of syntenin-1 knockdown. To identify surface localized ephrin-B in 
knockdown axons, we cotransfected DIV3 neurons with syn-GFP and syntenin-1 
shRNA or vector control. At DIV10, we treated live neurons with the extracellular 
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domain of EphB2 tagged to the human Fc fragment (EphB2-Fc) to label surface 
ephrin-B. Neurons were fixed and stained for GFP, the human Fc fragment to 
label EphB2-Fc, and ephrin-B1 or ephrin-B2. We then measured the percentage 
of ephrin-B puncta in syn-GFP positive axons that were labeled with EphB2-Fc. 
Consistent with a model in which syntenin links ephrin-Bs to presynaptic 
specializations, we found that syntenin-1 knockdown led to a decrease in the 
number of syn-GFP puncta colocalized with ephrin-B1 and EphB2-Fc 
(Supplementary Figure 2.2C and G).  Interestingly, we did not detect a change 
in the density of ephrin-B2 colocalized with syn-GFP (Supplementary Figure 
2.2E). When we evaluated the proportion of ephrin-B that was exposed to the 
surface, we found that the percentage of ephrin-B1 or ephrin-B2 puncta labeled 
with EphB2-Fc was unchanged with expression of syntenin-1 shRNA 
(Supplementary Figure 2.2D and F). These results suggest that the effects of 
syntenin-1 knockdown on EphB2-dependent presynaptic development are not 
caused by an effect on ephrin-B surface localization.   
 
Ephrin-B1 and Ephrin-B2 Co-immunostaining. To simultaneously 
immunostain with anti-ephrin-B1 and anti-ephrin-B2 primary antibodies that were 
both raised in goat, we used rabbit anti-goat Fab fragments to convert the goat 
IgG epitope of the antiephrin-B2 antibody to rabbit. We confirmed that ephrin-B1 
and ephrin-B2 recognize the target protein expressed in HEK293T cells and not 
other ephrin-B family members by Western blot, and the specificity of the ephrin-
B2 antibody has been confirmed in mice lacking ephrin-B2 (Grunwald et al., 
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2004). Before staining, goat antiephrin-B2 antibodies were preincubated with 
rabbit anti-goat Fab fragments at a ratio of 650:1 by weight. After fixation and 
blocking with standard conditions, cells were incubated with goat anti-ephrin-
B2/Fab conjugates for 2 h at room temperature followed by goat anti-ephrin-B1 
and guinea pig anti-VGlut1 primary antibodies overnight at 4 °C. Secondary 
labeling was performed with Cy2-conjugated donkey anti-goat, Cy3-conjugated 
donkey anti-rabbit, and Cy5-conjugated donkey anti-guinea pig (Supplementary 
Figure 2.3A). To validate the effectiveness of the Fab fragments, we evaluated 
two control conditions. First, we performed the identical staining as described 
above but without goat anti-ephrin-B1 primary antibody. In this condition, we 
observed normal staining of the goat anti-ephrin-B2/Fab conjugates with Cy3 
anti-rabbit secondary antibodies, but we did not observe any labeling with Cy2 
anti-goat antibodies, demonstrating that the Fab fragment effectively blocked the 
goat epitope of the ephrin-B2 antibody (Supplementary Figure 2.3B). Second, 
we performed the identical staining as described above but without the goat anti-
ephrin-B1 antibody or the rabbit anti-goat Fab fragment (Supplementary Figure 
2.3C). In this condition, the staining pattern for the Cy2 anti-goat secondary is 
identical to that as for the Cy3 anti-rabbit secondary in Supplementary Figure 
2.3A and B, indicating that the Fab fragment accurate converts the goat epitope 
of the ephrin-B2 antibody to rabbit. In addition, we did not observe any labeling 
with the Cy3 anti-rabbit secondary, demonstrating that the Cy3 labeling in 
Supplementary Figure 2.3A was only caused by the Fab fragment labeling of 
the goat anti-ephrin-B1 antibody.  Taken together, these results confirm that the 
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Fab fragment effectively blocks anti-goat secondary reagents and accurately 
converts the ephrin-B2 epitope into rabbit. Thus, the pattern observed with anti-
rabbit and anti-goat secondary reagents after application of goat-ephrin-B2/Fab 
conjugates with goat anti-ephrin-B1 antibody accurately represents the staining 
pattern of these antibodies.  
 
Ephrin-B Knockdown at DIV9. To confirm that the effects of ephrin-B shRNA 
constructs are caused by reduction in ephrin-B expression, we conducted 
experiments to determine whether the decreases in synaptic specializations 
induced by ephrin-B knockdown could be rescued by coexpressing ephrin-B1 
shRNA constructs with an HA epitope-tagged ephrin-B1 with silent mutations in 
the region targeted by our shRNA construct (HAeB1R). In these experiments, 
DIV0 cortical neurons were cotransfected with syn-GFP and ephrin-B shRNA or 
vector control, and the density of syn-GFP was determined at DIV9.  Compared 
with control conditions, axons of neurons expressing ephrin-B1 shRNA 
constructs had a ~25% decrease in the density of syn-GFP (Supplementary 
Figure 2.4). Coexpression of ephrin-B1 shRNA with HAeB1R constructs rescued 
the effects of ephrin-B1 knockdown, resulting in a syn-GFP puncta density similar 
to control (Supplementary Figure 2.4), suggesting that the effects we observed 
after transfection of shRNA are specific.   
 We also examined the effects of ephrin-B3 shRNA on the development of 
synaptic specializations. Consistent with the effect on EphB-dependent 
presynaptic induction, knockdown of ephrin-B3 did not lead to a decrease in syn-
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GFP puncta density (Supplementary Figure 2.4). In contrast, knockdown of 
ephrin-B3 resulted in syn-GFP puncta that were smaller and less evenly 
distributed than in control conditions, resulting in an increased syn-GFP density 
(Supplementary Figure 2.4). It has previously been shown that loss of ephrin-
B3 leads to a generalized increase in the expression of a number of synaptic 
proteins (Rodenas-Ruano et al., 2006), and this effect may lead to an increase in 
disorganized presynaptic clusters in ephrin-B3 knockdown conditions. In addition, 
as described, ephrin-B3 shRNA does not affect EphB-dependent presynaptic 
formation (Figure 2.1).  These results suggest that knockdown of ephrin-B3 
presynaptically leads to a phenotype that is consistent with that observed in mice 
lacking ephrin-B3, but ephrin-B3 does not appear to be required for EphB-
induced presynaptic specializations. Taken together, these results demonstrate 
that knockdown of ephrin-B1 or ephrin-B2 in axons leads to a reduction in 
excitatory synapse number and disrupts the ability of EphB2 to induce 
presynaptic differentiation. Thus, ephrin-Bs appear to mediate EphB-dependent 
presynaptic development but not all ephrin-Bs participate in this process.  
 
Identifying Reduced Amounts of Ephrin-B shRNA Constructs for Double 
Knockdown. To evaluate the potential redundancy of ephrin-B1 and ephrin-B2 
knockdown, we used a double-knockdown approach modeled on genetic 
experiments in which interactions between genes are identified by a phenotype in 
a double mutant that cannot be accounted for by the effects of the single mutants 
alone (Mani et al., 2008). In these genetic experiments, the interpretation of an 
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identified interaction depends on the nature of the genetic manipulation. An 
interaction between two null alleles suggests that the two gene products function 
in parallel pathways that converge on a shared function; in contrast, an 
interaction between two hypomorphs suggests that the two gene products 
function in a single pathway (Boone et al., 2007). To replicate the latter condition 
in our double-knockdown experiments, we used reduced amounts of shRNA for 
ephrin-B1 and ephrin-B2 that were more similar to hypomorphs than nulls.  To 
identify reduced amounts of ephrin-B1 and ephrin-B2 knockdown constructs that 
were suitable for use in double knockdown experiments, we evaluated the 
relationship between the amount of ephrin-B shRNA constructs transfected into 
cells and the amount of knockdown achieved. We transfected HEK293T cells 
with HA-ephrin-B1 or HA-ephrin-B2 and different amounts of ephrin-B1 shRNA2 
or ephrin-B2 shRNA1, respectively. The total amount of shRNA construct 
transfected was maintained at 1 µg in each condition with corresponding 
amounts of empty control vector. We found that there is a steady decrease in 
knockdown effect from 1 µg per well (of a six-well plate) to 0.083µg per well 
(Supplementary Figure 2.5). Very little knockdown was observed at low 
amounts of shRNA constructs (0.017 µg per well; Supplementary Figure 2.5). 
Knockdown levels were similar at equivalent shRNA construct amount between 
ephrin-B1 and ephrin-B2 (Supplementary Figure 2.5). These results suggest 
that ephrin-B shRNA constructs are effective over a wide range of amounts, but 
that absolute level of knockdown is proportional to the amount of shRNA 
construct transfected. For double-knockdown experiments (Figure 2.4 F-J), we 
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reduced the amount of ephrin-B1 shRNA2 by 50% relative to other experiments 
(0.375 µg per well of a 24-well plate) and by 75% for ephrin-B2 shRNA2 (0.187 
µg per well). To determine that our dual-knockdown assay could effectively 
measure increasing effects of simultaneous knockdown we considered and 
addressed possible limitations. As discussed in the main text, shRNA-mediated 
knockdown does not completely prevent protein expression; therefore, 
knockdown is likely to give a suitable background for measuring additive effects. 
To help to ensure this, we determined lower amounts of knockdown that could 
still generate effects (see Figure 2.4H-J and Supplementary Figure 2.5). An 
important potential concern arises from the fact that ephrin-B2 knockdown 
generates a larger effect on synapse number than ephrin-B1 knockdown, 
because the greater effect on synapse number of ephrin-B2 shRNA may 
represent the largest effect beyond which further decreases in synapse number 
are difficult to detect. However, this possibility is unlikely because the reduced 
level of knockdown results in only a partial knockdown of ephrin-B protein, and 
our assay has the sensitivity needed to detect larger decreases in synapse 
density (Figure 2.4I-J). 
 
Cell Culture and Transfection. Neurons were cultured in neurobasal 
(Invitrogen), B27 supplement (Invitrogen), glutamine (Sigma), and penicillin–
streptomycin (Sigma) on poly-D-lysine (BD Biosciences or Sigma) and laminin 
(BD Biosciences)-coated glass coverslips (12 mm; Bellco Glass) in 24-well plates 
(Costar). Cells were plated at 150,000 per well maintained in a humidified 
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incubator with 5% CO2 at 37 °C. As indicated, neurons were transfected either 
with Lipofectamine 2000 (Invitrogen) in suspension immediately before plating 
(Takasu et al., 2002) or at 3 DIV using the calcium phosphate method (Xia et al., 
1996). 
 
shRNA Constructs. Sequences used were:  
ephrin-B1 shRNA#1, 5’-GTTCCTAAGTGGGAAGGGC-3’;  
ephrin-B1 shRNA#2, 5’-CACTGTGCTTGATCCCAAT-3’;  
ephrin-B2 shRNA#1, 5’-GCAGACAGATGCACAATTA-3’;  
ephrin-B2 shRNA#2, 5’-GAGACAAATTGGATATTAT-3’;  
ephrin-B3 shRNA, 5’-GCCTTCGGAGAGTCGCCAC-3’; 
syntenin-1 shRNA#1, 5’-GTCTTTAAGTGAAGCTGAA-3’;  
syntenin-1 shRNA#2, 5’-CAGTGGACATGTTGGCTTT-3’; and GRIP1 shRNA, 5’-
GAGAGTTCCGGAGCGATTA-3’. Forward and reverse oligonucleotides were 
synthesized (Integrated DNA Technologies) such that, when annealed, they 
generated a dsDNA insert consisting of the forward and reverse complement 
RNAi sequences separated by a hairpin region and flanked by restriction site 
overhangs. Inserts were subcloned into pSuper (Brummelkamp et al., 2002).   
 
Expression Constructs. HA-ephrin-B2 was generated by cloning ephrin-B2 
from mouse cDNA using sequence-specific primers and then QuikChange 
(Invitrogen) to insert the HA coding sequence flanked by unique restriction sites 
immediately downstream of the signal sequences. The HA-ephrin-B1, HA-ephrin-
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B2, and FLAG-syntenin-1 rescue constructs were generated by creating seven to 
nine silent mutations within the sequence targeted by ephrin-B1 shRNA#1, 
ephrin-B2 shRNA#1, and syntenin-1 shRNA#1 sequences, respectively. HA-
ephrin-B1ΔPDZ was created by amplifying the full-length HA-ephrin- B1 without 
the four terminal amino acids. Syntenin-1ΔPDZ2 was created by QuikChange to 
remove the second PDZ domain (amino acids 198–272). Synaptophysin-GFP in 
pFUGW vector was a generous gift from M. Lush and J. Raper. FLAG-syntenin-1 
and myc-GRIP1 were kind gifts of E. Kim (Ko et al., 2006) and R. Huganir, 
respectively.  
 
Immunocytochemistry. Cultures were fixed in 4% paraformaldehyde/2% 
sucrose for 8 min at room temperature. Cells were washed three times in PBS 
and blocked and permeabilized in 1% ovalbumin (Sigma)/0.2% cold water fish 
scale gelatin (Sigma)/ 0.1% saponin (Sigma) for 1 h at room temperature. 
Antibody incubations were conducted overnight at 4 °C for primary antibody and 
1 h at room temperature in secondary antibody diluted in blocking reagents. 
Dilutions of each antibody used is reported below. For double labeling for ephrin-
B1 and ephrin-B2, the goat IgG epitope of ephrin-B2 was converted to rabbit by 
preincubation with goat anti-rabbit Fab fragments (Jackson ImmunoResearch).  
Antibodies used were: chicken anti-GFP (Upstate; 1:2,500), mouse anti-FLAG 
M2 (Sigma; 1:2,000), rabbit anti-ephrin-B3 (Zymed, 1:50), goat anti-ephrin-B1 
(R&D Systems; 1:500), goat anti-ephrin-B2 (R&D Systems; 1:500), mouse anti-
PSD95 (Affinity BioReagents; 1:200), rabbit anti-SynGAP (Affinity BioReagents; 
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1:1,000), guinea pig anti-VGlut1 (Chemicon; 1:5,000), mouse anti-syntenin-1 
(Synaptic Systems; 1:200), and mouse anti-GFAP (Boehringer Manheim; 1:500). 
 
Western Blot Analysis. Lysates from HEK293T cells were separated by 
SDS/PAGE and transferred onto 0.45-µm PVDF membranes (Millipore). 
Immunoblots were blocked in 5% milk in TBST (150 mM NaCl/10 mM Tris, pH 
8.0/0.05% Tween 20) and blotted for indicated proteins. Antibodies used were 
mouse anti-HA (Covance), mouse anti-Myc (DSHB; 9E10), mouse 
anti-FLAG M2 (Sigma), mouse anti-β-tubulin (DSHB; E19), and rabbit anti-actin 
(Sigma). 
 
Ephrin-B Surface Labeling. Cultured cortical neurons were treated with EphB2-
Fc (R&D Systems) preclustered with donkey antihuman Fc antibody (Jackson 
ImmunoResearch; see (Kayser et al., 2006)) for 60 min at 37 °C. Cultures were 
washed once in PBS and fixed as described. 
 
Imaging and Analysis. Images of primary neuronal cultures were acquired by 
using confocal scanning microscopy (Leica). All images were acquired and 
subsequently analyzed with custom designed National Institutes of Health 
ImageJ macros blind to experimental condition. Significance between 
experimental conditions was determined by ANOVA, except where noted.  
Statistical measures were conducted on a per-cell basis, collected from a 
minimum of three independent experiments. For puncta analysis, images were 
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converted to binary scale, and puncta were identified as continuous groups of 
pixels corresponding to 0.5–7.5 µm. Colocalization between puncta was defined 
as >1 pixel overlap between channels. Linear density measurements were 
obtained by identifying puncta along at least 50 µm of axon per image. 
 For heterologous coculture experiments, synaptophysin-GFP puncta 
density was determined as described above for axon regions colocalized with 
HEK293T cells and for adjacent axon regions (starting >5µm away from 
HEK293T cell border). Syn-GFP induction was determined by dividing puncta 
density colocalized with HEK293T cells by density in adjacent regions. 
 To determine endogenous ephrin-B3 staining intensity in GFP-expressing 
neurons cotransfected with constructs encoding ephrin-B3 shRNA, the average 
intensity of pixels colocalized with a GFP mask in which the soma had been 
removed was measured in nonsaturated images of ephrin-B3 staining in neurons 
cotransfected with either vector control or ephrin-B3 shRNA collected with 
identical microscope settings. 
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Supplementary Figure Legends 
 
Supplementary Figure 2.1. Validation of endogenous ephrin-B3 
knockdown. (a and b) Representative images of DIV10 neurons expressing 
GFP plus vector control (a) or ephrin-B3 shRNA (b) and stained with anti-GFP 
(green) and anti-ephrin-B3 (red) antibodies. (c and d) Endogenous ephrin-B3 
staining from a and b. (Scale bar: 10 μm.) (e1–f2) High-magnification views of 
boxed region of dendrite from neurons expressing GFP (green in e2 and f2) plus 
vector control (e1 and e2) or ephrin-B3 shRNA (f1 and f2). (e1 and f1) 
Endogenous ephrin-B3 staining (red in e2 and f2). Arrows indicate ephrin-B3 
puncta in transfected cells. Arrowheads indicate puncta in adjacent cells. (Scale 
bar: 3 μm.) (g and h) Quantification of ephrin-B3 staining intensity in arbitrary 
units (g) or ephrin-B3 puncta/μm (h) after transfection of vector control (n = 37) or 
ephrin-B3 shRNA (n = 41). Error bars indicate SEM. *, P < 0.0001. 
 
Supplementary Figure 2.2. Syntenin-1 knockdown does not affect ephrin-B 
surface localization. (a and b) Representative images of DIV10 neurons 
transfected at DIV3 with syn-GFP plus syntenin-1 shRNA#2 or vector control, 
treated with clustered EphB2-Fc for 60 min, fixed, and stained for anti-GFP 
(green), human Fc fragment of IgG (blue), and ephrin-B1 (a) or ephrin-B2 (b) 
(red). Arrowheads indicate triple colocalization. (Scale bar: 3 μm.) (c and d) 
Quantification of puncta density for colocalized syn-GFP and ephrin-B1 puncta 
(c) and percentage of colocalized ephrin-B1 and syn-GFP puncta that are 
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positive for EphB2-Fc in neurons transfected with vector control (n = 31) or 
syntenin-1 shRNA#2 (n = 28) (d). (e and f ) Quantification of puncta density for 
colocalized syn-GFP and ephrin-B2 puncta (e) and percentage of colocalized 
ephrin-B2 and syn-GFP puncta that are positive for EphB2-Fc in neurons 
transfected with vector control (n = 30) or syntenin-1 shRNA2 (n = 30) ( f). (g) 
Quantification of puncta density for colocalized syn-GFP and EphB2-Fc puncta 
for vector control (n=31) or syntenin-1 shRNA2 (n=28). Error bars indicate SEM. 
*, P < 0.02.  
 
Supplementary Figure 2.3. Immunostaining controls. (a) Representative 
images of DIV30 neurons stained with goat anti-ephrin-B1 antibodies recognized 
with Cy2 donkey anti-goat secondary antibodies (green), goat anti-ephrin-B2 
antibodies preincubated with rabbit anti-goat Fab fragment and recognized with 
Cy3 donkey anti-rabbit secondary antibodies (red), and guinea pig anti-VGlut1 
antibodies recognized with Cy5 donkey anti-guinea pig secondary antibodies 
(blue). (b) Representative images of DIV30 neurons stained identically to a, 
except anti-ephrin-B1 antibody was omitted. (c) Representative images of DIV30 
neurons stained identically to a, except anti-ephrin-B1 antibody and 
preincubation of anti-ephrin-B2 with rabbit anti-goat Fab fragment was omitted. 
Goat anti-ephrin-B2 antibodies are labeled with Cy2 donkey anti-goat secondary 
antibodies (green). See SI Text for details. (Scale bar: 3 μm.) 
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Supplementary Figure 2.4. Ephrin-B Knockdown at DIV9. (a) Ephrin-B in 
presynaptic development Representative axons from DIV9 cortical neurons 
transfected at DIV0 with syn-GFP plus indicated shRNA constructs. (Scale bar: 
3μm.) (b) Quantification of syn-GFP puncta density of axons transfected with 
vector control (n=77), ephrin-B1 shRNA#1 (n=93), ephrin-B1 shRNA#1 + rescue 
(n = 25), or ephrin-B3 shRNA (n = 77). Error bars indicate SEM. *, P < 0.002. 
 
Supplementary Figure 2.5. Titration of ephrin-B1 and ephrin-B2 knockdown 
in heterologous cells. (a and b) Western blots of lysates from HEK293T cells 
transfected with HA-ephrin-B1 (a) or HA-ephrin-B2 plus vector control (b) and the 
indicated amounts of ephrin-B1 shRNA#2 (a) or ephin-B2 shRNA#1 (b). Control 
plasmid was transfected as needed so that the total amount of shRNA vector 
was 1 μg. Blots were probed for HA antibody, stripped, and reprobed for actin.  
 
Supplementary Figure 2.6. Model EphB-dependent presynaptic 
development. 
 
Supplementary Table 2.1.  Puncta analysis of DIV30 cortical neuron culture 
immunostained for ephrin-B1, ephrin-B2, syntenin-1, and VGlut1 
 
Figure 2.1 
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A novel extracellular interaction mechanism controls the EphB-
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Abstract 
Trafficking of NMDA receptors to synaptic sites is critical for synaptic function 
and plasticity in the mature brain.  The type and number of NMDARs must be 
maintained and tightly regulated to enable changes in synaptic strength while 
preventing excitotoxicity.  Increased content of NR2B-containing NMDARs at 
synaptic sites increases synaptic plasticity and improves behavioral tasks of 
learning and memory.  In the mature brain, EphBs interact directly with NMDA 
receptors and regulate the synaptic localization of NR2B-containing NMDARs.  
EphB-dependent modulation of NMDARs promotes synaptic function, plasticity, 
and its misregulation results in disease.  However, whether the interaction 
between EphBs and NMDARs is important for these events have not been 
tested.  Here, we identify a single amino acid in the extracellular domain of 
EphB2 that is necessary and sufficient to mediate the EphB-NMDAR interaction.  
We define a novel molecular mechanism, where a specific extracellular tyrosine 
residue is phosphorylated after ephrin-B ligand binding, to induce the EphB-
NMDAR interaction.  Mutations at this site enhance or reduce synaptic currents 
of NR2B-containing NMDARs, receptor stabilization at the cell surface, and Ca2+-
dependent gene transcription.  These findings indicate that in EphBs are critical 
regulators of NMDAR subunit composition, function, and synaptic localization to 
prevent disease in the mature brain. 
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During development and in the adult brain, the NMDAR is required for the 
generation of normal circuitry and synaptic function (Lau and Zukin, 2007; Perez-
Otano and Ehlers, 2005). NR2B subunit-containing NMDARs have longer 
channel open time and increased calcium influx (Chen and Roche, 2007; Cull-
Candy and Leszkiewicz, 2004; Prybylowski and Wenthold, 2004).  Driving NR2B-
containing NMDARs to synapses in the mature brain increases the plasticity of 
synapses and improves performance on behavioral tasks of learning and 
memory (Philpot et al., 2007; Tang et al., 1999).  It appears that EphBs interact 
directly with NMDARs through their extracellular domains and cluster NMDARs 
at synaptic sites (Attwood et al., 2011; Dalva et al., 2000; Grunwald et al., 2001; 
Slack et al., 2008).  The EphB-NMDAR interaction is implicated in numerous 
synaptopathies such as: Alzheimer’s disease (Cisse et al., 2011; Simon et al., 
2009), anxiety disorders (Attwood et al., 2011), and neuropathic pain (Liu et al., 
2011; Liu et al., 2009; Slack et al., 2008; Song et al., 2008b).  In mature neurons, 
EphB2 regulates synaptic localization and Ca2+-dependent desensitization of 
NR2B-containing NMDARs (Nolt et al., 2011).  After EphB activation, the EphB-
NMDAR interaction results in enhanced calcium influx, tyrosine phosphorylation, 
and function of NMDARs (Dalva et al., 2000; Takasu et al., 2002).  The EphB-
NMDAR interaction induces phosphorylation of the NR2B subunit at intracellular 
Y1472, which can stabilize NR2B-containing NMDARs at synaptic sites (Dalva et 
al., 2000; Prybylowski et al., 2005; Takasu et al., 2002).   
EphB receptors are cell-surface localized, single-pass transmembrane 
receptor tyrosine kinases that are activated by their clustered, membrane-
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attached ephrin-B ligands (Egea and Klein, 2007).  Ephrin-B/EphB signaling in 
the CNS controls axon guidance, dendritic filopodia motility, pre-and postsynaptic 
excitatory synapse formation, synapse maturation, glutamate receptor 
localization and function, and synaptic plasticity (Egea and Klein, 2007; 
Sloniowski and Ethell, 2011).  For EphBs, the ability to coordinate these events 
requires tight regulation of receptor trafficking including EphB receptor cleavage, 
internalization, and degradation (Pitulescu and Adams, 2010).  While the 
differences between these modes of trafficking are poorly understood, regulation 
of EphB receptor trafficking is clearly important for regulation of NMDA receptors 
at synaptic sites.   
EphB1-/-, B2-/-, B3-/- (TKO) mice are defective in their ability to localize 
NR2B-containing NMDARs to synaptic sites (Henkemeyer et al., 2003; Kayser et 
al., 2006; Nolt et al., 2011).  EphBs interact directly with NMDARs through an 
undefined region of their extracellular domains (Attwood et al., 2011; Dalva et al., 
2000; Grunwald et al., 2001; Slack et al., 2008).  We generated numerous EphB 
expression constructs, but were unable to identify a small subregion (<100 amino 
acids) that mediates the EphB-NMDAR interaction.  Therefore, we undertook an 
unbiased mass spectrometry based approach to identify candidate interactions 
domains.  We expressed the FLAG epitope-tagged EphB2 (fB2) receptor in 
NG108 cells.  After 48 hours, cells were stimulated with clustered ephrin-B1-Fc 
for 45 minutes to activate the receptors (for verification see Supplementary 
Figure 3.1).  Ephrin-B treatment was used because induction of the EphB-
NMDAR interaction requires ephrin-Bs (Dalva et al., 2000).  EphB2 receptors 
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were immunoprecipitated using anti-FLAG antibodies, proteins were separated 
using SDS-PAGE, digested in-gel with trypsin, and phosphopeptides were 
enriched using TiO2 before LC-MS/MS (MW range 100-130kD).  Three known 
phosphopeptides were identified in the juxtamembrane and kinase domains 
(Supplementary Figure 3.2) in addition two novel phosphorylation sites 
(ELSEYNATAIK and AGAIYVFQVR) were identified that correspond to regions in 
the extracellular portion of the receptor (Figure 3.1A-C).  Due to the unusual 
nature of the location of these peptides Mascot results and MS/MS spectra were 
closely inspected.  We found that each peptide was identified on four 
independent experiments and twice in each labeling state, with Mascot scores of 
34 and 63 respectively and definable separation from the next peptide assigned 
to that spectrum.  Manual inspection of the MS/MS spectrum confirmed that the 
signals present are accounted for and ions critical to localization at the site of 
phosphorylation are present. 
The two phosphopeptides identified, ELSEYNATAIK and AGAIYVFQVR 
were each found in the C-terminal fibronectin type III repeat domains (cFN3; see 
Figure 3.1C for schematic) and correspond to tyrosine residues Y481 and Y504 
respectively.  Y504 and neighboring residues are well conserved (>51% identity 
in 15 of 18 neighboring amino acids) amongst the entire Eph family, whereas 
Y481 is less well conserved (>51% identity in 2 of 16 neighboring amino acids) in 
other Ephs (Figure 3.1D).  These findings suggest that phosphorylation at Y504 
may also be a common mechanism for regulation of other Eph family members.  
EphB receptors interact directly with NMDA-type glutamate receptors through an 
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undefined region of their extracellular domains (Attwood et al., 2011; Dalva et al., 
2000; Grunwald et al., 2001; Slack et al., 2008).  Since, both the EphB-NMDAR 
interaction and phosphorylation at Y481 and Y504 require activation by ephrin-B 
ligand; we hypothesized that one or more of these sites might play a role in the 
EphB-NMDAR interaction.  To test this possibility, we generated phosphomimetic 
(fB2 Y481E and Y504E) and non-phosphorylatable (fB2 Y481F and Y504F) point 
mutants to the FLAG-tagged EphB2 receptor.  We then transfected HEK293T 
cells with fB2 WT, fB2 Y481E, or fB2 Y481F, along with HA-NR1-GFP and NR2B 
constructs, to form a functional NMDAR that is trafficked to the cell surface.  
NR2B-containing receptors were used because their trafficking and function is 
specifically regulated at mature synapses by EphBs (Nolt et al., 2011).  EphB2 
receptors were immunoprecipitated using an anti-FLAG antibody, and then 
probed for the HA-tag of NR1.  We find that neither EphB2 Y481E (Figure 3.1E 
lane 3; Figure 3.1F quantification) nor Y481F (Figure 3.1E lane 4; Figure 3.1F 
quantification) affect the ability of EphBs to bind NR1.  These data suggest that 
Y481 does not play an important role in the EphB-NMDAR interaction.  We next 
tested whether the Y504 site might modulate the EphB-NMDAR interaction.  
When co-expressed in HEK293T cells, we find that EphB2 Y504F significantly 
reduced NR1 binding compared to WT (Figure 3.1G lane 4; Figure 3.1H 
quantification, ANOVA test, p < 0.05), while mutation of Y504E significantly 
increased binding compared to WT and Y504F (Figure 3.1G lane 3; Figure 3.1H 
quantification, ANOVA test, p < 0.05).  These findings suggest that Y504 may 
play an important role in the EphB-NMDAR interaction.   
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Next, we wanted to test whether Y504 mutant receptors affect the EphB-
NMDAR interaction in neurons.  Therefore, we generated lentiviruses 
transducing EphB2-YFP WT, EphB2-YFP Y504E, and EphB2-Y504F constructs 
into DIV2 cultured cortical neurons for co-IP experiments.  At DIV7, expressed 
EphB2 receptors were enriched using an anti-GFP antibody and level of NR1 
pull-down was assessed.  Consistent with previous reports (Dalva et al., 2000), in 
neurons over-expressing WT EphB receptors the EphB-NMDAR interaction is 
induced by ephrin-B stimulation (Figure 3.1I lanes 1 and 2; Figure 3.1J 
quantification).  Interestingly, in the phosphomimetic Y504E mutant, the EphB-
NMDAR interaction is induced without ephrin-B treatment (Figure 3.1I lane 3).  
Furthermore, ephrin-B stimulation does not potentiate the EphB-NMDAR 
interaction further in Y504E mutants (Figure 3.1I lane 4; Figure 3.1J 
quantification).  These data are consistent with phosphorylation at Y504 being 
sufficient for the EphB-NMDAR interaction to occur.  Consistently, non-
phosphorylatable Y504F mutants have little pull-down with NR1 in absence of 
ephrin-B treatment (Figure 3.1I lanes 5; Figure 3.1J quantification).  Ephrin-B 
stimulation did not potentiate the EphB-NMDAR interaction in Y504F mutant 
receptors (Figure 3.1I lanes 6; Figure 3.1J quantification).  Together, these 
data suggest that phosphorylation of Y504 is necessary and sufficient for the 
EphB-NMDAR interaction in neurons and HEK293T cells.  
Although most protein kinases have been studied inside the cell, evidence 
suggests that phosphorylation of proteins can occur in the extracellular space 
(Redegeld et al., 1999).  Both soluble and membrane attached kinases have 
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been found in numerous cell types including neurons (Chen et al., 1996; Fujii et 
al., 2000; Kumar et al., 2011).  In neurons extracellular protein kinases regulate 
processes including synaptic plasticity (Chen et al., 1996; Fujii et al., 2000) and 
aggregation of amyloid β-peptides (Aβ) in mouse and human brain (Kumar et al., 
2011).  To begin to test whether Y504 is phosphorylated extracellularly, we first 
generated a polyclonal phospho-specific antibody to tyrosine 504.  We tested this 
antibody in lysates from HEK293T cells transfected with FLAG-EphB2 constructs 
and found that full-length WT EphB2 receptors were recognized by this antibody 
at the appropriate molecular weight ~120 kD, but not Y504F non-
phosphorylatable mutants nor untransfected lysates (Figure 3.2A left).  To test 
whether Y504 might become phosphorylated in the extracellular space we next 
asked whether in HEK293T cells if a truncated fB2 construct lacking an 
intracellular domain (Kayser et al., 2006) would still be phosphorylated.  We have 
previously shown this construct localizes to the plasma membrane and can 
recruit presynaptic markers (Kayser et al., 2006).  We found that the truncated 
WT EphB2 receptor, but not Y504F mutant receptor was recognized by the 
pY504 antibody at the appropriate molecular weight ~75kD (Figure 3.2A right).  
These data suggest that the EphB tyrosine kinase is not required for 
phosphorylation of Y504.  Next, we wanted to test that our pY504 antibody was 
phospho-specific and recognized synaptic EphB2 protein.  Synaptosomes were 
prepared from two WT CD1 mouse brains before being subjected to SDS-PAGE 
in duplicate, and then immunoblots were cut in half.  One blot was treated with 
Calf Intestinal Alkaline Phosphatase (CIP, 1:500; New England BioLabs) 
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overnight to de-phosphorylate all proteins.  Blots were then probed with the 
pY504 antibody (Figure 3.2B top), then stripped and reprobed with an N-
terminal commercial EphB2 antibody to verify non-phosphorylated protein was 
present, and that the phospho-band ran at the appropriate molecular weight 
(Figure 3.2B bottom).  These data suggests our antibody recognizes a 
phospho-specific epitope.   
Next, to test whether phosphorylation of Y504 might occur on the cell 
surface, we asked if blocking internalization of EphB2 might block 
phosphorylation of Y504.  Since EphBs are internalized by clathrin-mediated 
mechanisms after ephrin-B stimulation (Irie et al., 2005; Litterst et al., 2007; 
Pitulescu and Adams, 2010; Vihanto et al., 2006), we blocked clathrin-mediated 
endocytosis using two pharmacological treatments (450mM hypertonic sucrose 
or 80 μM dynasore; Sigma-Aldrich) in DIV6-7 cultured cortical neurons in the 
presence or absence of ephrin-B stimulation.  To examine the effects of drug 
treatment on EphB2 phosphorylation, we immunoprecipitated with an N-terminal 
anti-EphB2 antibody then probed with pY504 or intracellular EphB2 antibodies.  
We found that treatment with either hypertonic sucrose or dynasore did not block 
the induction of Y504 phosphorylation after ephrin-B2 treatment (Figure 3.2C 
left).  To validate that drug treatments did not block intracellular kinase activity, 
we stripped and probed the same blots with an antibody against the EphB2 
intracellular kinase domain (pY662; (Dalva et al., 2000)).  Neither dynasore nor 
hypertonic sucrose blocked the ability for the EphB2 kinase activation.  These 
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data supports the model (Figure 3.2D) that EphB2 pY504 gets phosphorylated in 
the extracellular space by an exo- or ecto-protein kinase.   
 We next tested whether inhibition of extracellular phosphorylation alone 
was sufficient to block the EphB-NMDAR interaction.  To do this, we took 
advantage of the widely used, broad-spectrum extracellular kinase inhibitor k-
252b (Chen et al., 1996; Fujii et al., 2000; Nguyen et al., 2008).  In DIV6-7 
cortical neurons, treatment with activated ephrin-B for 45 minutes induces the 
EphB-NMDAR interaction (Figure 3.2E lanes 1 and 2; Figure 3.2F 
quantification) and resulted in phosphorylation of Y504 (Figure 3.2E lanes 1 
and 2; Figure 3.2G quantification).  Following k-252b treatment (10µM; Sigma-
Aldrich), ephrin-B stimulation failed to induce phosphorylation at Y504, although 
the kinase activity of the EphB receptor was unaffected (Figure 3.2E lanes 3 
and 4; Figure 3.2G quantification).  In addition, treatment of neurons with k-
252b is sufficient to block the ephrin-B induced EphB-NMDAR interaction (Figure 
3.2E lanes 3 and 4; Figure 3.2F quantification).  Taken together, these results 
suggest that ephrin-B-dependent phosphorylation of EphB2 Y504 occurs in the 
extracellular space and is required for the EphB-NMDAR interaction.             
  The ability of EphB2 receptors to properly regulate NMDAR surface 
localization at synapses is required for normal brain functioning, and dysfunction 
of these events are implicated in numerous human diseases such as Alzheimer’s 
disease (Cisse et al., 2011; Simon et al., 2009) and anxiety disorders (Attwood et 
al., 2011).  Therefore we asked whether phosphorylation at Y504 might alter the 
trafficking of the EphB2 receptors (Figure 3.3A).   We reasoned that since WT 
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EphB2 receptors are localized to the plasma membrane, mutation of Y504 to E 
should not stop insertion of mutant receptors into the plasma membrane.  In 
support of this idea, we find that fB2 Y504E receptors do localize to the cell 
surface, although at significantly reduced levels compared to other EphB2 
constructs (Figure 3.3B; Figure 3.3C quantification).  Furthermore, when 
expressed alone in HEK293T cells, total expression levels of fB2 Y504E are 
reduced compared to WT or Y504F constructs (Supplementary Figure 3.3).  
These data suggest that phosphorylation of Y504 may also regulate EphB 
trafficking as well as the EphB-NMDAR interaction (Figure 3.3A).  Furthermore, 
these data suggest the possibility that in the absence of the NMDAR, 
phosphorylation of Y504 may lead to the removal and proteolysis of EphB2     
 To test whether phosphomimetic Y504E mutant receptors were properly 
localized to the plasma membrane, but prematurely degraded, we blocked 
clathrin-mediated internalization using hypertonic sucrose (Heuser and 
Anderson, 1989) in HEK293T cells transfected with fB2 WT, Y504E, and Y504F 
constructs.  Sucrose treatment for only 15 minutes increased total fB2 Y504E 
expression back to baseline levels, but did not affect WT or Y504F constructs 
(Figure 3.3D lanes 5 and 6; Figure 3.3E quantification).  Because proper 
activation of the intracellular kinase domain in EphB2 is required for surface 
localization (Irie et al., 2005; Zimmer et al., 2003), we wanted to test if kinase 
activity was also required for Y504 surface localization.  Therefore, we used 
constructs with a point mutation (fB2 K663R or fB2 KD) in the EphB2 ATP-
binding domain that renders the kinase inactive (Dalva et al., 2000) to generate 
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both non-phosphorylatable and phosphomimetic double-point mutants with 
inactive kinases fB2 KD Y504E and fB2 KD Y504F respectively.  Consistent with 
this model, fB2 KD Y504E mutants were expressed at similar levels to WT and 
Y504F constructs (Figure 3.3D; Figure 3.3E quantification).  Together, these 
findings suggest that Y504E mutant EphB2 receptors are rapidly internalized by 
clathrin-mediated mechanisms that require EphB tyrosine kinase activity. 
 We next asked whether blocking endocytosis with dominant negative 
dynamin (K44A) constructs, which block the formation of clathrin-coated pits at 
the plasma membrane, might also rescue the expression level of EphB2 Y504E 
constructs (Conner and Schmid, 2003).  Over-expression of WT dynamin should 
lead to a large increase in protein degradation in total lysates, whereas K44A 
over-expression should block clathrin-mediated endocytosis.  We co-expressed 
these two dynamin constructs with fB2 WT, Y504E, and Y504F constructs in 
HEK293T cells.  We find that co-expressing K44A dynamin causes a significant 
increase in EphB2 expression in the total lysate of WT and Y504E, but not non-
phosphorylatable Y504F receptors (Figure 3.3F-G).  Furthermore, there is 
significantly more fB2 expression in Y504E mutants than Y504F mutants (Figure 
3.3G).  These data support a model (Figure 3.3A) where Y504E mutants are 
trafficked to the plasma membrane, but rapidly degraded via clathrin-mediated 
mechanisms.   
 To test the idea that phosphomimetic Y504E receptors are degraded in 
the proteasome, we used lactacystin (5µM; Calbiochem), an irreversible inhibitor 
of the 20S proteasome, to block all protein degradation (Litterst et al., 2007; 
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Margolis et al., 2010).  We reasoned that in the presence of lactacystin, there 
should be significantly more protein in the total lysate than under untreated 
conditions.  As expected, in the presence of lactacystin, the level of expression of 
fB2 Y504E was rescued to control levels (Figure 3.3H lanes 5 and 6; Figure 
3.3I quantification).  These data is consistent with a model (Figure 3.3A) in 
which Y504E mutant receptors are rapidly internalized off the plasma membrane 
after ephrin-B activation.   
To test whether a similar mechanism might function in neurons, we 
biotinylated surface-localized, endogenous EphB2 receptors in DIV7 cultured 
cortical neurons after ephrin-B activation.  Consistent with previous reports (Irie 
et al., 2005; Zimmer et al., 2003), we find that EphB2 receptors are internalized 
after ephrin-B activation (Supplementary Figure 3.4).  Furthermore, we find that 
these activated receptors move from the biotin-labeled surface fraction to an 
intracellular avidin fraction without affecting total expression (Supplementary 
Figure 3.4).  These data confirm that similar to HEK293T cells, EphB2 receptors 
are internalized in neurons after ephrin-B activation.  
 Phosphorylation of Y504 induces the EphB-NMDAR interaction; therefore 
we asked whether the presence of NMDAR receptors would affect the instability 
of Y504E mutant receptors.  To test this, we transfected fB2 WT, Y504E, and 
Y504F constructs alone, or with HA-NR1-GFP and NR2B in HEK293T cells 
before performing a steady-state cell surface biotinylation.  We find that Y504E 
mutants have reduced surface localization compared to WT or Y504F receptors 
(Figure 3.3J; Figure 3.3K quantification).  However, when co-expressed with 
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NMDARs, the levels of Y504E mutant receptors are rescued back to levels 
comparable to WT and Y504F receptors (Figure 3.3J lanes 3 and 4; Figure 
3.3K quantification).  These data suggests that the EphB-NMDAR interaction 
stabilizes EphB receptors on the plasma membrane.  Moreover, a cell surface 
biotinylation in cultured cortical neurons infected with our EphB2-YFP lentiviruses 
resulted in no significant differences in surface localization between Y504E, WT, 
or Y504F receptors (Supplementary Figure 3.5).  These data suggests that in 
the presence of endogenous NMDARs, over-expressed Y504E mutant receptors 
are stabilized on the membrane.   
 To test whether the EphB-NMDAR interaction might affect NR1 surface 
retention, we transfected fB2 WT, Y504E, and Y504F constructs with HA-NR1-
GFP and NR2B, or NR1/2B alone in HEK293T cells before performing a steady-
state cell surface biotinylation and probing for the HA-tag of NR1 (same lysates 
as in Figure 3.3L-M).  We find that co-expression of fB2 Y504E significantly 
increased the fraction of NR1 receptors on the plasma membrane compared to 
all other conditions (Figure 3.3L lane 3; Figure 3.3M quantification).  
Interestingly, co-expression of non-phosphorylatable Y504F mutant receptors 
causes a significant decrease of NR1 receptors on the cell surface compared to 
WT EphB2 (Figure 3.3L; Figure 3.3M quantification).  These data suggests 
that the EphB-NMDAR interaction stabilizes NMDA receptors on the plasma 
membrane.            
 Late in neuronal development (after DIV14), EphBs are not required to 
maintain synapse number (Kayser et al., 2008), but are instead key regulators of 
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NMDAR localization and functional at mature synapses (Nolt et al., 2011).  To 
test whether the EphB-NMDAR interaction is required to maintain the normal 
number of NR2B-containing NMDARs at synapses, we asked if mutation to Y504 
would alter the functional properties of synapses in mature cultured cortical 
neurons.  Neurons were transfected at DIV14 with EGFP and vector control, 
EphB2-YFP-WT, Y504E, or Y504F constructs.  Then at DIV21-23, spontaneous 
miniature EPSCs (mEPSCs) were recorded using whole-cell patch clamp at 
+50mV including tetrodotoxin and blockers of GABAergic channels to isolate 
NMDAR-mediated spontaneous currents.  No changes on mEPSC frequency 
were observed between conditions (Control, n=9; WT, n=10; Y50E, n=10; Y504F 
n=13).  However, EphB2 WT and EphB2 Y504E over-expression both caused a 
significant increase in amplitude compared to control or non-phosphorylatable 
Y504F mutants (Figure 3.4A).  These changes in mEPSC amplitude are 
attributable specifically to NMDARs because treatment of the NMDAR antagonist 
D-APV (50µM) blocked these affects (Figure 3.4A-B: Control n=5 cells, 491 
mEPSCs w/o APV, 421 mEPSCs w/ APV; WT, n=7 cells, 1182 mEPSCs w/o 
APV, 758 mEPSCs w/ APV; Y504E, n=6 cells, 705 mEPSCs w/o APV, 349 
mEPSCs w/ APV; Y504F, n=9 cells, 912 mEPSCs w/o APV, 541 mEPSCs w/ 
APV: p<0.001).  While there is a modest effect on Y504F mutants with APV 
treatment, a much larger effect is observed for Y504E mutants (Figure 3.4B).  
These data suggests that phosphorylation at Y504 is a functional regulator of 
NMDAR currents at mature synapses.               
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 We have shown that EphB2 is a subunit-specific regulator of synaptic-
NR2B containing NMDARs (Nolt et al., 2011) at mature synapses.  Based on the 
finding that Y504 regulates the function of NMDAR currents at mature synapses 
(Figure 3.4A-B), we hypothesized that this change was due to recruitment of 
NR2B-containing NMDARs to synaptic sites.  To test this, we treated neurons 
with Ro25-6981 (Ro25) the NR2B-selective antagonist (2.5 µM; Tocris 
Bioscience) and then measured mEPSC amplitude.  We find that treatment with 
Ro25 caused a large decrease on mEPSC amplitude in cells expressing 
phosphomimetic Y504E mutant receptors (Figure 3.4C; Y504E, n=7 cells, 767 
mEPSCs w/o Ro25, 456 mEPSCs w/ Ro25).  However, no changes were 
observed in current amplitude from cells expressing Y504F mutant receptors 
after Ro25 treatment (Figure 3.4D; Y504F, n=6 cells, 457 mEPSCs w/o Ro25, 
444 mEPSCs w/ Ro25).  These data demonstrate that at mature synapses, 
phosphorylation of Y504 results in increased trafficking of NR2B-containing 
NMDARs to synaptic sites, which alters synaptic currents. 
 To confirm our physiological findings, we performed immunostaining 
experiments at the same developmental timepoints, using the same conditions, 
and looking at NR2B staining intensity at synapses.  We looked at NR2B staining 
intensity at synaptic sites (positive for the presynaptic vesicle protein SV2; 
Figure 3.4E-G: Control, n=539 synapses; WT, n=516; Y504E, n=527; Y504F, 
n=539).  In accordance with our physiological findings, we find that synaptic 
NR2B is significantly reduced in EphB2 Y504F expressing neurons compared to 
EphB2 Y504E (Figure 3.4E-G; ANOVA test, p < 0.01).  Furthermore, neurons 
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expressing Y504F mutant receptors had significantly reduced synaptic NR2B 
compared to controls (Figure 3.4E-F; ANOVA test, p < 0.05).  We find similar 
increases in EphB2 Y504E, as expected from our physiological experiments with 
Ro25 (Figure 3.3C-D).      
  EphB regulates NMDAR-dependent gene transcription by modulating 
calcium influx through NR2B-containing NMDARs (Takasu et al., 2002).  To test 
whether the ability of EphB2 to recruit NR2B receptors to synaptic sites might 
impact NMDAR-dependent gene expression, we used a synaptic stimulation 
paradigm and asked if our EphB Y504 mutant receptors altered CREB-
dependent reporter gene expression. We transfected DIV7 cultured cortical 
neurons with GFP control, EphB2 WT, EphB2 Y504E, or EphB2 Y504F 
constructs along with CRE-luciferase reporter construct or Renilla luciferase as a 
transfection control.  Neurons were stimulated with 4-AP and BIC in the presence 
of nifedipine to block L-type calcium channels; and then some neurons were 
treated with Ro25-6981 (2.5 µM) to block NR2B-containing receptors.  We find 
that expression of EphB2 Y504E constructs potentiates CREB-dependent gene 
transcription (Figure 3.4H).  Furthermore, this effect is totally abolished with 
treatment of Ro25 (Figure 3.4H).  Taken together, these results suggest that 
phosphorylation at Y504 potentiates calcium-dependent gene transcription 
through NR2B-containing NMDARs.                                    
 It was previously shown that the EphB-NMDAR interaction requires the 
EphB extracellular domain, but the specific residues required for this interaction 
have remained elusive for over a decade.  Here, we report that EphB2 Y504 is 
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both necessary and sufficient for the EphB-NMDAR interaction to occur.  Our 
findings support a model in which phosphorylation of extracellular domains of 
EphB2, in a ligand-dependent manner, alters the direct protein-protein 
interactions with NMDARs.  Mislocalization of NMDARs from the cell surface and 
synaptic sites is a hallmark of the diseased brain.  Specifically, deficits in EphB-
dependent regulation of NMDAR localization is associated with synaptopathies 
including neuropathic pain (Slack et al., 2008; Song et al., 2008b), Alzheimer’s 
disease (Cisse et al., 2011; Simon et al., 2009) and anxiety disorders (Attwood et 
al., 2011).  Our data indicates that the EphB-NMDAR interaction in brain is 
responsible for modulating NMDARs at the surface and altering receptor 
function, signaling, and gene expression in a subunit specific manner.   
 Notably, we find that a broad-spectrum inhibitor of extracellular kinases, k-
252b can block the EphB-NMDAR interaction and phosphorylation at Y504 in 
neurons.  An extensive literature shows that in the spinal cord and periphery, 
blocking EphB1 signaling is sufficient to block hyperalgesia and NMDAR-
dependent hyperexcitability in neuropathic and cancer-induced pain (Liu et al., 
2011; Liu et al., 2009; Slack et al., 2008; Song et al., 2008b).  Our data suggests 
that k-252b inhibits the phosphorylation of Y504 and suggests that extracellular 
inhibition of the EphB-NMDAR interaction could be a viable approach to treat 
neuropathic and cancer-induced pain.   
While extracellular phosphorylation has previously been reported on 
serine and threonine residues (Chen et al., 1996; Fujii et al., 2000; Kumar et al., 
2011; Redegeld et al., 1999), this is the first example of extracellular tyrosine 
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phosphorylation.  One possible kinase that might mediate these events is a 
reported soluble form of the FGFR that lacks a transmembrane domain 
(Johnston et al., 1995; Katoh et al., 1992; Sturla et al., 2003).  Our data define a 
new type of protein modification: phosphorylation of extracellular tyrosines that 
can enable novel forms of interactions at sites of cell-cell contact or give cells the 
ability to respond directly to their environment.  Based on the conservation of 
Y504 amongst the EphB family, we expect that extracellular phosphorylation is 
an underappreciated mechanism for human disease.  Taken together our finding 
suggests that extracellular phosphorylation of EphB2 at Y504 is a critical 
regulator of NMDAR synaptic localization and function with profound implications 
on synaptic plasticity and disease.       
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Figure Legends 
 
Figure 3.1.  Novel phosphorylation sites on the EphB2 receptor modulate 
the EphB-NMDAR interaction.  (A-B) MS/MS spectra of peptides (A) 
ELSEYNATAIK and (B) AGAIYVFQR are shown.  Fragments critical for 
localization of phosphorylation sites are labeled in red.  Most abundant signals 
are accounted for by sequence specific ions as indicated by labeling.  (C) 
Schematic of the known functional domains of EphB2 receptor.  LBD, Ligand-
binding domain; Cys, cysteine-rich domain; FN3, Fibronectin type III repeat 
domain; TM, Transmembrane domain; JM, juxtamembrane domain; SAM, sterile-
α-motif; PDZ, PSD-95/DLG1/ZO-1 domain.  (D) Alignment of all mouse Eph 
family members cFN3 domains (Uniprot database) for 40 amino acids beginning 
at indicated site using ClustalW2 and Jalview software.  EphB2 Y504 
corresponds to a very well conserved tyrosine residue (red) whereas Y481 is not 
well conserved amongst the Eph family (yellow box).  Blue color indicates % 
identity score with a threshold set at greater than 51%.  Darker blue colors 
correspond to the most conserved residues.  (E-F) HEK293T cells were co-
transfected with HA-NR1-GFP and NR2B alone, or NR1/2B and fB2 WT, fB2 
Y481E, or fB2 Y481F.  EphB2 receptors were immunoprecipitated with anti-
FLAG antibodies, and immunoblotted with anti-HA (NMDAR1) or EphB2 
antibodies.  Right Lysates from the same preparation as in E are shown 
immunoblotted with the same antibodies.  (F) Quantification of relative amount of 
HA-NR1 immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=5).  
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(G-H)  As in E, HEK293T cells were co-transfected with NR1/2B construct alone, 
or with fB2 WT, fB2 Y504E, or fB2 Y504F mutants.  EphB2 receptors were 
immunoprecipitated with anti-FLAG antibodies, and immunoblotted with anti-HA 
(NMDAR1) or EphB2 antibodies.  Right, Lysates from the same preparation as in 
G are shown immunoblotted with the same antibodies.  (H) Quantification of 
relative amount of HA-NR1 immunoprecipitated compared to input (*p < 0.05, 
ANOVA test; n=5).  (G-H) DIV2 cultured cortical neurons were infected with 
EphB2-YFP WT, EphB2-YFP Y504E, or EphB2-YFP-Y504F constructs as 
indicated.  At DIV7, neurons were stimulated for 45 minutes using ephrin-B2-Fc 
or Fc control as indicated.  Infected EphB2 receptors were immunoprecipitated 
using an anti-GFP antibody.  Resulting western blots were probed with anti-
NMDAR1 or GFP (EphB2) antibodies.  (H) Quantification of relative amount of 
NMDAR1 immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=6).  
 
Figure 3.2.  Extracellular phosphorylation modulates the EphB-NMDAR 
interaction and generation of a phospho-specific antibody to Y504.  (A-B) 
HEK293T cell lysates transfected with indicated FLAG-EphB2 constructs then 
probed with a phospho-specific polyclonal antibody generated against EphB2 
Y504 (EphB2 pY504).  (B) Pure synaptosome fractions from WT CD1 mice were 
subjected to SDS-PAGE.  Resulting western blots were left untreated or were 
treated overnight with gentle shaking at 37°C with calf intestinal alkaline 
phosphatase (CIP; 1:500) as indicated then probed with EphB2 pY504 
antibodies.  Immunoblots were then stripped and reprobed with a commercial 
 112
antibody against the N-terminal domain of EphB2.  (C) DIV6-7 cultured cortical 
neurons were treated as indicated with 450mM hypertonic sucrose for 15min at 
37°C, or 30 min at 37°C with 80μM dynasore followed by 45 min of stimulation 
with Fc control or ephrin-B2-Fc (eB2).  EphB2 receptors were 
immunoprecipitated with an N-terminal anti-EphB2 antibody, and immunoblotted 
against EphB2 pY504, EphB2, or the phosphorylated EphB2 kinase (EphB2 
pY662).  (D) Model of how extracellular phosphorylation at Y504 modulates the 
EphB-NMDAR interaction.  (E-G) DIV6-7 cultured cortical neurons were treated 
as indicated with 10µM of the broad spectrum extracellular protein kinase 
inhibitor K-252b for 60 minutes, before 45 minutes of stimulation with Fc control 
or ephrin-B2-Fc.  EphB2 receptors were immunoprecipitated with an N-terminal 
EphB2 antibody and resulting western blots were probed with anti-NMDAR1, 
anti-EphB2, anti-EphB2 pY504 extracellular, or anti-EphB2 pY662 intracellular 
kinase antibodies.  (F) Quantification of relative amount of NMDAR1 
immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=5).  (G) 
Quantification of relative amount of EphB2 pY504 phosphorylation 
immunoprecipitated compared to input (*p < 0.05, ANOVA test; n=5).  
 
Figure 3.3. Tyrosine 504 regulates EphB2 surface localization, degradation, 
and affects NMDAR surface retention.  (A) Model of how extracellular 
phosphorylation at Y504 modulates EphB receptor trafficking and the EphB-
NMDAR interaction.  (B-C) Mutation of Y504 to E causes decreased surface 
localization of EphB2 Receptors. (B) Representative immunoblots of biotinylated 
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EphB2 with no actin biotinylated.  (C) Quantification of percent localized to the 
cell surface of total lysate.  (*p < 0.05, ANOVA test; n=4).  (D-E) Mutation of 
Y504 to E causes EphB2 internalization by a clathrin-mediated mechanism.  (D) 
Western blots of lysates from HEK293T cells transfected with indicated 
constructs for 16-18 hours, then treated with 450mM sucrose for 15 minutes at 
37°C before lysis.  Lysates were probed for EphB2, or β-actin. (E) Quantification 
of fold change normalized to actin in total protein lysate after sucrose treatment 
(*p < 0.05, ANOVA test; n=4-5).  (F-G) Expression of dominant negative (K44A) 
dynamin increases WT and Y504E EphB2 receptor expression, but not Y504F.  
(F) Western blots of lysates from HEK293T cells co-transfected with indicated 
fB2 constructs and either wild-type (WT Dyn) or dominant-negative dynamin 
K44A (DN Dyn) constructs.  Blots were and probed for EphB2, dynamin-1, or β-
actin.  (G)  Quantification of relative amount of EphB2 in the presence of DN 
K44A dynamin compared to when co-expressed with WT dynamin.   (*p < 0.05, 
ANOVA test; n=5).  (H-I) Mutation of Y504 to E causes EphB2 increased 
degradation in the proteasome.  (H) Representation immunoblots from HEK293T 
cells transfected with indicated constructs for 16-18 hours, then treated with 5µM 
lactacystin for 4 hours at 37°C before lysis.  Lysates were probed for EphB2, and 
β-actin.  (I) Quantification of fold change normalized to actin in total protein lysate 
after lactacystin treatment.  (*p < 0.05, ANOVA test; n=5).  (J-M)  Mutations at 
EphB2 Y504 modulates EphB2 and NMDAR1 trafficking.  (J) Expression of 
NMDARs rescues EphB2 Y504 to E surface localization, and (L) co-expression 
of EphB2 Y504E increases NMDAR1 surface localization.  (J, L) Representative 
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immunoblots of biotinylated EphB2 (J) or NMDAR1 (L) with no actin biotinylated 
from HEK293T cells.  (K, M) Quantification of percent localized to the cell surface 
of total lysate.  (*p < 0.05, ANOVA test; n=5).  Error bars indicate SEM.  
 
Figure 3.4.  Tyrosine 504 regulates the function of synaptic NR2B-
containing NMDARs in mature neurons.  (A-D) Phosphomimetic mutants at 
Y504 regulate mEPSC amplitude in mature neurons in a subunit-specific 
manner.  (A) Quantification of mean mEPSCs before and after the application of 
50µM APV.  An increase in mEPSC amplitude was observed with overexpression 
of EphB2 WT and Y504F, whereas NMDAR blockade using APV reduced 
mEPSC in all conditions. Control: n=5 cells, 491 mEPSCs w/o APV, 421 
mEPSCs w/ APV; EphB2 WT: n=7 cells, 1182 mEPSCs w/o APV, 758 mEPSCs 
w/ APV; EphB2 Y504E: n=6 cells, 705 mEPSCs w/o APV, 349 mEPSCs w/ APV; 
EphB2 Y504F: n=9 cells, 912 mEPSCs w/o APV, 541 mEPSCs w/ APV.  
(ANOVA test, p < 0.001).  Error bars indicate SEM.  (B) Cumulative probability 
histogram of mEPSC amplitude for Y504E and Y504F mutants at ~20-35 ms 
before (dark shading) and after (light shading) NMDAR blockage with 50µM APV.  
Inset, Mean traces of mEPSCs after NMDAR blockage with APV.  (C-D) 
Cumulative probability histogram of mEPSC amplitude for Y504E (C) and Y504F 
(D) mutants before and after application of NR2B-specific antagonist Ro25-6981 
(2.5 µM).  Inset, Mean traces of mEPSCs after treatment with Ro25.  EphB2 
Y504E: n=7 cells,767 mEPSCs w/o Ro25,456 mEPSCs w/ Ro25; EphB2 Y504F: 
n=6 cells, 457 mEPSCs w/o Ro25, 444 mEPSCs w/ Ro25. (E-G) Distribution of 
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synaptic NR2B-containing NMDARs.  (E) Representative images of DIV21-23 
cultured cortical neurons expressing EGFP and vector control (n=539), EphB2-
YFP-WT (n=516), Y504E (n=527), or Y504F (n=539) constructs, immunostained 
for GFP (green), NMDAR2B (red), and SV2 (blue).  Arrowheads indicate 
measurement site (Scale bar: 5 μm). (F) Quantification of average of normalized 
intensity for synaptic NR2B in spines. (*p < 0.05, **p < 0.01, ANOVA test).  Error 
bars indicate SEM.  (G) Cumulative probability histograms of normalized intensity 
of NR2B on synaptic spines for Y504E and Y504F receptors.  ANOVA test, 
p<0.001 (H) CREB-dependent gene transcription is enhanced with synaptic 
NMDAR stimulation in Y504E mutants and blocked by NR2B antagonist Ro25.  
CRE-luciferase activity is reported as fold-induction (*p<0.05, ANOVA test), Error 
bars indicate 0.05 confidence.  
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Supplemental Online Material 
Materials and Methods 
Expression Constructs 
Full length FLAG-EphB2, truncated FLAG-EphB2 (fEphB2 Tr) and FLAG-
tagged kinase dead (KD; K663R) EphB2 and truncated were previously 
described (Dalva et al., 2000).  Single amino acid point mutations to Y481 and 
Y504 were introduced using sequence specific primers and site-directed 
mutagenesis (Strategene, La Jolla, CA).  Sequences used were: EphB2 Y504F, 
5’-GCCTCAAAGCCGGTGCCATCTTTGTCTTCCAGGTGCGG-3’; EphB2 
Y504E, 5’-GCCTCAAAGCCGGTGCCATCGAAGTCTTCCAGGTGCGG-3’; 
EphB2 Y481F, 5’-ATGAGAAGGAGCTAAGTGAGTTCAACGCCACGGCCATA-3’; 
EphB2 Y481E, 5’-ATGAGAAGGAGCTAAGTGAGGAGAACGCCACGGCCATA-
3’.  Forward and reverse oligonucleotides were synthesized (Integrated DNA 
Technologies, Coralville, IA).  Generation of EphB2-YFP was previously 
described (Kayser et al., 2006).  AgeI and MfeI sites were added to EphB2-YFP 
using site-directed mutagenesis and sequence specific primers: EphB2-
YFP_AgeI, 5’-AAACCGGTTTACCGTGGAAGAAACCCTGATG-3’; EphB2-YFP 
MfeI, 5’-TTAATCCAATTGGAGTGACAGAGCAGCAGGGAC-3’.  Then point 
mutations at Y504 were introduced using site-directed mutagenesis.  PCR 
products were ligated into the pFUGW vector using Age1 (bp3860) and EcoR1 
(bp4609) sites.  Lentivirus were produced and purified by the Gene Therapy 
Program Penn Vector Core Facility at the University of Pennsylvania. 
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Generation of a phosphorylation-specific antibody 
The phosphorylated peptide Ac-CKGLKAGAI-pY-VGQVRA-NH2 was 
conjugated to Keyhole Limpet Hemocynein (KLH) in position 1 (EZBiolab, 
Carmel, IN).  This conjugated, phosphorylated peptide was injected into rabbits 
for polyclonal antibody production (Covance, Denver, PA).  Antibody titer was 
assessed using an ELISA (Covance, Denver, PA) with a non-phosphorylated 
form of the injection peptide Ac-CKGLKAGAIYVGQVRA-NH2 (EZBiolab, Carmel, 
IN).  Serum from each animal was affinity purified using SulfoLink Coupling Resin 
(Thermo Scientific – Pierce Biotechnology, Rockford, IL) according to 
manufacturer’s instructions and the phosphorylated peptide without KLH 
conjugation.  Protein concentration was calculated using a Bradford assay 
(BioRad, Hercules, CA).  Eluates were dialyzed overnight in Slide-A-Lyzer 10K 
Dialysis Cassettes (Thermo Scientific – Pierce Biotechnology, Rockford, IL), then 
aliquoted with a final concentration of 10% glycerol and stored at 4°C. 
 
Cell Culture and Transfection 
Dissociated cortical neurons were prepared from embryonic day 17 (E17) 
to E18 rats as previously described (Kayser et al., 2008; Nolt et al., 2011) on 
poly-D-lysine (BD Bioscience, Bedford, MA) and laminin (BD Biosciences, 
Bedford, MA) coated glass coverslips (12 mm; Bellco Glass, Vineland, NJ) in 24-
well plates (Corning Life Sciences, Lowell, MA).  For immunostaining and 
electrophysiology experiments neurons were transfected as indicated at either 7 
or 14 days in vitro (DIV) using Lipofecatmine 2000 (Invitrogen, Carlsbad, CA) as 
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previously described (Kayser et al., 2008; Nolt et al., 2011).  For biochemistry 
cortical neurons were plated at a density of 10 × 106 cells per 100 mm dishes 
(BD Bioscience, Franklin Lakes, NJ) pre-coated with poly-D-lysine and laminin. 
       
HEK293T Culture and Transfection 
 HEK-293T cells were maintained in DMEM (Invitrogen), 10% Fetal Bovine 
Serum (Thermo Scientific – Hyclone, Logan, UT), penicillin-streptomycin (Sigma-
Aldrich, Saint Louis, MO), and glutamine (Sigma-Aldrich, Saint Louis, MO).  For 
transfection, HEK293T cells were plated in 6-well or 35mm culture plates (BD 
Bioscience, Franklin Lakes, NJ) and transfected with indicated EphB2, NR1, or 
NR2B constructs using the calcium phosphate method (Kayser et al., 2006; 
McClelland et al., 2009; Xia et al., 1996).  100 μm APV (Sigma-Aldrich, Saint 
Louis, MO) was added to the culture medium after NMDAR transfection to 
prevent excitotoxicity. 
 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde/ 2% sucrose for 5 minutes 
followed by 10 minutes in 0.25% Triton X-100 at room temperature.  Cells were 
washed three times in PBS then blocked and permeabilized in 1% ovalbumin 
(Sigma-Aldrich, Saint Louis, MO) / 0.2% cold water fish skin gelatin (Sigma-
Aldrich, Saint Louis, MO) / 0.1% saponin (Sigma-Aldrich, Saint Louis, MO) for 1 
hour at room temperature.  Primary antibody was incubated overnight at 4°C in 
blocking reagents.  Cells were again washed three times in PBS then incubated 
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with secondary antibody in blocking reagents for 45-60 minutes at room 
temperature.  Cells were then washed three times in PBS before mounting using 
Aqua-Mount (Thermo Scientific -- Lerner, Kalamazoo, MI).  Antibodies used 
were: chicken polyclonal anti-GFP (1:2500; Millipore, Temecula, CA), rabbit anti-
NR2B polyclonal (1:1000; (Dalva et al., 2000)), mouse monoclonal anti-NMDAR1 
(1:500; BD Pharmingen, San Diego, CA) and mouse monoclonal anti-synaptic 
vesicle protein 2 (SV2) (1:200; Developmental Studies Hybridoma Bank, 
University of Iowa, Iowa City, IA).  Cy2, Cy3, and Cy5 secondary antibodies were 
used 1:250 (Jackson ImmunoResearch, West Grove, PA). 
 
Synaptosome Preparation 
Synaptosomes were prepared as previously described (Nolt et al., 2011).  
Briefly, whole brains from P30 WT CD1 mice were homogenized in HEPES-
buffered sucrose.  Centrifugation was used to remove the nuclear fraction and 
generate a S1 fraction.  A crude membrane (P1) fraction was generated by 
centrifugation of the S1 fraction.  The P1 fraction was resuspended in HEPES-
buffered sucrose and centrifuged again to generate a crude synaptosome.  The 
crude synaptosome was layered onto a sucrose gradient and found at the 
interface of buffer and 1.2 M sucrose.  The interface was diluted and centrifuged 
again at 230,000 X g to obtain the final pure synaptosomal (Syn) pellet.   
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Western Blot Analysis 
Lysates from HEK293T cells or neurons were separated using 8% SDS-
polyacrylamide gels and transferred onto 0.45µM PVDF membranes (Millipore, 
Temecula, CA).  Immunoblots were then blocked in 5% nonfat dry milk in TBS-T 
(150mM NaCl, 10mM Tris pH 8.0, 0.05% Tween-20).  Indicated primary 
antibodies were presented in blocking solution for 2 hours at room temperature 
or overnight at 4°C:  mouse monoclonal anti-GFP (1:1000; Roche, Mannheim 
Germany), mouse monoclonal anti-Dynamin (1:1000, BD Transduction 
Laboratories, Lexington, KY), goat polyclonal anti-EphB2 (1:500; R&D Systems; 
Minneapolis, MN), mouse monoclonal anti-NMDAR1 (1:500; BD Pharmingen, 
San Diego, CA), mouse monoclonal anti-FLAG (M2; 1:2500; Sigma-Aldrich, Saint 
Louis, MO), rabbit polyclonal anti-EphB2 (1:500; (Dalva et al., 2000)), rabbit 
polyclonal anti-EphB2 pY662 (1:1000; (Dalva et al., 2000)).  HRP-conjugated 
secondary antibodies were used at 1:20,000 in blocking solution for 1 hour (EMD 
Biosciences – Calbiochem, San Diego, CA or Santa Cruz Biotechnology, Santa 
Cruz, CA) then visualized using ECL (PerkinElmer, Waltham, MA) and 
autoradiography film (Kodak, Rochester, NY or TruMark Scientific, Edison, NJ).  
Protein band immunoreactivity was quantified using NIH ImageJ software.   
 
Cultured Neuron Biotinylation and HEK293T Cell Biotinylation 
Biotinylations were preformed as previously described (Nolt et al., 2011).  
Briefly, cells were washed twice in ice-cold PBS-Ca2+/Mg2+ rinsing solution then 
cell surface proteins were bulk labeled using 1mg/mL Sulfo-NHS-SS-Biotin 
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(Thermo Scientific – Pierce Biotechnology, Rockford, IL).  Unreacted biotin was 
quenched using rinsing solution with 100mM glycine.  Cells were then washed 
and lysed using radioimmunoprecipitation assay (RIPA) buffer.  Lysates were 
harvested and centrifuged to remove cellular debris.  Biotinylated proteins were 
extracted using monomeric avidin agarose (Thermo Scientific – Pierce 
Biotechnology, Rockford, IL). Surface proteins were solubilized off the avidin 
beads using 2X-SDS sample buffer.  Equal amounts of total cell lysate and 
biotinylated (surface) proteins were subjected to SDS-PAGE and western blot 
analysis.   
 
Immunoprecipitation  
Immunoprecipitations were performed as previously described with small 
changes (Dalva et al., 2000; Takasu et al., 2002).  After treatment with clustered 
ephrin-B2-Fc or Fc control, cortical neuron cultures (or untreated HEK293T cells) 
were lysed in radioimmunoprecipitation assay (RIPA) buffer (750µl for 100mm 
dishes or 300µl per well for 6-well plates) containing protease inhibitors and 
agitated at 4°C for 15 minutes.  Cell lysates were harvested and centrifuged at 
13,000 rpm for 25 minutes to pellet cellular debris.  A fraction of the resulting 
supernatant (100µl for 100mm dishes or 75 µl per well for 6-well plates) was 
removed as an input control.  The remaining supernatant was incubated with 
appropriate antibody to conjugate on ice for 2 hours: rabbit polyclonal anti-GFP 
(ab290; Abcam, Cambridge MA), goat polyclonal anti-EphB2 (R&D Systems, 
Minneapolis, MN), or mouse monoclonal anti-FLAG (M2; Sigma-Aldrich, Saint 
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Louis, MO).  Antibody bound proteins were then isolated using pre-blocked 
protein-G agarose beads (Invitrogen, Carlsbad, CA) 75µl for 100mm dishes or 50 
µl per well for 6-well plates on a rotator for 60 minutes at 4°C.  Samples were 
then centrifuged and beads were washed four times in RIPA lysis buffer and two 
times in TBS-V.  Immunoprecipitates were eluted from the agarose beads by 
adding 25μl boiling 6X SDS-sample buffer and boiled for 5 minutes at 95°C.   
  
Inhibitors and Reagents 
K-252b and D(-)-2-Amino-5-phosphonopentanoic acid (D-APV) were 
obtained from Sigma-Aldrich (Saint Louis, MO).  Lactacystin was obtained from 
Calbiochem (EMD Biosciences, San Diego, CA).  Alkaline Phosphatase, Calf 
Intestinal (CIP) was purchased from New England BioLabs (Ipswich, MA).  
Ephrin-B2-Fc and Fc control were obtained from R&D Systems (Minneapolis, 
MN) and clustered using anti-Human IgG (Jackson ImmunoResearch, West 
Grove, PA) then used as previously described (Kayser et al., 2006; Nolt et al., 
2011).   
 
Cre-luciferase transcription 
Cre-luciferase assay were performed as previously described with small 
changes (Takasu et al., 2002).  Briefly, neurons were transfected at DIV7 by the 
lipofectamine method (Kayser et al., 2006; Nolt et al., 2011) with a ratio of 8:1 of 
CRE-luciferase reporter construct and Renilla luciferase as a transfection control. 
In this CRE-luciferase construct, there are four copies of somatostatine CRE 
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before firefly luciferase.  EphB2-YFP-WT, EphB2-YFP-Y504E, EphB2-YFP-
Y504F, and pFUGW vector control were co-transfected with EGFP to assess 
transfection efficiency, along with the CRE-luciferase reporter and the Renilla 
luciferase at the ratio previously described in (Takasu et al., 2002).  At DIV10, 
neurons were silenced for 6 hours with TTX, before synaptic stimulation with a 
mixture of 4-aminopyridine (4-AP) and bicuculline (BIC) in the presence of 
nifedipine to block L-type Ca2+ channels for 3-4 hours before lysis (Kawashima 
et al., 2009).  Lysates were then collected and analyzed for luciferase expression 
using the Dual Luciferase Reporter Assay System (Promega, Madison, WI). 
 
Imaging and Analysis 
 Images of cultured cortical neurons were obtained using confocal 
scanning microscopy (Leica Microsystems, Wetzlar, Germany) as previously 
described (McClelland et al., 2009; Nolt et al., 2011).  Briefly, images were 
acquired at 63X resolution, numerical aperture 1.4, and oil-immersion objective.  
Analysis was done using MetaMorph software (Molecular Devices, Sunnyvale, 
CA) blind to experimental condition.  Images were collected from at least three 
independent experiments.  Puncta were considered to be co-localized when 
there was greater than one pixel overlap between channels.  During image 
collection all gain values were held constant.  Amount of NR2B intensity were 
normalized to the maximum intensity observed from all three conditions for each 
experiment.       
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Electrophysiology 
 Recordings from DIV21-23 cultured rat cortical neurons were performed 
using whole-cell patch methods as previously described (McClelland et al., 2009; 
Nolt et al., 2011).  Briefly, coverslips were moved into a recording chamber and 
bathed in a HEPES-buffered artificial CSF (ACSF) solution in mM: 140 NaCl, 5 
KCl, 2 CaCl2, 1 MgCl2, 20 glucose, and 10 HEPES, pH 7.2). Tetrodotoxin (TTX) 
and picrotoxin were used at 1 and 10 μM, respectively (Sigma-Aldrich, St. Louis, 
MO). Bicuculline was used at 50 μM, D-APV was used at 10 μM, and (αR, βS)-α-
(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate 
(Ro25-6981) was used at 2.5 μM (Tocris Bioscience, Ellisville, MO). All data were 
collected at 5 kHz and filtered at 1 kHz; events were detected in Clampfit 9.2 
(Molecular Devices, Sunnyvale, CA). Event analysis and statistics were 
performed using Clampfit software (Molecular Devices, Sunnyvale, CA). To 
isolate the NMDAR component, neurons were held at +50 mV in the presence of 
TTX (1 μM), bicuculline (50 μM), and picrotoxin (10 μM). 
 
SILAC Assay 
Cell culture, metabolic labeling and stimulation 
Two NG108-15 (mouse neuroblastoma x rat glioma hybrid) cell lines were 
used, a “wild type” cell line without stable transfection and another stably 
overexpressing EphB2 (Holland et al., 1997).  Both cell lines were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen Corporation, Carlsbad, 
CA) or lysine and arginine depleted DMEM (Special Media, Philipsburg, NJ) and 
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supplemented with 10% dialyzed fetal bovine serum (Invitrogen Corporation, 
Carlsbad, CA), HAT (Sigma-Aldrich, St. Louis, MO), 100 units/ml of penicillin / 
streptomycin, and either normal or 13C6 lysine and 13C6 arginine (Cambridge 
Isotope Labs, Andover, MA). In experiments that employed metabolic labeling 
cells were grown for at least 6 doublings to allow full incorporation of labeled 
amino acids.   
 
Transient Transfection of FLAG-EphB2 
FLAG-EphB2 plasmid was amplified and purified according to 
manufactures instructions using Plasmid Midi kit (Qiagen, Valencia, CA).  Cells 
were cultured to approximately 50% confluence and transiently transfected using 
Superfect (Qiagen, Valencia, CA) according to manufactures instructions.  
Briefly, 10µg of vector was diluted in 298µL of DMEM and incubated with 60µL of 
superfect reagent for10 minutes at RT.  7mL of pre-condition media (media 
removed directly from the cells that were to be transfected) was added to 
superfect/plasmid mixture.  Cells were then washed with sterile PBS and the 
mixture was then added to cells, incubated for 3 hours at 37°C, removed and 
replaced with fresh culture media.  24 hours later media was removed, cells were 
washed with PBS and media was replaced with above mentioned formulation 
without FBS.  At 48hrs cells were stimulated and lysed. 
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Starvation, ephrin stimulation, and phosphatase treatment  
For all experiments that involved ephrin stimulation, cells were subjected 
to 24hrs of serum starvation before treatment with 2 µg/mL pre-clustered 
ephrinB1-Fc (Sigma-Aldrich, Saint Louis, MO) for 5 or 45 minutes.  The 
clustering procedure consisted of incubation of 250 µg/mL ephrinB1-Fc with 65 
μg/ml anti-human Fc (Jackson ImmunoResearch, West Grove, PA) at RT for 1 
hr.  In a separate experiment cells received a general phosphatase inhibitor 
solution (1:75 phos. inhib. solution: culture media) containing 1mM pervanadate 
and 50nM calyculin A for 1 hr. 
 
Cell lysis, anti-FLAG immunoprecipitation and Western Blot  
Cells were lysed in lysis buffer containing 1% Triton X-100, 150 mM NaCl, 
20 mM Tris, pH8, 0.2mM EDTA, pH8, 2 mM Na3VO4, 2mM NaF, and protease 
inhibitors (Complete tablet; Roche, Mannheim, Germany).  For SILAC 
experiments lysates were mixed in a 1:1 ratio (v:v) and incubated with agarose-
conjugated anti-FLAG M2 antibody (Sigma-Aldrich, Saint Louis, MO) overnight.  
After incubation the beads were spun down in a bench top Megafuge 1.0R 
basket centrifuge (Thermo Scientific – Heraeus Instruments, Asheville, NC) at 
2000 RPM for 1 min and the supernatant was removed.  Beads were then 
washed in ~25mL lysis buffer 4 times in a similar fashion.  Precipitated proteins 
were eluted by boiling in SDS-PAGE sample buffer for 5 min.  After elution 
sample volume was reduced by ½ by vacuum centrifugation.  Phosphatase 
inhibitor treated cell lysates were also mixed 1 to 1 with SDS-PAGE sample 
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buffer and boiled for 5 min.  Samples were separated on a 7.5% (receptor IPs) or 
10% (Phos. treated lysates) Tris-HCl gel (BioRad, Hercules, CA).  Gels were 
stained with Coomassie Blue and EphB2 band was excised (receptor IPs) or the 
gel lane was cut horizontally into 6 sections (Phos. treated lysates).  
 
In-gel and in-solution tryptic digestion 
For in-gel digestions excised gel bands were cut into small pieces and 
destained in 50 mM ammonium bicarbonate / 50% acetonitrile, dehydrated with 
acetonitrile and dried. The gel pieces were rehydrated with 10 ng/µl trypsin 
solution in 50 mM ammonium bicarbonate and incubated overnight at 37°C. 
Peptides were extracted twice with 5% formic acid / 50% acetonitrile followed by 
a final extraction with acetonitrile (Shevchenko et al., 1996). For in-solution 
digests samples were dried in vacuum centrifuge, resuspended in 50mM 
ammonium bicarbonate and denatured at 55°C for 30 minutes.  Trypsin was 
added at a 1:100 trypsin:sample ratio and incubated overnight at 37°C.  After 
either in-gel or in-solution digestion samples were dried by vacuum 
centrifugation.  
  
Enrichment by peptide-pipette tip TiO2 chromatography 
TiO2 tips (NuTip, 1-10µL for affinity purified proteins and 10-100uL for 
complex mixtures, (Glygen Corp., Columbia, MD) were conditioned TiO2 tips by 
pipetting 10 (purified protein) or 100µL (complex mixture) of 1.0% TFA in 80% 
acetonitrile loading buffer through the tip 10 times.  Peptides were dissolved in 10  
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or 100µL of loading buffer and loaded on to tip by pipetting peptide solution 
through the tip at least 10 times.  The tip was then washed with an additional 10 
or 100 µL of loading buffer by pipetting the solution through the tip at least 10 
times.  The tip was washed a second time with 10 or 100 µL of 0.1% TFA in 80% 
acetonitrile by pipetting the solution through the tip at least 10 times.  Bound 
peptides were eluted by pipetting 3.5-10  or 25-100µL of 500 mM NH4OH through 
the tip 10 times.  Solvent was removed by vacuum centrifugation and stored at -
20°C until MS analysis.  
 
Analysis of methyl esterified peptides by MALDI-TOF/TOF MS 
Methanolic HCl solution was prepared by dropwise addition of 160 µl of 
acetyl chloride to 1 ml of dry methanol (Ficarro et al., 2002).  Phosphopeptide 
standards and tryptic digests were redissolved in 50 µl of 2 M methanolic HCl 
reagent.  Methyl esterification was allowed to proceed for 2–3 h at room 
temperature.  Solvent was removed by lyophilization, and peptide mixtures were 
resuspended in 0.2% TFA, 30% acetonitrile.  MALDI matrix was prepared by 
dissolving 5mg/mL of α-cyano-4-hydroxycinamic acid (HCCA) in 900 uL of a 
50/50 mix 0.1% TFA: ACN to which 100 uL of 0.1M solution of Ammonium 
Phosphate was added.  Sample was then mixed with MALDI matrix 1:1 (v/v), 1.2 
µl was spotted onto MALDI sample stage and allowed to air dry.  Positive and 
negative ion mode MALDI MS spectra were obtained using an Applied 
Biosystems 4700 Proteomics Analyzer with TOF/TOF ion optics (Applied 
Biosystems, Wilmington, DE); in MS/MS mode the instrument was always 
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operated with the collision gas off. A diode pumped Nd:YAG laser with a 600 ps 
pulse length was used.  The instrument was controlled by ABI 4700 Series 
Explorer (version 3.0). The ABI calibration mixture was used to calibrate the 
instrument in MS mode and MS/MS mode was calibrated using the y-series 
fragment ions of Glu-fibrinogen peptide, m/z 1570.677.  An additional internal 
calibrant of the N-terminal y1 fragment (either K or R) m/z 147.113 or 175.119 
was applied in MS/MS mode.  Spectra were obtained for each sample using 500 
laser shots in MS mode and 3500 shots in MS/MS.  Precursor ions were 
fragmented by accelerating to 8 keV, selecting them with the timing gate set to a 
resolution of 50 and then accelerating fragment ions to 14 keV before entering 
the reflector.  Positive and negative ion mode MS spectra where acquired for in-
solution digests of 100fmol of Beta casein with or without methyl esterification.  
All MS/MS spectra were acquired in positive ion mode and sequenced manually. 
 
SILAC ratio determination and assignment of EphB2 phosphorylation Sites 
Quantification was carried out using the open-source software MSQuant 
(Peter Mortensen and Matthias Mann, http://msquant.sourceforge.net/).  To 
identify the most likely sites of phosphorylation for EphB2 observed peptides, 
spectra identified as phosphopeptides by Mascot were processed and validated 
using MSQuant software.  MSQuant calculated the probabilities for 
phosphorylation at each potential site and generated PTM scores as described 
previously (Olsen et al., 2006). 
 
 131
Supplementary Figure Legends 
 
Supplementary Figure 3.1.  Activity of FLAG-EphB2.   FLAG and pY99 IPs 
followed by anti-FLAG and pY99 Western blotting verified that transfected 
construct was tyrosine phosphorylated in an ephrin-dependent fashion.  Also 
observed in a general increase in overall tyrosine phosphorylation after ligand 
treatment suggesting the FLAG-tagged receptor is signaling properly.    
 
Supplementary Figure 3.2.  Phosphorylation Sites and Individual Ratios   
 
Supplementary Figure 3.3.  Mutation of amino acid Y504 to glutamic acid 
(E) in HEK293T cells generates receptors with reduced expression.  Left, 
Western blots of lysates from HEK293T cells transfected with 1μg of indicated 
fEphB2 constructs and probed for EphB2, or β-actin.  Right.  DNA titration for 
indicated amount of fEphB2 constructs cDNA transfected into HEK293T cells and 
immunoblotted for EphB2, or β-actin.  
 
Supplementary Figure 3.4.  Clustered ephrin-B2-Fc treatment causes 
internalization of EphB2 receptors in neurons.  (A-C) DIV 7 cultured cortical 
neurons were stimulated as indicated with either Fc control (Control), unclustered 
ephrin-B2-Fc (inactivating eB2), or clustered ephrin-B2-Fc (activating eB2).  (A) 
Representative immunoblot of biotinylated EphB2 from DIV7 cultured cortical 
neurons with no actin biotinylated.  (B) Quantification of percent localized to the 
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cell surface compared to Fc treated control.  (C) Quantification of percent in 
intracellular avidin fraction compared to Fc treated control. Error bars indicate 
SEM. (*p < 0.05, ANOVA test; n=4).  
 
Supplementary Figure 3.5.  EphB2 Y504E mutants in cultured cortical 
neurons are retained on the plasma membrane. (A-B) DIV2 cultured cortical 
neurons were infected with indicated YFP-EphB2 lentiviral constructs, then at 
DIV7 cell surface EphB2 receptors were biotinylated.  (A) Representative 
immunoblot of biotinylated infected EphB2 with no actin biotinylated.  (B) 
Quantification of percent localized to the cell surface compared to YFP-EphB2 
WT. Error bars indicate SEM.  (p > 0.5, ANOVA test; n=3).  
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Supplementary Figure 3.2 
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 CHAPTER 4 
DISCUSSION 
 
Since the identification of the EphB receptor tyrosine kinase as a regulator 
of excitatory synapse formation and NMDA receptor synaptic localization, our 
laboratory has been striving to understand how these processes work at a 
molecular level.  Of particular interest was how postsynaptic EphBs mediate 
formation of presynaptic specializations through cognate ephrin-B ligands and 
how signaling occurs at the molecular level; and the specific binding domain and 
mechanism for the direct EphB-NMDAR interaction.  Synaptopathies, or 
disruption of synaptic structure and function, have been described as key 
features of neurodevelopmental, neurodegenerative, and psychiatric diseases.  
The research presented in this dissertation improves our understanding of the 
roles of EphB receptor tyrosine kinases in synapse formation, function, and 
mechanisms of disease.   
 
Summary of main results 
 There are several main findings of these studies.  First, from Chapter 2 
focusing on ephrin-B-dependent presynaptic formation, it was found that: 1) 
Postsynaptic EphBs induce formation of presynaptic specializations via ephrin-
B1 and ephrin-B2 early in neuronal development.  2) Presynaptic ephrin-B1 and 
ephrin-B2 are able to recruit the machinery required for neurotransmitter release 
through a PDZ-domain dependent interaction with syntenin-1.  Second, Chapter 
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3 of this dissertation focused specifically on the EphB-NMDAR interaction and 
found that: 1) The extracellular domain of postsynaptic EphB2 receptors 
undergoes phosphorylation at tyrosine residue 504 after binding ephrin-B 
ligands.  2) Phosphorylation at Y504 promotes the EphB-NMDAR direct 
interaction stabilizing both receptors on the plasma membrane. 3) Mutations at 
Y504 affect the synaptic function of NR2B-containing NMDARs late in neuronal 
development altering synaptic currents and gene transcription.  In this chapter, I 
will discuss the results from both Chapter 2 and Chapter 3 separately, focusing 
on the consequences and future directions for the EphB research field.    
 
EphBs in formation of presynaptic specializations  
 Prior to the work presented in Chapter 2 of this dissertation, it was shown 
that EphBs can induce the formation of both pre- and postsynaptic 
specializations (Kayser et al., 2006).  This is accomplished through bi-directional 
EphB signaling; both “forward” signaling in the EphB receptor expressing cell or 
“reverse” signaling in the ephrin-B expressing cell (Egea and Klein, 2007).  While 
EphB signaling was well characterized, the roles for different membrane attached 
ephrin-B (B1-3) ligands were poorly understood.  In the hippocampus, a 
postsynaptic role began to emerge for ephrin-B2 (Essmann et al., 2008; 
Grunwald et al., 2004) and ephrin-B3 (Aoto and Chen, 2007; Rodenas-Ruano et 
al., 2006).  Interestingly, it was shown in Xenopus retinotectal system that ephrin-
B1 controlled presynaptic formation (Lim et al., 2008).  Therefore, the roles of 
ephrin-B1, ephrin-B2, and ephrin-B3 on the development of EphB-dependent 
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presynaptic formations were investigated in cultured cortical neurons.  As this 
work began, some of the known intracellular signaling domains including Grb4 
and GIT1 on ephrin-Bs were reported (Segura et al., 2007).  Therefore, I also 
sought to identify the molecular mechanisms that mediate EphB-dependent 
development of presynaptic specializations via ephrin-Bs. 
This work moved the fields of synapse formation and EphB receptor 
biology forward in several important ways.  First, this work demonstrates that 
postsynaptic EphB2 interacts trans-synaptically with presynaptic ephrin-B1 or 
ephrin-B2, but not ephrin-B3, and that this interaction is necessary and sufficient 
for formation of a functional synapse.  Second, knockdown of the adaptor protein 
syntenin-1 is sufficient to block EphB-dependent presynaptic formation.  Based 
on this work and others, a model emerges (Supplementary Figure 2.6) where 
postsynaptic EphB binds presynaptic ephrin-B1/2, recruiting the adaptor protein 
syntenin-1, through its PDZ domain 2, which binds ERC2/CAST1 (Ko et al., 
2006), that is directly linked to vesicles of neurotransmitter through Rim and the 
synaptic vesicle protein Rab3a (Jin and Garner, 2008).  Thus, the trans-synaptic 
interaction between EphBs and ephrin-B1/2 can recruit the necessary machinery 
including receptors and changes in the actin cytoskeleton for presynaptic 
neurotransmitter release via syntenin-1.  In support of this model, syntenin-1, 
ephrin-B1, and ephrin-B2 are co-localized at synaptic sites.  However, it is 
important to note that ephrin-Bs are not responsible for formation of all 
presynaptic specializations.  Therefore, our data are consistent with EphB/ephrin-
B signaling directing a subset (~45% co-localization with VGLUT1 for ephrin-B1 
 145
and ~23% for ephrin-B2; Supplementary Table 2.1) of excitatory presynaptic 
specializations.   
There are a number of interesting future directions that come out of this 
work.  One of the most intriguing results from these studies was that 
simultaneous knockdown of both ephrin-B1 and ephrin-B2 does not further 
reduce synapse number, but does increase the amount of syntenin-1 at synaptic 
sites.  However, the differences between the ephrin-B1 and ephrin-B2 signaling 
pathways were never identified.  Therefore, I hypothesize that ephrin-B1 and 
ephrin-B2 are members of distinct signaling pathways for formation of 
presynaptic specializations and cannot compensate for the loss of the other.  
One way to test this hypothesis would be to generate double knockout mice for 
both ephrin-B1 and ephrin-B2 and then perform immunostaining experiments 
comparing the number of presynaptic specializations between homozygous and 
heterozygous animals.  However, both ephrin-B1-/- and ephrin-B2-/- null mice are 
embryonic lethal.  Therefore, I would need to breed together the conditional 
knockout lines for both ephrin-B1 and ephrin-B2.  I could then directly inject Cre-
recombinase into these double conditional knockout mice to delete efnb1 and 
efnb2 gene expression.  Brains from these animals could sectioned and 
immunostained for presynaptic marker SV2, postsynaptic marker SynGAP, and 
syntenin-1.  Based on our knockdown experiments using ephrin-B1 and ephrin-
B2 shRNAs (Chapter 2), I would expect that double knockout mice would not 
have fewer synapses than animals lacking either ephrin-B1 or ephrin-B2.  
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However, synaptic syntenin-1 levels should be reduced in the double knockout 
mice compared to mice lacking either ephrin-B1 or ephrin-B2.   
Another interesting future direction would be to follow-up on our 
observation that ephrin-B2 is expressed in glial cells.  These data leads to the 
intriguing hypothesis that ephrin-B2 might be involved in neuron-glial 
communication at synapses (Filosa et al., 2009; Murai and Pasquale, 2011; 
Zhuang et al., 2010).  Glial glutamate transporters are known to modulate 
synaptic transmission by clearing glutamate from the synaptic cleft (Tzingounis 
and Wadiche, 2007).  At the CA3-CA1 synapse, the loss of presynaptic ephrin-
A3 caused deficits in synaptic plasticity and overexpression of ephrin-A3 in 
astrocytes reduced levels of glutamate transporters (Filosa et al., 2009).  
Therefore, I hypothesize that ephrin-B2 would be a regulator of glial glutamate 
transporters in the cerebral cortex.  To test this hypothesis, cortical lysates from 
wild-type and conditional ephrin-B2 knockout mice could be probed for levels of 
the glial glutamate/aspartate transporter (GLAST) and glutamate transporter 
subtype-1 (GLT-1).  Based on the findings of (Filosa et al., 2009), I would expect 
an upregulation in either GLAST or GLT-1 proteins in mice where ephrin-B2 gene 
expression was removed.  Alternatively, ephrin-B2 constructs could be generated 
with a GFAP promoter for overexpression studies in cortical neuron culture and 
density of presynaptic specializations could be assessed.  I would expect that 
glial over-expression of ephrin-B2 would increase density of presynaptic 
specializations.   
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Role of the EphB-NMDAR interaction at mature synapses  
 Prior to the work presented in Chapter 3 of this thesis, it was shown that 
EphBs directly bind NMDA-type glutamate receptors in an unknown region of 
their extracellular domains (Dalva et al., 2000).  The EphB-NMDAR interaction is 
dependent on binding of ephrin-B ligand, but does not require activation of the 
EphB intracellular kinase (Dalva et al., 2000).  The EphB-NMDAR interaction 
changes cellular signaling by causing changes in Ca2+ influx, phosphorylation of 
NMDARs by Src kinases, and changes in NMDAR-dependent gene transcription 
(Takasu et al., 2002).  Furthermore, EphBs are required for synapse formation 
early in neuronal development (DIV7-14), but not after DIV21 (Kayser et al., 
2008).  Late in neuronal development (DIV14-23), EphBs specifically regulate the 
expression levels, Ca2+-dependent desensitization, and synaptic currents of 
NR2B-containing NMDARs (Nolt et al., 2011).  However, for the EphB-NMDAR 
interaction; the specific binding domain, mechanism, and pharmacological agents 
that modulate the interaction remained unknown.  
  We have identified a single amino acid, tyrosine residue 504, in the 
extracellular domain of EphB2 that is necessary and sufficient for the EphB-
NMDAR interaction to occur.  Presynaptic ephrin-B binding to EphB2 leads to 
Y504 phosphorylation, which is required to induce the EphB-NMDAR interaction.  
Furthermore, the EphB-NMDAR interaction stabilizes both receptor proteins on 
the plasma membrane and blocks their internalization.  We also show that late in 
neuronal development, mutations at Y504 affect synaptic regulation and function 
including; synaptic currents and gene transcription of NR2B-containing NMDARs.  
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Finally, I have identified a non-membrane permeable extracellular kinase inhibitor 
k-252b, which inhibits the EphB-NMDAR interaction.   
 This work moves the fields of EphB receptor biology, synapse maturation 
and function, and potentially treatment for synaptopathies forward in several 
important ways.  In the sections below, I will specifically discuss how this work 
resolves between different receptor fates at the plasma membrane (including a 
model summarizing EphB2 Y504 in terms of receptor trafficking and the EphB-
NMDAR interaction), how the EphB-NMDAR interaction can be targeted to treat 
neuronal disease, and future directions for this work.   
 
EphB Receptor Fates at the Plasma Membrane 
Ephrin-B binding to EphB receptors regulates a diverse number of 
receptor trafficking events from cleavage by γ-secretase / MMP system (Lin et 
al., 2008; Litterst et al., 2007; Xu et al., 2009), internalization by clathrin-mediated 
mechanisms (Andersson, ; Irie et al., 2005; Nishimura et al., 2006; Pitulescu and 
Adams, 2010), trans-endocytosis of the receptor-ligand complex  (Marston et al., 
2003; Zimmer et al., 2003), to EphB ubiquitination and degradation by the 
proteasome (Fasen et al., 2008; Margolis et al., 2010), or direct binding to NMDA 
receptors (Dalva et al., 2000; Takasu et al., 2002).  However, what differentiates 
between these trafficking events at the plasma membrane is a major gap in the 
literature.  One intriguing idea from this thesis work (Chapter 3), is that 
extracellular phosphorylation at Y504 might direct EphBs towards internalization 
and NMDAR binding, but away from cleavage events.  Interestingly, it appears in 
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an environment without NMDARs present like HEK293T cells (Chapter 3); a 
negative charge at Y504 is a signal for receptor internalization and subsequent 
degradation.  In this system, I was unable to detect the EphB2 receptor 
ectodomain in the supernatant (S.I.S-C and M.B.D., unpublished observations).  
However, in cortical neuron cultures where endogenous NMDAR are widely 
expressed or HEK293T cells over-expressing NMDARs, a negative charge at 
Y504 acts as a signal to promote the EphB-NMDAR interaction stabilizing both 
proteins at the plasma membrane and therefore inhibiting their internalization 
(Chapter 3).   
 These observations are summarized into a working model (Figure 4.1) to 
explain the role of extracellular phosphorylation of EphB2 on EphB receptor 
internalization and NMDAR density at the plasma membrane.  Briefly, ephrin-B 
binding to EphB2 receptors at the plasma membrane leads to extracellular 
phosphorylation of Y504 and activation of the EphB kinase domain (including 
intracellular phosphorylation at Y662).  Next, comes the main decision point for 
this signaling pathway, which depends on whether NMDARs are closely localized 
to EphB receptors after ligand binding and extracellular phosphorylation at Y504.  
Once EphB receptors are phosphorylated and unbound to NMDARs, (Figure 4.1 
bottom) they are internalized by clathrin-mediated mechanisms, and degraded 
through ubiquitin-dependent mechanisms in the proteasome (Fasen et al., 2008; 
Margolis et al., 2010).  However, if NMDARs are present (Figure 4.1 top), 
phosphorylated EphBs bind NMDARs blocking internalization of both proteins.  
The EphB-NMDAR interaction starts a number of signaling events including 
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src-mediated phosphorylation of NR2B-containing NMDARs (Takasu et al., 
2002), trafficking of more NR2B-containing receptors to synaptic sites, increased 
NMDAR currents, calcium influx (Nolt et al., 2011; Takasu et al., 2002), and 
changes in gene expression.     
A number of intriguing future directions arise from the observation that 
when NMDARs are absent, EphBs that are phosphorylated at Y504 are rapidly 
degraded.  First, one attractive hypothesis is that phosphorylation at Y504 may 
allow for the developmental switch between axon guidance and synapse 
formation.  The role of EphB/ephrin-B signaling is well established in both of 
these processes, but involves different molecular mechanisms.  During axon 
guidance (DIV0-7), ephrin-Bs act as repulsive cues.  Upon binding ephrin-Bs, 
EphB activation leads to receptor internalization and eventually growth cone 
collapse (Fasen et al., 2008; Marston et al., 2003; Zimmer et al., 2003).  In 
contrast, at DIV7-14, EphB activation is not repulsive anymore but acts as an 
adhesion molecule promoting synapse formation (Kayser et al., 2008).  This 
switch in EphB function could result from differences in NMDAR expression.  
Thus, low NMDAR expression such as seen in growth cones (Wang et al., 2011) 
would induce ephrin-B-dependent internalizations of EphBs and growth cone 
collapse; whereas higher levels of NMDARs, as observed in dendritic filopodia, 
would favor EphB-NMDAR interaction, and EphB-NMDAR retention at the 
surface. 
One way to test the hypothesis that ephrin-B-dependent phosphorylation 
at EphB Y504 promotes growth cone collapse is to make retinal explants cultures 
 152
from retinal ganglion cell (RGC) neurons which endogenously express EphBs 
(Petros et al., 2010).  Then, growth cone collapse could be assessed using live 
imaging or immunostaining after bath pretreatment with ephrin-B2 or Fc-control 
in the presence or absence of k-252b the broad spectrum, membrane 
impermeable, extracellular kinase inhibitor.  If phosphorylation at Y504 is critical 
to ephrin-B-mediated growth cone collapse, then collapse should be blocked by 
k-252b treatment. Similarly, I would expect that over-expression of Y504F 
mutants would prevent growth cone collapse.   
To assess the hypothesis that the presence of NMDARs blocks repulsion 
through Y504, RGC explants could be transfected with EphB2 WT and Y504 
mutant constructs in the presence or absence of NR1/2B constructs.  I would 
predict that because binding NMDARs stabilizes EphBs that over-expression of 
NR1/2B receptors would block growth cone collapse.  We have shown in Chapter 
3 that over-expression of Y504F mutant receptors decreases synaptic currents 
and NMDARs at postsynaptic specializations.  Alternatively, it is also possible 
that the change from repulsive signaling during axon guidance at growth cones, 
to stabilization during synaptogenesis at dendritic filopodia is mediated by 
intracellular signaling events through different GEFs.  Rho-GEF Vav2 is required 
for internalization during growth cone collapse (Cowan et al., 2005); whereas 
Rho-GEF intersectin-1 (Irie and Yamaguchi, 2002), Rac-GEF Tiam1 (Tolias et 
al., 2007), and Rho/Rac1-GEF Kalirin-7 (Penzes et al., 2003) help EphBs 
associate with NMDAR at synaptic sites to form dendritic spine synapses.  
Unfortunately, the differences in signaling mechanisms amongst GEFs remains 
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poorly understood.  However, shRNAs could be generated against each 
individual GEF, and co-expressed with EphB WT and Y504 mutant constructs in 
cultured cortical neurons.  Then dendritic filopodia motility and density of 
postsynaptic specializations could be assessed as previously described in 
(Kayser et al., 2008).   
 
Targeting the EphB-NMDAR interaction to treat CNS disease 
A number of recent reports have specifically implicated the EphB-NMDAR 
interaction as a critical regulator of the deleterious effects of both Alzheimer’s 
disease and neuropathic pain.  In this thesis (Chapter 3), I have identified a 
specific amino acid (Y504) that mediates the EphB-NMDAR interaction and a 
pharmacological agent (k-252b) that blocks this interaction.  Therefore, the most 
exciting future direction for this thesis work is to test whether modulating EphB2 
Y504 phosphorylation and the EphB-NMDAR interaction with k-252b can 
ameliorate either of these devastating diseases.  While EphBs are not required 
for localization of NMDARs or NR2B-conatining NMDARs at all synaptic sites, 
our data suggests they are at a substantial fraction (~50%) of mature synapses 
(Kayser et al., 2006; Nolt et al., 2011).  Here, I will discuss future directions to 
test the hypothesis that EphB2 Y504 is a critical regulator of Alzheimer’s disease 
and neuropathic pain. 
A strong link has emerged between EphBs and Alzheimer’s disease (AD) 
through Amyloid-β (Aβ) including in vitro, in vivo, and clinical reports (Chen et 
al.).  Furthermore, EphB2 expression levels are reduced in AD patients (Simon et 
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al., 2009).  Aβ appears to bind directly to EphB2 in its extracellular FnIII domains 
(which contains Y504) promoting EphB receptor degradation (Cisse et al., 2011).  
Thus, viral overexpression of EphB2 can rescue LTP, NMDAR current deficits, 
and cognitive abilities in a mouse model of AD (Cisse et al., 2011).  Therefore, it 
is intriguing to propose that EphB2, and modulation of the EphB-NMDAR 
interaction through phosphorylation at Y504 could yield a therapeutic target for 
Alzheimer’s disease.     
Based on the work of Cisse et al., (2011), it has been suggested that 
EphB binding directly to Aβ is a critical event to AD progression.  First, it would 
be important to test the hypothesis that Y504 is the binding domain for EphBs 
and Aβ.  This hypothesis could be tested in vitro using the human amyloid-beta 
(hAβ) protein precursor mouse model of AD (Cisse et al., 2011; Simon et al., 
2009) and performing co-immunoprecipitation experiments.  Cortical neurons 
from the hAPP mouse could be cultured, and then infected with EphB2-YFP WT, 
Y504E, and Y504F lentiviruses (Chapter 3).  Over-expressed EphB2 receptors 
could be pulled down using an anti-GFP antibody, and then probed with an 
antibody against Aβ.  Furthermore, these blots could be stripped and reprobed 
with anti-NMDAR antibodies to see if the EphB-NMDAR interaction is affected.  If 
EphB2 Y504 is the binding domain for Aβ-binding, one would expect that due to 
the change in charge, EphB2 Y504E mutants would have decreased Aβ-binding, 
and more EphB-NMDAR interactions.  Next, it would be important to see if 
infection of the EphB-YFP lentiviruses into the hAPP mice could rescue the 
deficits in LTP, NMDAR currents, and behavior as described by (Cisse et al., 
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2011).  If Y504 is the critical residue for EphB-Aβ-binding, I would expect that 
infection of EphB2 Y504F receptors would not rescue the deficits in hAPP mice 
because it would preferentially bind Aβ over NMDARs.  However, it is possible 
that the Aβ-binding domain is not located at Y504, but somewhere else in the 
FnIII repeat domains.  If Y504 were not the Aβ-binding domain, it would be 
interesting to see if the other extracellular phosphorylation site identified by our 
mass spectrometry experiments (Y481) is involved in this process.    
In addition to a role of EphB in AD, a robust literature links EphB1/ephrin-
B signaling to regulate neuropathic pain in the spinal cord and periphery through 
modulation of NMDAR signaling.  Specifically, EphB1 and ephrin-Bs are 
upregulated in the spinal cord and periphery after injury (Kobayashi et al., 2007; 
Song et al., 2008a; Song et al., 2008b).  The upregulation of EphB1/ephrin-Bs 
leads to hyperexcitable NMDARs with lower LTP thresholds (Battaglia et al., 
2003; Cao et al., 2008; Guan et al., 2010; Ruan et al., 2010; Slack et al., 2008; 
Song et al., 2008b) and NR2B phosphorylation by src kinase (Battaglia et al., 
2003; Slack et al., 2008; Song et al., 2008b).  Therefore, it is hypothesized that 
the EphB-NMDAR interaction plays a critical role in the enhancement of pain 
sensitivity.  EphB1 Y502 is the structurally homologous interaction domain on 
EphB1 that should modulate NMDAR binding.  Based on our findings that k-252b 
is necessary and sufficient to block the EphB-NMDAR interaction, I hypothesize 
that k-252b injection could ameliorate neuropathic pain.  To test this hypothesis, 
hyperalgesia could be induced by intrathecal injection of ephrin-B2-Fc (Battaglia 
et al., 2003; Slack et al., 2008; Song et al., 2008b) in the presence or absence of 
 156
k-252b pre-injection.  Thermal hyperalgesia or mechanical allodynia models 
could be used to assess the behavioral affects of k-252b on pain, and the EphB-
NMDAR interaction could be assessed biochemically in spinal tissues from 
injected rats.  If EphB1 Y502 phosphorylation is required for neuropathic pain, 
then k-252b should block the induction of neuropathic pain mediated by ephrin-
Bs by inhibiting the EphB-NMDAR interaction in behavioral and biochemical 
assays.   
Alternatively, if we knew the kinase that phosphorylates Y504, antagonism 
of that receptor would also have large therapeutic potential because it may have 
fewer side effects than k-252b.  While no extracellular tyrosine kinases have 
been reported, extracellular serine/threonine kinases have been found in 
numerous cell types including neurons (Chen et al., 1996; Fujii et al., 2000; 
Kumar et al., 2011; Redegeld et al., 1999).  Three soluble FGFR splice variants 
have been reported with kinase domains intact, but lacking transmembrane 
domains (Johnston et al., 1995; Katoh et al., 1992; Sturla et al., 2003).  Another 
possibility is known extracellular kinase Casein Kinase 2 (CK2) (Bohana-Kashtan 
et al., 2005; Maik-Rachline et al., 2005; Nguyen et al., 2008; Zimina et al., 2007) 
which has been reported to phosphorylate tyrosine residues in addition to its 
known function on serine/threonine residues (St-Denis and Litchfield, 2009).   
There a few different ways to determine which kinase phosphorylates 
EphB2 Y504.  A first approach, currently being taken by Dr. Kenji Hanamura a 
postdoc in the laboratory, is to use pharmacological inhibitors of known tyrosine 
kinases to find ones that inhibit phosphorylation of Y504, but not other 
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intracellular phospho-tyrosine residues.  Then, effective inhibitors could be used 
to see if they can block the EphB-NMDAR interaction.  Using a variety of 
inhibitors would narrow down the list to a few known kinases.  Then, these 
kinases could be tested individually in in vitro kinase assays and in neuron 
culture for the EphB-NMDAR interaction.  Preliminary experiments suggest that 
PD161570 an FGFR antagonist; and PD166285 an antagonist of FGFR, PDGFR, 
and src kinases blocks phosphorylation of EphB2 at Y504 (K.H., S.I.S-C, and 
M.B.D., unpublished observations).  To build on the first approach, Dr. Hanamura 
is also performing an in vitro kinase assay with only the extracellular domain of 
EphB2 (EphB2-Fc).  Commercially available soluble receptor tyrosine kinases 
like FGFRs, CK2, EphB, EGFR, and other RTKs are combined in the presence 
or absence of ATP.  The EphB2-Fc is then immunoprecipitated using anti-human 
IgG antibodies and lysates are probed using the anti-EphB2 pY504 antibody.   
A final approach based on mass spectrometry (similar to Y504 
identification) would express EphB2 TR (extracellular domain only) constructs in 
cell lines.  Then, the cells could be treated with ephrin-B2 ligand to induce Y504 
phosphorylation.  Next, a chemical cross-linking reagent like 
Dithiobis(succinimidyl propionate) (DSP) (Sinz, 2006; Wiseman et al., 2009) or 
formaldehyde (Sutherland et al., 2008) could be used to crosslink kinase and 
substrate.  This cross-linking would need to be done at different timepoints 
including 5, 7.5, 15, and 30 minutes to makes sure to catch receptor and kinase 
together.  Then, phospho-tyrosine residues could be immunoprecipitated using 
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PY99, and tryptic peptides identified could be bioinformatically linked to known 
tyrosine kinases (Sinz, 2006).   
 
Conclusion 
 The work presented in this thesis has strived to understand basic 
mechanisms of EphB receptor biology with the goal of understanding how to 
better understand synaptopathies.  These findings move the field of EphB 
receptor biology, synapse formation, and synapse maturation forward in four 
important ways.  First, the mechanisms for EphB-dependent presynaptic 
signalling have been elucidated from ephrin-B adhesion molecule to vesicles of 
glutamate.  Second, this dissertation is the first report of extracellular tyrosine 
phosphorylation of any protein, and a significant advance for the field of EphB 
receptor biology by revealing new signalling mechanisms.  Thirdly, it has shown 
a single residue that is necessary and sufficient for the EphB-NMDAR interaction 
to occur.  Finally, a novel mechanism of extracellular tyrosine phosphorylation for 
regulating protein-protein interactions has emerged with the potential to treat 
diseases of the central nervous system and beyond.  Future studies will address 
which specific tyrosine kinase is responsible for this extracellular phosphorylation 
event and whether inhibiting this phosphorylation event, using k-252b, to block 
the EphB-NMDAR interaction could have therapeutic potential for treating 
neuropathic pain.  Also, potentiating the EphB-NMDAR interactions could be 
protective against Alzheimer’s disease.  Therefore, it is hoped that this 
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dissertation research moves the field of synapse formation and EphB receptor 
biology towards the goal of treating human disease.        
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Abstract 
Dynamic regulation of the localization and function of NMDA receptors 
(NMDARs) is critical for synaptic development and function. The composition and 
localization of NMDAR subunits at synapses are tightly regulated and can 
influence the ability of individual synapses to undergo long-lasting changes in 
response to stimuli. Here, we examine mechanisms by which EphB2, a receptor 
tyrosine kinase that binds and phosphorylates NMDARs, controls NMDAR 
subunit localization and function at synapses. We find that, in mature neurons, 
EphB2 expression levels regulate the amount of NMDARs at synapses, and 
EphB activation decreases Ca2+-dependent desensitization of NR2B-containing 
NMDARs. EphBs are required for enhanced localization of NR2B-containing 
NMDARs at synapses of mature neurons; triple EphB knockout mice lacking 
EphB1–3 exhibit homeostatic upregulation of NMDAR surface expression and 
loss of proper targeting to synaptic sites. These findings demonstrate that, in the 
mature nervous system, EphBs are key regulators of the synaptic localization of 
NMDARs.  
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Introduction 
The NMDA receptor (NMDAR) is essential for neuronal development and 
function, synaptic plasticity, and adaptive responses to sensory experience (Cull-
Candy and Leszkiewicz, 2004; Lau and Zukin, 2007; Perez-Otano and Ehlers, 
2005). These functions require glutamate-dependent calcium influx into neurons 
through the NMDAR. The NMDAR is a heteromeric protein complex of two 
obligate NR1 subunits and typically two NR2 subunits, which each convey 
distinct functional properties to the receptor (Cull-Candy and Leszkiewicz, 2004). 
NR2A is the principal subunit at mature cortical and hippocampal synapses. 
Although NR2B subunits are more prevalent at these synapses during 
development, they are still expressed in the mature brain (Monyer et al., 1994; 
Sheng et al., 1994; Tovar and Westbrook, 1999). NR2B-containing NMDARs 
have a slower inactivation rate and longer decay times compared with NR2A 
subunits (Cull-Candy and Leszkiewicz, 2004). Thus, synapses with higher 
proportions of NR2B can integrate synaptic currents across broader time 
intervals than those with more NR2A. In addition, NR2B-containing NMDA 
receptors carry more Ca2+ current per unit charge (Sobczyk et al., 2005), are 
preferentially tethered to the plasticity protein CaMKII (calcium/calmodulin-
dependent protein kinase II) (Barria and Malinow, 2005), and exhibit a lower 
threshold to undergo potentiation of synaptic responses (Philpot et al., 2007; 
Philpot and Zukin, 2010). Thus, understanding the molecular mechanisms that 
direct trafficking of NR2B subunits to and from synapses will provide insights into 
synaptic plasticity.  
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NMDARs are recruited to and retained at synapses through well studied 
mechanisms (Chen and Roche, 2007; Kim and Sheng, 2004; Lau and Zukin, 
2007, including postsynaptic density-95/Discs large/zona occludens-1 (PDZ) 
binding domain interactions and phosphorylation of the receptor itself 
{Prybylowski, 2005 #112; Perez-Otano and Ehlers, 2005). Activation of EphB 
leads to a Src kinase-dependent phosphorylation of the NR2B subunit at three 
tyrosine residues (Antion et al., 2010; Takasu et al., 2002). One of these 
residues, Y1472, is important for regulating NMDAR surface and synaptic 
localization (Salter and Kalia, 2004), suggesting that EphBs might play a role in 
the synaptic targeting/retention of NMDARs.  
The EphB family of receptor tyrosine kinases is enriched at excitatory 
synapses and is important during synapse and spine formation and maintenance 
(Aoto and Chen, 2007; Klein, 2009; Shi et al., 2009; Tolias et al., 2007). Triple 
knock-out mice lacking EphB1–3 have fewer excitatory synapses (Henkemeyer 
et al., 2003; Kayser et al., 2006), whereas animals lacking only EphB2 have 
reduced NMDAR content at synapses (Henderson et al., 2001). In addition to 
modulating NMDAR-mediated calcium influx, activation of EphBs leads to a 
direct association between EphB and the NMDAR NR1 subunit (Dalva et al., 
2000); EphBs also associate with and regulate trafficking of AMPA receptors 
(AMPARs) (Irie et al., 2005; Kayser et al., 2006). We examined whether EphBs 
impact synaptic NMDAR function and contribute to subunit-specific synaptic 
localization of NMDARs. We find that expression levels of EphB2 control the 
amount of NMDAR at synapses, and that EphB2 kinase activity regulates the 
 164
calcium inactivation rate of NR2B-containing NMDARs. EphB2 activation also 
preferentially targets and stabilizes NR2B-containing NMDARs at synapses. 
These results suggest that EphBs may be important regulators of NMDAR 
targeting, subunit composition, and function at mature synapses.  
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Materials and Methods 
 
Cell culture and transfection. Dissociated cortical neurons were prepared from 
embryonic day 17 (E17) to E18 rats of either sex and cultured as described 
previously (Kayser et al., 2006). Briefly, neurons were cultured in Neurobasal 
(Invitrogen), B27 supplement (Invitrogen), glutamine (Sigma-Aldrich), and 
penicillin–streptomycin (Sigma-Aldrich) on poly-d-lysine (BD Biosciences or 
Sigma-Aldrich) and laminin (BD Biosciences)-coated glass coverslips (12 mm; 
Bellco Glass) in 24-well plates (Corning Life Sciences). Cells were plated at 
150,000 per well and maintained in a humidified incubator with 5% CO2 at 37°C. 
Neurons were transfected with Lipofectamine 2000 (Invitrogen) at 14 d in vitro 
(DIV) using methods described previously (Kayser et al., 2008).  
 
HEK-293 cell culture and transfection. HEK-293 cells were maintained as 
described (Lin et al., 2004). For transfection, HEK-293 cells were plated at a 
density of 1 × 106 cells per milliliter on 12 mm glass coverslips coated with poly-
d-lysine (10 μg/ml) in 24-well culture plates and transfected with NR1, NR2A, or 
NR2B and green fluorescent protein (GFP) or EphB2-YFP plasmid (1 μg of 
plasmid cDNA per 12 mm coverslips in 1:1:1 ratio) using the calcium phosphate 
method according to the manufacturer's protocol (Invitrogen). For the EphB2-KD 
experiment, we transfected YFP-NR1, NR2B, and EphB2-KD into HEK-293 cells 
in 1:1:1 ratio.  
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Immunocytochemistry. Cultures were fixed in 4% paraformaldehyde/2% 
sucrose for 8 min at room temperature. Cells were washed three times in PBS 
and blocked and permeabilized in 1% ovalbumin (Sigma-Aldrich)/0.2% coldwater 
fish scale gelatin (Sigma-Aldrich)/0.1% saponin (Sigma-Aldrich) for 1 h at room 
temperature. Antibody incubations were conducted overnight at 4°C for primary 
antibody and 1 h at room temperature in secondary antibody diluted in blocking 
reagents. Antibodies used were as follows: chicken anti-GFP (Millipore; 1:2500), 
guinea pig anti-VGlut1 (Millipore Bioscience Research Reagents; 1:5000), and 
mouse anti-NR1 (Millipore Bioscience Research Reagents; 1:1000). Cy2, Cy3, 
and Cy5 secondary antibodies were obtained from Jackson ImmunoResearch 
and used at 1:250.  
 
cDNA and short hairpin RNA constructs. EphB2 short hairpin RNA (shRNA) 
was described previously (Kayser et al., 2006). The EphB2 rescue construct was 
generated and described previously (Kayser et al., 2006; Kayser et al., 2008). 
Full-length FLAG-tagged EphB2 and FLAG-tagged kinase inactive EphB2 were 
described previously (Dalva et al., 2000).  
 
Imaging and analysis. Images of primary neuronal cultures were acquired by 
confocal scanning microscopy (Leica) using methods described previously 
(Kayser et al., 2006; Kayser et al., 2008). Briefly, all images were acquired using 
a 63×, numerical aperture 1.4, oil-immersion objective with z-steps of 0.5 μm and 
subsequently analyzed with custom-designed NIH ImageJ macros blind to 
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experimental condition. Images were collected from at least three independent 
experiments. For puncta analysis, images were converted from maximum 
projections to binary scale, and puncta were identified as continuous groups of 
pixels corresponding to 0.5–7.5 μm2. Colocalization between puncta was defined 
as >1 pixel overlap between channels. To determine amount of NR1 at the 
synapse, images were collected for each condition with the same gain values. 
Intensity of NR1 staining at the synapse was then calculated for each condition. 
Amounts for each condition were normalized to the maximum intensity observed 
from all three conditions.  
 
Electrophysiology. Whole-cell recordings were made from 21–23 DIV rat 
cortical neurons. Coverslips were moved into a recording chamber and bathed in 
a HEPES-buffered artificial CSF (ACSF) solution (in mm: 140 NaCl, 5 KCl, 2 
CaCl2, 20 glucose, and 10 HEPES, pH 7.2). GFP-positive pyramidal neurons 
were chosen for recording. The internal solution contained the following (in mm): 
125 CsGlu, 5 EGTA, 2 MgCl2, 1 CsCl2, 2 K2-ATP, 10 HEPES, and 0.42 Na-GTP, 
pH 7.2. Pipettes were pulled to a 6–9 MΩ resistance, and recordings were made 
for 2–5 min at −65 mV before bath application of APV. After application of APV, 
the cell was again recorded for 2–5 min. For experiments conducted at +50 mV, 
similar recording conditions were used except that coverslips were moved into a 
recording chamber and bathed in a HEPES-buffered ACSF solution (in mm: 140 
NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 20 glucose, and 10 HEPES, pH 7.2). Tetrodotoxin 
(TTX) and picrotoxin were used at 1 and 10 μm, respectively (Sigma-Aldrich). 
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Bicuculline was used at 50–100 μm, APV was used at 10 μm, and (αR,βS)-α-(4-
hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate (Ro25-
6981) was used at 1–2 μm (Tocris Bioscience). All data were collected at 5 kHz 
and filtered at 1 kHz; events were detected in Clampfit 9.2 (Molecular Devices). 
Event analysis and statistics were performed using Matlab (The MathWorks) and 
Clampfit software (Molecular Devices). Decay time was calculated as the time 
from peak amplitude of the current to 30% of the peak amplitude.  
 
Whole-cell recording from HEK-293 cells. Electrophysiological recordings 
were performed 1–2 d after transfection. Once whole-cell-recording configuration 
was obtained, NMDA plus glycine was applied several times for 5 s periods 
separated by 25 s recovery intervals. Rapid agonist application was achieved 
by placing cells in a laminar solution stream that was delivered from a multibarrel 
array fed by gravity. Currents activated by NMDA (300 μm) in the presence of 
glycine (10 μm) were recorded in the whole-cell mode at a holding potential of 
−60 mV, filtered at 2 Hz, and digitized on-line at 1 kHz. Importantly, we did not 
observe an increase in desensitization during the few minutes of recording. 
Electrodes with open-tip resistances of 2–5 MΩ were used. Data were acquired 
and analyzed using pClamp 9 software and AxoPatch-1D amplifier (Molecular 
Devices). The internal pipette solution was composed of the following (in mm): 
145 KCl, 4 Mg-ATP, 10 HEPES, and 5.5 EGTA, adjusted to pH 7.25 with KOH. 
External solution contained the following (in mm): 145 NaCl, 5.4 KCl, 2 CaCl2, 11 
glucose, and 10 HEPES, adjusted to pH 7.3 with NaOH.  
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Cultured neuron biotinylation. After treatment with clustered ephrin-B2-Fc or 
Fc control, cortical neuron cultures were placed on ice and rinsed twice with ice-
cold rinsing solution (PBS, pH 7.5, containing 0.1 mm CaCl2 and 1 mm MgCl2). 
Clustering of ephrin-B2-Fc and human-Fc control proteins (R&D Systems) was 
achieved by incubation with anti-human IgG (Jackson ImmunoResearch) using 
methods described previously (Dalva et al., 2000). Cells were incubated in 
rinsing solution containing 1 mg/ml Sulfo-NHS-SS-Biotin (Pierce Protein 
Research Products; Thermo Fisher Scientific) with gentle agitation at 4°C for 30 
min. Cells were then washed in quenching solution (rinsing solution with 100 mm 
glycine) and incubated in this solution with gentle agitation at 4°C for 30 min to 
quench unbound biotin. Cells were washed in rinsing solution, and then agitated 
at 4°C for 60 min using radioimmunoprecipitation assay (RIPA) buffer containing 
protease inhibitors for cell lysis. Cell lysates were harvested and centrifuged at 
13,000 rpm for 20 min at 4°C. Aliquots were taken for total lysate fraction, for 
Bradford protein assay analysis (Bio-Rad), and for incubation with monomeric 
avidin agarose (Pierce Protein Research Products; Thermo Fisher Scientific) at 
25°C for 60 min. After incubation, lysates were centrifuged at 13,000 rpm for 15 
min, and the supernatant (intracellular fraction) was removed. The 4× sample 
solubilizing buffer was added to the total and intracellular fractions. Avidin beads 
were then washed three times with RIPA buffer, before incubation in 2× 
solubilizing buffer at 37°C for 30 min. Samples were then centrifuged for 5 min at 
14,000 rpm, and the supernatant (surface fraction) was extracted. Five to 10 μg 
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of surface and total lysate fraction were subjected to SDS-PAGE and Western 
blot analysis. Experiments were excluded from additional analysis if Western 
blots of the biotinylated fractions were positive for the cytosolic protein β-actin. 
Band intensities were quantified by densitometric analysis using NIH ImageJ 
software, and comparisons were made between total and biotin labeled fractions.  
 
Biotinylation assay for surface NMDARs from slices. Hippocampal or cortical 
slices were prepared from postnatal day 21 (P21) to P28 mice of either sex. After 
washing twice in ice-cold ACSF, slices were incubated in 1 mg/ml NHS-SS-biotin 
(Pierce) for 30 min at 4°C to biotinylate surface proteins as described previously 
(Huang et al., 2009). After removing nonspecifically bound NHS-SS-biotin, the 
tissue was homogenized and sonicated in PBS-based lysis buffer containing 
protease and phosphatase inhibitors (in mm: 1 EDTA, 1 EGTA, and 1% Triton X-
100, 0.1% SDS, pH 7.4), followed by end-to-end rotating for 30 min at 4°C. After 
centrifugation at 13,000 rpm for 30 min at 4°C, the supernatant was incubated 
with Neutravidin beads (Thermo Fisher Scientific) to capture biotinylated surface 
proteins. After washing three times with lysis buffer, the surface proteins were 
eluted with protein sample buffer containing DTT and subjected to Western 
blotting. Membranes were probed with polyclonal anti-NR2A (1:1000; Millipore), 
with monoclonal anti-NR2B (1:2000; Millipore), monoclonal anti-NR1 (1:2000; 
54.1; a generous gift from J. Morrison, Mount Sinai School of Medicine, New 
York, NY), and with anti-β-actin (1:5000; Sigma-Aldrich). Samples with actin 
labeling in the surface fraction were excluded from additional analysis. 
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Membranes were stripped with Restore reagent (Thermo Fisher Scientific) to 
reprobe the membranes with a different antibody. Band intensities were 
quantified by densitometric analysis using NIH ImageJ software.  
 
Synaptosome preparation. This protocol was adapted from previous work 
(Blackstone et al., 1992; Lau et al., 1996). Briefly, whole brains from male and 
female P30 wild type (WT), EphB double knock-out (DKO), and triple knock-out 
(TKO) mice were homogenized in HEPES-buffered sucrose [0.32 m sucrose, 4 
mm HEPES, pH 7.4, and protease inhibitor mixture (Sigma-Aldrich)]. The nuclear 
fraction was removed from the homogenate by centrifugation at 1000 × g for 15 
min. The resulting supernatant (S1) was then centrifuged at 10,000 × g for 15 
min to yield the crude membrane fraction (P1). The P1 pellet was resuspended in 
10 vol of HEPES-buffered sucrose and spun again at 10,000 × g for 15 min to 
yield washed crude synaptosomal fraction (P2). The P2 fraction was layered onto 
4 ml of 1.2 m sucrose containing protease inhibitors (Sigma-Aldrich) and 
centrifuged at 230,000 × g for 15 min. The interface was collected and diluted 
into final volume of 6 ml with HEPES-buffered 0.32 m sucrose and layered onto 
0.8 m sucrose containing protease inhibitors. The sample was centrifuged at 
230,000 × g for 15 min to obtain a pure synaptosomal (Syn) pellet. The 
intensities of glutamate receptors from each fraction were determined by 
densitometric analysis using ImageJ software. The raw intensities were then 
normalized to actin intensities in each fraction. The relative levels of synaptic 
versus membrane-associated glutamate receptors were calculated by taking a 
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ratio of normalized synaptic fraction values (Syn) to normalized crude membrane 
fraction values (P1). Statistical significance was assessed by ANOVA.  
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Results 
Early in development, the EphB receptor couples filopodia motility to 
synaptogenesis (Kayser et al., 2008). As neurons and synapses mature, EphB is 
no longer required to maintain normal numbers of established synapses (Kayser 
et al., 2008). However, EphB2 is still highly expressed in the adult nervous 
system (Bouvier et al., 2008), suggesting that it likely has an active role in mature 
neurons. We examined the impact of EphB2 on NMDAR surface and synaptic 
localization in the mature nervous system. We used an shRNA that targets 
EphB2 and has been extensively characterized previously in the following ways: 
(1) it has no detectable effects on neurons from EphB1-3 triple knock-out mice; 
(2) it causes selective inhibition of EphB2-dependent synapse formation; (3) it 
knocks down EphB2 expression with high efficacy in neurons and non-neuronal 
cells; and (4) the effects of expressing it can be reversed with expression of 
EphB2 constructs rendered insensitive to the shRNA by the introduction of silent 
mutations (Kayser et al., 2006; Kayser et al., 2008). Previous work using this 
shRNA has shown that knockdown of EphB2 in cortical neurons at either 3 or 10 
DIV leads to a robust decrease in synapse number at 21 DIV, whereas later 
knockdown of EphB2 from 14–21 or 14–24 DIV has no effect on synapse number 
(Kayser et al., 2008). Importantly, knockdown at each of these times leads to 
similar decreases in EphB2 expression.  
To selectively determine how changes in EphB2 expression later in 
neuronal development affect NMDAR localization in mature neurons, we first 
used immunohistochemical methods in cultured cortical neurons. Neurons were 
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transfected with enhanced green fluorescent protein (eGFP) and shRNA vector 
(control), EphB2.1 shRNA, or EphB2.1 shRNA with rescue at 14 DIV. We 
rescued EphB2 knockdown with a shRNA-insensitive EphB2 construct—an 
approach that generates functional overexpression (McClelland et al., 2010; 
McClelland et al., 2009). We used this approach to control the amount of EphB2 
expressed in neurons. At 21 DIV, neurons were processed to determine the 
amount of NR1 labeling at synapses. In these experiments, we focused on NR1 
immunolabeling because (1) this subunit is present in all NMDARs (Cull-Candy 
and Leszkiewicz, 2004), (2) EphB directly binds NR1 through an interaction 
involving extracellular domains (Dalva et al., 2000), and (3) the anti-NR1 
antibody most reliably colocalizes with other presynaptic and postsynaptic 
marker proteins (data not shown). Synapses were defined as locations where 
NR1 puncta (red) colocalized with GFP-positive dendrites (green) within <1 μm of 
anti-vGlut1-positive puncta (blue) (Figure 5.1A-C). We determined the size and 
intensity of NMDAR staining at each synapse. Although there were no effects on 
the size of the NMDAR puncta, functional overexpression and knockdown of 
EphB2 did alter the amount of NMDAR localized at synapses as measured by 
the normalized intensity of synaptic puncta. We plotted the cumulative probability 
distribution of the amount of NMDAR staining at synaptic sites and found that 
knockdown of endogenous EphB2 caused a decrease in the amount of NR1 at 
synapses, whereas functional overexpression of EphB2 in the context of EphB2 
knockdown resulted in a marked increase in synaptic NR1 (Figure 5.1D) 
[Kolmogorov–Smirnov (K-S) test, p < 0.001]. More specifically, EphB2 
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knockdown caused a preferential reduction in the number of synapses with large 
amounts of NR1. Conversely, functional overexpression of EphB2 resulted in a 
preferential increase in the number of synapses with smaller amounts of NR1. 
We next determined whether there were any differences between the effects of 
EphB2 manipulation on shaft and spine synapses. Analysis revealed that EphB2 
knockdown or overexpression resulted in similar changes in the amount of 
NMDAR content at both shaft and spine synapses (Figure 5.1E, F) (K-S test, p < 
0.001). Consistent with the role of EphB2 in control of dendritic spine shape in 
mature neurons, changes in the amount of NR1 at spine synapses were larger 
after EphB2 overexpression than the changes seen at shaft synapses. Together, 
these results suggest a role for EphB2 in directing or maintaining NMDARs at 
mature synapses.  
To examine the functional significance of these immunohistochemical 
findings, we next measured spontaneous miniature EPSC (mEPSC) frequency in 
cultured cortical neurons at 21 DIV after endogenous EphB2 knockdown with or 
without expression of our EphB2 rescue construct at 14 DIV. As expected from 
previous work (Kayser et al., 2008), knockdown or functional overexpression of 
EphB2 at 14–21 DIV resulted in no change in mEPSC frequency (Figure 5.2A, 
C), confirming that EphBs are not likely to be important for the maintenance of 
overall excitatory synapse number in mature neurons. To determine whether 
modulation of EphB2 expression levels impacts synaptic receptor content, we 
studied mEPSC amplitude. To isolate glutamatergic mEPSCs, whole-cell patch-
clamp recordings were conducted in Mg2+-free solutions to increase NMDAR-
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mediated currents in the presence of tetrodotoxin and blockers of GABAergic 
channels (see Materials and Methods). Although neither knockdown nor 
functional overexpression of EphB2 changed excitatory synapse number, 
functional overexpression of EphB2 did result in a significant increase in mEPSC 
amplitude (Figure 5.2B, D, E) (control, −15.45 ± 0.14 pA; EphB2, −22.79 ± 0.37; 
K-S test, p < 0.001). Similar changes in mEPSC amplitude were found in an 
independent series of experiments in which we overexpressed wild-type EphB2 
without knockdown, in the presence of the endogenous protein (Figure 5.3). The 
small size of the NMDAR-dependent component of mEPSCs in cultured neurons 
(2–3 pA) prevents reliable isolation of this current alone. Therefore, to examine 
whether EphB-dependent changes in mEPSC amplitude are attributable to 
increased recruitment of NMDARs to synapses, we recorded from neurons in the 
presence or absence of the NMDAR antagonist APV (50–100 μm), applied via 
the bath perfusate. We found that NMDAR blockade significantly reduced 
mEPSC amplitude in all conditions (control, EphB2.1 shRNA, or functional 
EphB2 overexpression). To estimate the average NMDAR component of the 
mEPSC, we measured the difference between mean mEPSC amplitude before 
and after APV blockade. The estimated NMDAR component was 60% larger 
than control when EphB2 was functionally overexpressed [control, 3.13 pA; 
EphB2 overexpression (OE), 4.98 pA] (Figure 5.2B, D), indicating that the level 
of EphB2 expression might determine the amount of NMDARs at synapses. 
These findings were confirmed by cumulative probability histograms of mEPSC 
amplitude demonstrating that functional overexpression of EphB2 results in an 
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increase in the NMDAR-dependent component of mEPSCs (Figure 5.2E). 
Functional overexpression of EphB2 also appeared to increase the AMPAR-
dependent component of mEPSCs, assessed by measuring mEPSCs in the 
presence of APV for all three conditions. These findings are consistent with 
previous work showing that EphB2 can regulate AMPAR retention in the 
recycling pool through its PDZ binding domain (Kayser et al., 2006). Although 
there appears to be a change in the AMPAR component, we focused on the role 
of EphB2 in the regulation of the NMDAR in this study because of the importance 
of this interaction in human disease (Cisse et al., 2011).  
NMDARs contribute significantly to the decay component of synaptic 
currents, and thus measuring changes in these currents provides a sensitive 
measure for the presence of these channels at synapses. We found that, 
compared with controls, the average decay time (from peak to 30% amplitude) in 
neurons where EphB2 was functionally overexpressed was significantly longer, 
whereas knockdown of EphB2 resulted in a significant shortening of the average 
decay time. After blocking NMDARs with the antagonist APV, significantly shorter 
decay times were seen for all conditions (Figure 5.3C) (control, 5.88 ± 0.06 ms; 
control plus APV, 4.66 ± 0.05; EphB2.1 shRNA, 5.60 ± 0.06; EphB2.1 plus APV, 
4.96 ± 0.06; functional EphB2 OE, 7.32 ± 0.10; functional EphB2 OE plus APV, 
6.17 ± 0.08; ANOVA, p < 0.001). To further examine these data, we plotted 
cumulative probability distributions of the decay times for mEPSCs in control, 
knockdown, and functional overexpression conditions that represent all the 
measured decay times in our data set (Figure 5.3D, E). We found that before 
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blocking NMDARs with the antagonist APV, control and EphB2-overexpressing 
cells exhibit a larger proportion of mEPSCs with longer decay times, whereas 
EphB2 knockdown substantially reduces the fraction of events with longer decay 
times (Figure 5.3C-E). Specifically, in neurons expressing EphB2 shRNA, 5% 
of events have decay times of >10 ms; in control neurons, 10% fall into this 
group; in neurons overexpressing EphB2, 15% of events have decay times of 
>10 ms (Figure 5.3D, E). The difference between decay times in the control and 
EphB2 knockdown conditions were mostly eliminated by pharmacologic NMDAR 
blockade. Interestingly, the decay times of mEPSCs recorded from neurons 
functionally overexpressing EphB2 were longer than those of events in control or 
EphB2 knockdown neurons even in the presence of NMDAR blockade. These 
effects are most consistent with a change in AMPAR subunit composition at 
synapses, although additional work will be needed to determine whether this is 
the case. Regardless, our findings indicate that EphB2 expression levels might 
bidirectionally modulate the synaptic localization of NMDARs.  
To further examine the role of EphB2 in the control of NMDAR trafficking, 
we recorded from neurons held at +50 mV to remove Mg2+ voltage-dependent 
blockade of the NMDAR. In these experiments, we overexpressed EphB2 alone, 
without expression of shRNAs targeting EphB2. Consistent with our findings from 
functional overexpression of EphB2 in the presence of EphB2 shRNA (Figure 
5.2), overexpression of EphB2 without knockdown resulted in a significant 
increase in mEPSC amplitude, whereas knockdown resulted in a reduction in 
mEPSC amplitude (control, 12.35 ± 0.23 pA, n = 957 events/9 neurons; EphB2 
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shRNA, 11.53 ± 0.19 pA, n = 1189/11; EphB2 OE, 15.44 ± 0.29 pA, n = 795/5; 
ANOVA, p < 0.01). To isolate the NMDAR component, neurons were held at +50 
mV in the presence of TTX (1 μm), bicuculline (50 μm), and picrotoxin (10 μm). 
Using established methods (Myme et al., 2003), we examined the NMDAR 
component of mEPSCs by taking the average current 10–15 ms after the initial 
rise phase of each mEPSC (a time when the AMPAR-dependent current has 
already decayed). We found that knockdown of EphB2 resulted in a significant 
decrease in the NMDAR-dependent component of the mEPSCs, whereas 
overexpression of EphB2 resulted in a significant increase (Figure 5.3F, G) 
(control, 2.09 ± 0.13 pA, n = 368 events/6 cells; EphB2 shRNAi, 1.74 ± 0.11 pA, 
n = 744/11; OE, 2.83 ± 0.08 pA, n = 1247/9; ANOVA, p < 0.01). To test whether 
the effects of EphB2 overexpression might be linked to the recruitment of a 
specific NMDAR subunit, we treated neurons with an NR2B-selective NMDA 
receptor antagonist, Ro25-6981 (1–2 μm), and measured the percentage change 
in mEPSC amplitude. The NMDAR-dependent component of mEPSCs was 
reduced significantly (25%) by the selective antagonist in neurons transfected 
with EphB2 compared with control transfected neurons (control, n = 5 cells; 
EphB2 OE, n = 5 cells; ANOVA, p < 0.03) (data not shown), suggesting that 
EphB2 overexpression increases the amount of NR2B-containing NMDARs 
found at synapses. We also conducted analysis of the decay times of mEPSCs 
recorded at +50 mV. Consistent with the effects observed at −65 mV, we found 
that EphB2 knockdown reduces the decay time, whereas overexpression of 
EphB2 causes a marked increase in the decay time of mEPSCs (control, 6.36 ± 
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0.19; EphB2.1 shRNA, 5.52 ± 0.14; EphB2 OE, 7.35 ± 0.16; ANOVA, p < 0.001) 
(data not shown). Together, our experiments demonstrate that, in mature 
neurons, EphB2 expression levels regulate the localization of NMDARs at 
synapses and their contribution to synaptic currents.  
We investigated whether EphB signaling might modulate NMDAR function 
and localization in a subunit-specific manner. Activation of endogenous EphB 
receptors with soluble ephrin-B ligand results in an interaction between EphBs 
and NMDARs followed by phosphorylation of the NR2B subunit and increased 
NMDAR-dependent Ca2+ influx (Takasu et al., 2002). The mechanism through 
which this increased calcium influx occurs is unknown. To both test whether this 
functional modification is subunit specific and determine the underlying 
mechanism, we coexpressed EphB2 with NR1-1a and either NR2A or NR2B 
subunits in HEK-293 cells (Zukin and Bennett, 1995). We examined whether the 
EphB–NMDAR interaction specifically alters NMDAR channel function by 
recording NMDA-evoked currents from transfected HEK-293 cells using the 
whole-cell patch-clamp method described in detail previously (Skeberdis et al., 
2006; Zheng et al., 1997). Briefly, in control cells held at −60 mV, application of 
NMDA (300 μm) with glycine (10 μm) for 5 s by laminar flow elicited an inward 
current that rapidly declined to a steady-state value (Legendre et al., 1993; 
Skeberdis et al., 2006; Tong et al., 1995; Zheng et al., 1997; Zorumski et al., 
1989). Measurements were made from the average of two to three trials per cell. 
In cells transfected with EphB2, NR1-1a, and NR2B, the peak amplitude was not 
significantly altered but the desensitization/inactivation in the NMDA response 
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was greatly reduced (Figure 5.4A). These effects required EphB kinase activity, 
as NMDAR currents in HEK-293 cells cotransfected with a kinase-dead form of 
EphB2 were normal. The absence of an effect with the kinase-dead mutant is not 
simply attributable to a disrupted interaction between EphB and NMDARs, as 
previous work has shown this mutant and the NMDAR still interact through their 
extracellular domains (Dalva et al., 2000). In cells transfected with EphB2, NR1-
1a, and NR2A, we found no significant difference in NMDA-evoked currents 
compared with control cells transfected with only NR1 and NR2A (Figure 5.4B). 
These results suggest that EphB2 preferentially modulates 
desensitization/inactivation of NMDARs containing NR2B subunits, and that the 
enhanced Ca2+ influx through NMDARs occurs by altering the kinetics of the 
channel in a kinase-dependent manner.  
Activation of EphBs results in phosphorylation of the NR2B subunit at 
Y1472 (Takasu et al., 2002), which in turn controls the internalization and 
localization of NR2B-containing NMDARs (Chen and Roche, 2007; Lavezzari et 
al., 2003; Prybylowski et al., 2005). Given the subunit-specific modulation of Ca2+ 
desensitization/inactivation in NR2B-containing NMDARs by EphB2, we 
examined whether EphB2 activation might preferentially control NR2B surface 
localization. We studied NMDAR subunit trafficking/localization with surface 
biotinylation experiments in cultured cortical neurons after treatment with control 
or activated ephrin-B2 at different times during development. Biotinylated surface 
proteins were pulled down and the fraction of the total protein labeled with biotin 
determined by Western blot analysis. Only samples lacking detectable actin in 
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the biotinylated fraction were included for additional analysis. We conducted 
these experiments at 7, 14, and 21 DIV—times when cultured cortical neurons 
have just entered a period of rapid EphB-dependent synapse addition (7 DIV), 
just ended the period of rapid synapse addition (14 DIV), or when synapses have 
matured (21 DIV) (Kayser et al., 2006). At each time point, NR2B was found on 
the cell surface under control conditions (Figure 5.5). We then asked whether 45 
min to 1 h of ephrin-B2 treatment might alter the surface localization of the 
NMDAR. We compared the fraction of total NR2B with biotin before and after 
ephrin-B2 treatment. At 7 DIV, ephrin-B2 treatment failed to induce a significant 
increase in the surface localization of NR2B. In contrast, at 14 and 21 DIV, when 
EphB is no longer required for synapse addition or to maintain normal numbers 
of functional synapses, ephrin-B2 treatment induced a significant increase in 
NR2B surface expression (Figure 5.5). These results show that activation of 
EphB2 increases NR2B on the cell surface of neurons and confirm that EphB2 
undergoes an age-dependent change in the control of NR2B trafficking.  
To determine whether EphB also controls the localization of specific 
NMDAR subunits in organized neural tissue, we examined the surface 
expression of the NMDAR in acute brain slices from TKO mice lacking EphB1–3. 
We chose to examine TKO animals because the presence of any EphB family 
members often masks the effects of genetic loss of one or two EphBs 
{Henkemeyer, 2003 #32; Kayser, 2006 #7. Indeed, throughout our experiments, 
we failed to detect effects on NMDAR localization in DKO mice lacking EphB1 
and 3, which maintain normal EphB2 function (Figures 5.6-5.9). To investigate if 
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the trafficking and localization of NMDARs is disrupted after the loss of EphB 
expression, we made hippocampal or cortical brain slices from wild-type, DKO, or 
TKO mice. The brain slices were then incubated live with Sulfo-NHS-SS-biotin 
(Pierce Protein Research Products; Thermo Fisher Scientific) on ice, and tissue 
was processed to determine the surface fraction of the NMDAR using methods 
similar to those for the cultured cortical neurons.  
Cortical and hippocampal brain slices were collected and labeled in 
parallel. Surprisingly, surface and total expression of the NR2B subunit of the 
NMDAR was increased significantly in TKO mice compared with controls (Figure 
5.6A, E-G). NR2A and NR1 expression were unchanged in cortex in the absence 
of EphBs, although the variability in this data set was large for NR1 (Figure 5.6A-
D, Figure 5.8). These findings were not mirrored in hippocampus, where total 
NR2A levels were reduced and surface NR2B increased in TKO compared with 
WT (Figure 5.7); surface levels of NR1 were also significantly reduced in 
hippocampus of TKO mice (Figure 5.8). These effects suggest that the role of 
EphBs may differ between different brain regions and that the interaction 
between EphBs and NMDARs is more complex than simple recruitment or 
retention of NMDARs on the cell surface, in which case we would expect NR2B 
surface localization to be decreased in the absence of EphBs.  
One possible explanation for the paradoxical increase in NR2B total and 
surface expression in the absence EphBs is that homeostatic mechanisms lead 
to upregulated expression and surface delivery because of a specific deficiency 
of NR2B at synapses. EphBs are localized to the postsynaptic complex at mature 
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synapses, and we have shown that increased expression or activation of EphB2 
increases the amount of NR2B on the cell surface and NMDARs at the synapse 
in vitro (Figures 5.1-5.3). Thus, we tested whether EphBs might help to direct 
NMDARs to synaptic sites in vivo. Using fractionation experiments, we compared 
the normalized amount of NMDAR found in the crude membrane fraction (P1) 
and at synaptosomes (Syn) from EphB DKO, TKO, and control WT mice by 
quantifying the amount of specific proteins by Western blot. The P1 fraction is 
enriched for all membranes, whereas the synaptosomal fraction is enriched for 
synaptic components. As expected, synaptic proteins such as NR1, GluR1, PSD-
95, and EphB2 were enriched in the Syn versus the P1 fraction from WT mice 
(Figure 5.9A). We then asked whether loss of the EphB proteins would disrupt 
the synaptic localization of the NMDAR. In the DKO mice lacking EphB1 and 3, 
NR2B expression and synaptic localization did not differ from wild-type animals, 
and we did not detect changes in the other synaptic proteins examined. 
However, TKO brains showed a significant decrease in the fraction of NR2B 
subunits at synapses (Figure 5.9A, D). Interestingly, there was also reduced 
localization of NR2A subunits at synapses in TKO brains (Figure 5.9A, C). 
Consistent with the direct nature of the EphB–NMDAR interaction, the loss of 
EphBs did not alter the localization of other synaptic components such as PSD-
95 and GluR2 (Figure 5.9A, E). Together with the biotinylation experiments, 
these findings suggest that EphBs direct the NR2B subunit to synaptic sites, and 
in the absence of EphBs, neurons unsuccessfully attempt to compensate, 
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resulting in increased overall expression and nonsynaptic surface expression of 
the NR2B subunit.  
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Discussion 
Multiple mechanisms contribute to the tightly regulated yet dynamic 
control of NMDAR trafficking. Here, we provide evidence that the EphB2 receptor 
tyrosine kinase is also an important regulator of synaptic NMDAR localization, 
but preferentially at mature contacts. Our results indicate that expression levels 
of EphB2 in mature cells can determine NMDAR content at synapses without 
impacting synapse number. We also find that EphB2 kinase activity specifically 
reduces the temporal decline of the NR2B subunit-mediated currents, resulting in 
prolonged currents and increased Ca2+ influx. In the absence of EphBs, total 
NR2B abundance and surface NR2B expression is increased, whereas synaptic 
expression is decreased, indicating mistargeting of this subunit without EphB 
signaling. These findings extend previous work demonstrating that EphB2 binds, 
clusters, and increases Ca2+ flux through NMDARs in young neurons {Dalva, 
2000 #9; Takasu, 2002 #8}, and suggest that the EphB–NMDAR interaction is 
significant throughout multiple phases of development and particularly in the 
mature brain.  
We find an age-dependent change in how EphBs modulate NMDAR 
activity. Early in development, EphBs are essential for the formation of normal 
numbers of excitatory synaptic connections made on dendritic spines (Kayser et 
al., 2008). During this time period, activation of EphB does not appear to 
increase recruitment of NR2B subunits to the cell surface. As neurons mature, 
EphBs are no longer required to maintain normal numbers of functional excitatory 
synapses but function to control the number of NMDARs localized to synaptic 
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sites. These results begin to answer the question posed by in vitro work 
indicating distinct mechanisms of NMDAR recruitment at differing neuronal ages 
(Bresler et al., 2004; Washbourne et al., 2002). Moreover, our data indicate that 
EphB specifically regulates trafficking of NR2B subunits in mature neurons, 
although our results do not exclude the possibility that EphBs play some role in 
NR1 and NR2A localization as well. Localization of the NR2B subunit of the 
NMDAR is of particular interest, as the proportion of NR2B-containing receptors 
can affect NMDAR channel open time and Ca2+ flux. Recent work has shown that 
phosphorylation of NR2B by casein kinase 2 (CK2) at a distinct site from EphB-
dependent phosphorylation leads to NR2B endocytosis and increased NR2A 
expression (Sanz-Clemente et al.). The interplay between CK2 and EphB2 
activity on NR2B, leading to endocytosis or retention, respectively, would be a 
sensitive mechanism for determining NR2B content at synapses. Functional 
consequences of increased NR2B content at synapses in certain areas of brain 
are known to include improved performance on memory tasks and enhanced 
visuocortical plasticity (Philpot et al., 2007; Tang et al., 1999). During normal 
development, the ratio of NR2A/NR2B at synapses increases over time ((Sheng 
et al., 1994), raising the threshold for long-lasting changes in synaptic strength in 
response to external stimuli (Philpot et al., 2007). Given that EphBs serve to 
drive NR2B into synapses only later in development, one interpretation of our 
data is that EphBs define mature synapses with a relatively low NR2A/NR2B 
ratio. These inputs would remain more plastic in the adult brain, with a lower 
threshold for long-term potentiation (LTP). Consistent with this role for EphBs in 
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maintaining or generating plastic synapses, EphB2 knock-out mice have reduced 
LTP, long-term depression (LTD), and quality of performance in the Morris water 
maze (Grunwald et al., 2001; Henderson et al., 2001). Although one feature of 
mature neurons by virtue of a higher NR2A/NR2B ratio is an increased selectivity 
for specific stimuli, it is clear that, even in the adult CNS, some inputs remain 
remarkably malleable (Holtmaat and Svoboda, 2009). Future work will need to 
specifically examine whether and how EphBs contribute to this sustained 
plasticity.  
Two likely mechanisms mediating EphB-dependent control of synaptic 
localization of NMDARs are the direct EphB–NMDAR interaction and EphB-
dependent phosphorylation of NR2B. We showed previously that ephrin-B 
activation of EphB2 results in the direct interaction of the NMDAR with EphB2 
and the phosphorylation of three tyrosine residues on the NMDAR (Dalva et al., 
2000; Takasu et al., 2002). One of the phosphorylated residues, Y1472, has 
since been shown to be important for the synaptic localization and retention of 
NMDARs, acting to prevent binding of AP-2 that in turn targets proteins for 
internalization by clathrin-mediated endocytosis (Chen and Roche, 2007; 
Lavezzari et al., 2003). Notably, there is a significant reduction in the level of 
NR2B phosphorylated at Y1472 found at synapses in EphB TKO brains 
compared with controls (data not shown). Although the magnitude of this change 
is matched by the decrease in total NR2B at synapses in TKOs, these data are 
consistent with a model in which EphB2 regulates retention of the NMDAR at 
synapses by phosphorylating the NR2B subunit at Y1472. In the absence of 
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EphBs, more NR2B is endocytosed, triggering the homeostatic drive of neurons 
to deliver more NR2B to synapses. This drive appears to fail in the absence of 
EphBs, as NR2B total and surface expression increase without effective synaptic 
delivery. Thus, the EphB–NMDAR interaction likely has a role in synaptic 
targeting of NMDARs in addition to retention. The loss of EphBs also results in 
decreased NR2A at synapses. This effect could be attributable to the direct 
interaction between EphB2 and the NMDAR or to the previously described 
phosphorylation of the NR2A subunit. Importantly, we cannot rule out a role for 
the direct EphB–NMDAR interaction in the synaptic localization of the NMDAR. In 
fact, the EphB–NMDAR interaction is likely to be central to the ability of EphB2 to 
specifically phosphorylate NR2 subunits, making it difficult to distinguish effects 
of the physical interaction and kinase activation.  
Although EphBs are important for the proper localization of NMDARs to 
synapses, they are not essential for all NMDARs to localize properly, nor for all 
facets of NR2B trafficking. These conclusions are consistent with the observation 
that EphBs direct formation of a subset of excitatory synapses (Kayser et al., 
2006) and our new findings that EphBs control a substantial fraction (50%) of 
NMDAR localization to mature contacts. Although additional research is needed 
to characterize the significance of this subpopulation, loss of EphB2 causes 
abnormal LTP and LTD in mouse hippocampus (Grunwald et al., 2001; 
Henderson et al., 2001), suggesting a functionally important role. Other proteins 
are undoubtedly required in these events as well, however, and synaptic 
transmission still occurs. For example, neuroligins (NLGs) cluster NMDARs and 
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signal to regulate excitatory synapse maturation (Chih et al., 2005; Graf et al., 
2004); more recent work suggests that loss of NLG1 results in reduced NMDAR 
expression and NMDAR-mediated synaptic transmission in hippocampus 
(Chubykin et al., 2007). These findings are similar to those for EphBs and 
suggest that both EphBs and NLGs, and very likely others, impact NMDAR 
localization at synaptic sites.  
In addition to the effects that we observe on NMDAR localization and 
function, our analysis of mEPSCs reveals a change in the AMPAR-dependent 
component of synaptic currents (Figures 5.2, 5.3). This finding is consistent with 
previous work showing that EphB2 activation can increase the surface 
localization of the AMPAR via PDZ domain-dependent interactions (Irie et al., 
2005; Kayser et al., 2006). However, our biotinylation and fractionation 
experiments in EphB TKO mice failed to detect changes in the localization of the 
GluR2 subunit of the AMPAR compared with controls. Thus, it appears possible 
that, although EphB2 overexpression results in increased AMPAR-dependent 
currents at synapses, mice lacking EphBs fail to show changes in the synaptic 
localization of GluR2. EphBs are therefore unlikely to regulate AMPAR function 
by simply controlling the overall amount of AMPARs at synapses. EphB2 
associates with AMPAR-interacting proteins PICK1 and GRIP (Torres et al., 
1998), which are important for trafficking of specific AMPAR subunits to 
synapses (Gardner et al., 2005; Liu and Cull-Candy, 2005). As with NMDARs, 
different AMPAR subunit combinations confer distinct channel properties (Greger 
and Esteban, 2007; Isaac et al., 2007). Thus, one interesting possibility is that 
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the EphB2-dependent changes in AMPAR current we observe (Figures 5.2, 5.3) 
are attributable to modulation of AMPAR subunit ratios at synapses rather than 
changes in overall AMPAR content. Additional work will be needed to determine 
the mechanisms by which EphBs regulate AMPAR synaptic currents.  
In addition to their role in the localization of NMDARs, EphBs modulate 
NMDAR-mediated calcium flux through Src family kinase-dependent 
phosphorylation of NR2B. This enhanced calcium influx is likely mediated by a 
reduction in the rate of calcium-dependent inactivation in NMDAR channels that 
contain the NR2B subunit, although in our current analysis we cannot rule out a 
role for glycine-independent desensitization. Importantly, the effects of EphB2 
appear selective for NR2B, as a similar change in time course is not found in 
NMDAR channels containing the NR2A subunit. Yet previous work has 
suggested that ephrin-B activation of EphB may increase tyrosine 
phosphorylation of not only NR2B subunits but also NR2A subunits (Grunwald et 
al., 2001; Takasu et al., 2002). The functional significance of EphB2/NR2A 
interactions has yet to be extensively examined, but given that EphB2 does bind 
to NR2A (Dalva et al., 2000), future investigation into whether EphBs modulate 
NR2A function will be of interest.  
The expression level of EphBs has recently been shown to be 
downregulated in models of Alzheimer's disease (Simon et al., 2009), and 
phosphorylation of NMDARs is reduced in brains of Alzheimer's disease patients 
relative to controls (Sze et al., 2001). One intriguing possibility is that the late 
function of EphBs in synaptic localization of NMDARs may be relevant to 
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neurodegenerative diseases. Consistent with this hypothesis, both ephrin-Bs and 
EphBs undergo posttranslational modification via γ-secretase activity (Litterst et 
al., 2007; Tomita et al., 2006), and overexpression of EphB2 has recently been 
shown to rescue cognitive defects in a mouse model of Alzheimer's disease 
(Cisse et al., 2011). Additional work will be needed to determine how EphBs and 
their ligands are linked to Alzheimer's and other diseases, but the recruitment to 
and modulation of NMDARs at synapses is likely a key part of any potential role.  
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Figure Legends. 
 
Figure 5.1. EphB2 regulates localization of NMDAR receptors to synapses 
in mature cortical neurons. A–C, Confocal microscopy maximum projection 
images of cultured cortical neurons at 21 DIV expressing eGFP and shRNA 
vector (control), EphB2.1 shRNA, or EphB2.1 shRNA plus “rescue” EphB2 
(functional EphB2 OE), immunostained for GFP (green), NR1 (red), and the 
presynaptic marker vGlut (blue). The magnified sections (top) of high-contrast 
image with arrows show spine (yellow arrows) and shaft (white arrows) 
synapses, defined as the locations where NR1, GFP, and vGlut immunostaining 
colocalize. The bottom panels show same region with anti-NR1 staining in red. 
D–F, Cumulative probability histograms of synaptic NR1, NR1 at spine synapses, 
and NR1 at shaft synapses. Functional EphB2 OE using a rescue construct in 
the context of endogenous EphB2 knockdown caused a significant increase in 
the amount of NR1 colocalizing with vGlut, whereas knockdown of EphB2 
resulted in a decrease (Kolmogorov–Smirnov test, p < 0.001). Amount of NR1 for 
each condition is normalized to the maximum intensity observed from all three 
conditions. Control, n = 27 cells, 432 synapses; EphB2.1 shRNA, n = 27, 359; 
functional EphB2 OE, n = 21, 319.  
 
Figure 5.2. EphB2 expression regulates mEPSC amplitude but not 
frequency in mature cortical neurons. Whole-cell patch-clamp recordings were 
made from 21–23 DIV cultured rat cortical neurons expressing eGFP and 
 194
shRNAi vector (control; blue), EphB2 shRNA (EphB2.1 shRNA; red), or EphB2.1 
shRNA plus “rescue” EphB2 (functional EphB2 OE; green). Recordings were at 
−65 mV in Mg2+-free solution. A, Example whole-cell patch-clamp recordings 
from cortical neurons in each condition; functional EphB2 OE neurons (row 3) 
show occasional miniature synaptic events at higher amplitude (left) that are 
blocked by the NMDAR antagonist APV (right). B, Mean traces of mEPSCs after 
NMDAR blockade with APV. Control: n = 5 cells without APV, 2298 mEPSCs; n = 
5 cells with APV, 2490 mEPSCs; EphB2 shRNA: n = 5 cells without APV, 2528 
mEPSCs; n = 5 cells with APV, 2040 mEPSCs. Functional EphB2 OE: n = 3 cells 
without APV, 1037 mEPSCs; n = 3 cells with APV, 1052 mEPSCs. C, No change 
in mEPSC frequency was observed for any condition (ANOVA, p > 0.05). D, 
Quantification of mean mEPSC amplitude before and after application of 50–100 
μm APV. An increase in mEPSC amplitude was observed with functional 
overexpression of EphB2, whereas NMDAR blockade with APV significantly 
reduced mEPSC amplitude for all conditions (ANOVA, *p < 0.01, **p < 0.001). E, 
Cumulative probability histograms of mEPSC amplitude for each condition. Error 
bars indicate SEM.  
 
 Figure 5.3. EphB2 regulates synaptic localization of functional NMDARs in 
mature cortical neurons. Whole-cell patch-clamp recordings were made from 
21–23 DIV cultured rat cortical neurons expressing eGFP and shRNA vector 
(control; blue), EphB2 shRNA (EphB2.1 shRNA; red), or EphB2 shRNA plus 
“rescue” EphB2 (functional EphB2 OE; green) (A–E). A, Mean traces of EPSCs 
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for each condition. B, Sample trace of whole-cell patch-clamp recording 
illustrating decay time. Decay time was calculated as the time from peak 
amplitude of the current to 30% of the peak amplitude, indicated by the arrows. 
C, Quantification of average decay time for each condition. D, E, Cumulative 
probability histograms of mEPSC decay times for each condition, plotted together 
(D) and individually for clarity (E). Control/EphB2.1 shRNA, p < 0.05; EphB2.1 
shRNA/functional EphB2 OE, p < 0.0001; without APV/with APV, p < 0.0001 for 
all conditions; control with APV/functional EphB2 OE with APV, p < 0.0001; 
EphB2.1 shRNA with APV/functional EphB2 OE with APV, p < 0.0001; K-S tests; 
N as in Figure 5.1. These findings indicate that the slow NMDAR component of 
mEPSCs is reduced by EphB2 knockdown (EphB2.1 shRNA) and increased 
when EphB2 is functionally overexpressed (EphB2.1 shRNA plus “rescue” 
EphB2). F, Whole-cell patch-clamp recordings were made from 21–23 DIV 
cultured rat cortical neurons expressing eGFP and vector (control; blue), 
EphB2.1 shRNA (red), or EphB2 (EphB2 OE; green). Normalized amplitude plot 
of the mean mEPSCs recorded at +50 mV in control, EphB2 shRNA, and EphB2 
OE neurons. G, Quantification of NMDAR component of the mEPSCs recorded 
at +50 mV in the presence of Mg2+ (control, n = 368 events/6 cells; EphB2 
shRNAi, n = 744/11; EphB2 OE, n = 1247/9). *p < 0.05, **p < 0.001, ANOVA. 
Error bars indicate SEM.  
 
Figure 5.4. EphB2 attenuates Ca2+-dependent desensitization of NR2B- but 
not NR2A-containing NMDARs. A, Top, NMDA-elicited currents recorded from 
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HEK-293 cells expressing NR1-1a/NR2B receptors in the absence (left) or 
presence of EphB2 (center), or the kinase-dead mutant EphB2-KD (right). 
Recordings at −60 mV in Mg2+-free solution. Bottom, Summary data showing 
peak current, steady-state current, and Ca2+-dependent desensitization of NMDA 
current (quantified as 1 − steady-state current/peak current × 100) (n = 8, 9, and 
7 for cells in the absence of cotransfected EphB2, presence of EphB2, or EphB2-
KD, respectively). B, Top, NMDA-elicited currents recorded from HEK-293 cells 
expressing NR1-1a/NR2A receptors in the absence (left) or presence (right) of 
EphB2. Bottom, Summary data showing peak current, steady-state current, and 
Ca2+-dependent desensitization of NMDA current [n = 10 and 8 cells (3 
independent experiments) in the absence or presence of EphB2, respectively]. *p 
< 0.05, **p < 0.01. Error bars indicate SEM.  
 
Figure 5.5. Ephrin-B2 activation of EphB2 increases NR2B surface 
localization. A–C, Cortical neurons at 7 DIV (A), 14 DIV (B), or 21 DIV (C) were 
treated for 45 min with control Fc (C) or activated ephrin-B2-Fc (eB2). 
Biotinylated (surface) and total NR2B protein was visualized by immunoblotting 
with specific antibodies (top gels). β-Actin was used as a loading control for total 
protein (bottom gels). Absence of actin in surface (biotinylated) gels indicates 
validity of surface labeling. Representative immunoblots show no actin 
immunolabeling in the biotinylated surface fraction. The bottom bar graphs show 
the ratio of amount of surface NR2B to total NR2B at 7 DIV (n = 5 experiments), 
14 DIV (n = 6 experiments), or 21 DIV (n = 6 experiments). Ephrin-B2-Fc versus 
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Fc (control) conditions were analyzed by an unpaired t test. *p < 0.05. Error bars 
indicate SEM.  
 
Figure 5.6. Surface and total NR2B expression levels are increased in the 
cortex of EphB1−/−, 2−/−, 3−/− TKO mice. A, Representative Western blots 
depicting NR2A and NR2B surface expression (left) and total expression (right) in 
WT, EphB1−/−, 3−/− DKO, and TKO mice. B–D, Quantification of NR2A surface, 
total, and surface/total expression. E–G, Quantification of NR2B surface, total, 
and surface/total expression. Values were normalized to DKO (n = 6, 9, and 7 
animals for WT, DKO, and TKO, respectively). *p < 0.05, **p < 0.01. Error bars 
indicate SEM.  
 
Figure 5.7. NR2B surface expression is increased and total NR2A levels are 
decreased in the hippocampus of TKO mice. A, Left, Representative Western 
blots depicting NR2A and NR2B surface expression in WT, EphB DKO, and 
EphB TKO mice. Right, Western blots showing total expression of NR2A and 
NR2B in WT, EphB DKO, and EphB TKO mice. Actin was used as a loading 
control in total protein fraction and as a control for surface staining in surface 
fraction. B, Quantification of NR2A and NR2B surface, total, and surface/total 
expression. Values are normalized to DKO (n = 6, 9, and 7 animals for WT, DKO, 
and TKO, respectively). *p < 0.05, **p < 0.01, ANOVA. Error bars indicate SEM.  
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Figure 5.8. NR1 surface expression is decreased in hippocampus of TKO 
mice. Top left, Western blot illustrating surface and total NR1 expression in 
cortex of WT, EphB DKO, and EphB TKO mice. Top right, Western blot depicting 
surface and total NR1 levels in hippocampus of WT, EphB DKO, and EphB TKO 
mice. Actin is shown as a loading control in total protein fraction and as a control 
for surface staining in surface fraction. Below, Quantification of NR1 surface, 
total, and surface/total levels in cortex and hippocampus of WT, EphB DKO, and 
EphB TKO mice. Values are normalized to WT (n = 2 animals each for WT, DKO, 
and TKO, samples were then divided and labeled with two independent 
reactions). *p < 0.05, ANOVA. Error bars indicate SEM.  
 
Figure 5.9. EphB TKO brains exhibit reduced synaptic expression of NR2A 
and NR2B. A, Lysates from brains of WT, EphB DKO, and EphB TKO animals 
were fractionated to isolate supernatant (S1), crude membrane (P1), and pure 
synaptosome (Syn) fractions. Western blots were probed with indicated 
antibodies and show enrichment of glutamate receptor subunits in the 
synaptosome fraction of all animals. PSD-95 and EphB2 are enriched in the 
same fraction. B–E, Syn/P1 ratio was used to compare synaptic versus 
nonsynaptic expression of NMDA and GluR2 glutamate receptors subunits. 
Compared with the WT and EphB DKO brains, EphB TKO animals exhibit 
reduced synaptic expression of NR2A (C) and NR2B (D) subunits of the NMDAR. 
There is no change in synaptic expression the GluR2 subunit (E) of AMPA 
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receptors between different genotypes. ANOVA, *p < 0.005; n = 3 animals for 
each condition. Error bars indicate SEM.  
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